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Abstract 
Nonribosomal peptide synthetases (NRPSs) are modular mega-enzymes found in bacteria and 
fungi that produce nonribosomal peptides (NRPs) in an assembly line fashion. Each module is in 
charge of adding a specific amino acid (AA) to the growing peptide chain. Three basic domains 
constitute one NRPS module: the adenylation (A), peptidyl carrier protein (PCP) and 
condensation (C) domains. The A domain recognizes and activates the AA. An external enzyme, 
the PPtase, attaches a phosphopantetheine (PPant) arm to the PCP domain which then picks up 
the activated AA and delivers it to the C domain. The C domain recognizes the growing peptide 
chain (donor) as well as the new AA (acceptor) and fuses the two together. A special feature of 
NRPSs is their ability to recognize and incorporate not only proteinogenic AAs, but also other 
building blocks like fatty acids (FAs) or non-proteinogenic AAs. All building blocks can be further 
modified through the action of additional domains: epimerization (E), methylation (M) and 
oxidation (Ox) domains, among others. In this manner a great variety of different NRPs can be 
synthesized, many of which are bioactive and exhibit anti-microbial or anti-cancer properties. 
Thus, it is highly desirable to understand how NRPS domains and modules function and find 
ways to genetically re-engineer them for custom NRP production. 
Since the discovery of NRPSs, many efforts have already been made to engineer these enzymes 
in order to create custom NRPs, but general design rules yet remain elusive. The successful 
attempts to re-create functional NRPS for the production of novel NRPs include: (i) mutations of 
the A domain, (ii) subdomain modifications and (iii) rearrangements on the module level. Yet, 
many engineered NRPSs exhibit only slow reaction rates and low product yields. In some cases, 
the desired NRP products cannot be detected at all, possibly due to additional control 
mechanisms that have not been taken into account during the engineering process, such as 
substrate specificity of C domains. Hence there is still a great need to identify the general rules 
for successful NRPS engineering in order to exploit the ever-growing molecular toolbox of newly 
discovered NRPSs for recombinant production of novel bioactive compounds. 
In this work I present my attempts to develop an approach to easily monitor the outcome of 
NRPS manipulation using a pigment-producing synthetase as a genetic tag. To this end, I first 
investigated two homologous synthetases, IndC and BpsA, which produce the blue pigment 
indigoidine, and mutants thereof and revised the proposed biosynthesis mechanism. I then 
created a series of fusion constructs between modules coming from different NRPSs and 
IndC/BpsA to test if indigoidine-tagged peptides could be produced. I identified a promising 
construct for which point mutations in the upstream module resulted in weaker or null pigment 
production. However, the expected indigoidine-tagged AA was not detectable, which could be 
due to the fact that indigoidine production inevitably leads to the separation of the donor AA. 
These results raised further questions as to whether in a native NRPS, the same modifications 
lead to congruent effects in neighboring modules. I addressed this question using a fragment of 
a non-engineered NRPS to monitor the activity of the native and modified versions in an in vitro 
assay, which I present in the last part of the results. Surprisingly, the effects of the same set of 
modifications on neighboring modules did not only differ between the engineered NRP-pigment 
synthetase and the native NRPS, but also between different modules within the native NRPS. 
These results hint at highly individual behavior of NRPS modules, depending on the context they 
are in. 
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Zusammenfassung 
Nichtribosomale Peptidsynthetasen (NRPSs) sind modulare Megaenzyme, die in Bakterien und 
Pilzen vorkommen und nichtribosomale Peptide (NRPs) in Fließband-Art produzieren. Jedes 
Modul ist dafür verantwortlich, der wachsenden Peptidkette eine spezifische Aminosäure (AA) 
hinzuzufügen. Drei grundlegende Domänen bilden ein NRPS-Modul: die Adenylierungs- (A-), 
Peptidyl-Carrier-Protein- (PCP-) und Kondensations- (C-)Domänen. Die A-Domäne erkennt und 
aktiviert die AA. Ein externes Enzym, die PPtase, bindet einen Phosphopantethein-Arm (PPant) 
an die PCP-Domäne, der dann die aktivierte AA aufnimmt und an die C-Domäne weiterleitet. Die 
C-Domäne erkennt die wachsende Peptidkette (Donor) sowie die neuen AA (Akzeptor) und 
verbindet die beiden miteinander. Das Besondere an NRPSs ist ihre Fähigkeit, nicht nur 
proteinogene AAs zu erkennen und einzubauen, sondern auch andere Bausteine wie Fettsäuren 
(FA) oder nicht-proteinogene AAs. Alle Bausteine können durch zusätzliche Domänen weiter 
modifiziert werden: dazu gehören die Epimerisierungs- (E-), Methylierungs- (M-) und Oxidations- 
(Ox-)Domänen. Auf diese Weise kann eine große Vielfalt verschiedener NRPs synthetisiert 
werden, von denen viele bioaktiv sind und antimikrobielle oder tumorunterdrückende 
Eigenschaften haben. Daher ist es äußerst wünschenswert, die Funktionsweise von 
NRPS Domänen und Modulen zu verstehen und Wege zu finden, um sie genetisch für die 
benutzerdefinierte NRP-Produktion neu zu konstruieren. 
Seit der Entdeckung von NRPSs wurden bereits viele Anstrengungen unternommen, um diese 
Enzyme zu rekonstruieren, um benutzerdefinierte NRPs herzustellen, aber allgemeine Regeln 
dafür sind immer noch schwer aufzustellen. Experimentelle Ansätze funktionelle NRPSs für die 
Herstellung neuartiger NRPs zu rekonstruieren umfassen: (i) Mutationen der A-Domäne, (ii) 
Modifikationen von Subdomänen und (iii) Neuanordnungen ganzer Module. Viele neu 
angeordnete NRPSs weisen jedoch niedrige Reaktionsgeschwindigkeiten und geringe 
Produktausbeuten auf. In einigen Fällen konnte das gewünschte Produkt überhaupt nicht 
nachgewiesen werden, was möglicherweise auf zusätzliche Kontrollmechanismen, z.B. durch die 
C-domäne, zurückzuführen ist und bei der Neukonstruktion der NRPSs nicht berücksichtigt 
wurde. Es besteht daher nach wie vor ein großer Bedarf, die allgemeinen Regeln für ein 
erfolgreiches NRPS-Engineering zu ermitteln, um die ständig wachsende molekulare Toolbox neu 
entdeckter NRPS für die rekombinante Produktion neuartiger bioaktiver Verbindungen zu 
nutzen. 
In dieser Arbeit zeige ich Ansätze zur Entwicklung einer Methode zur einfachen Evaluierung des 
Effekts von NRPS Manipulationen auf deren Aktivität anhand der Bildung eines farbigen 
Produkts durch eine genetisch an das modifizierte NRPS angehängten Pigmentsynthetase. Zu 
diesem Zweck untersuchte ich zwei  homologe Synthetasen, IndC und BpsA, die das blaue 
Pigment Indigoidin produzieren. Die Analyse verschiedener Mutanten dieser Synthetasen 
führten zu der Überarbeitung des bisher anerkannten Biosynthesemechanismus. Anschließend 
erstellte ich eine Reihe von Fusionsenzyme aus Modulen verschiedener NRPSs und IndC/BpsA, 
um zu testen, ob mit Indigoidin markierte Peptide hergestellt werden. Eines der Fusionsenzyme 
war vielversprechend, da Punktmutationen im Upstream-Modul zu einer abgeschwächten oder 
gar keiner Pigmentproduktion führten. Jedoch ließ sich die erwartete mit Indigoidin markierte 
AA nicht nachweisen, was darauf zurückzuführen sein könnte, dass die Indigoidinproduktion 
zwangsläufig zur Abspaltung der Donor-AA führt. Diese Ergebnisse warfen weitere Fragen auf, 
z.B. ob in einem natürlichen NRPS die gleichen Mutationen zu den gleichen Effekten in 
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benachbarten Modulen führen. Um diese Frage zu beantworten, habe ich drei natürlich 
zusammenhängende Module eines NRPS in vitro untersucht. Dabei habe ich herausgefunden, 
dass sich die Auswirkungen der gleichen Modifikationen auf benachbarte Module nicht nur 
zwischen dem konstruierten NRP-Pigment Fusionsenzym und dem natürlich 
zusammenhängenden NRPS, sondern auch zwischen verschiedenen Modulen innerhalb des 
natürlichen NRPS, unterscheiden. Diese Ergebnisse deuten auf ein sehr individuelles Verhalten 
von NRPS-Modulen hin, je nachdem, in welchem Kontext sie sich befinden.   
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1. Introduction 
1.1 Preface 
“Antimicrobial resistance has become one of the biggest threats to global health and endangers 
other major priorities, such as human development.”  
The United Nations (UN)1 as well the World Health Organization (WHO)2 have recognize this fact 
and issued a global action plan3. The five major objectives of this plan are: (i) to raise and 
increase awareness of antimicrobial resistance through more effective communication, 
education and training; (ii) to accumulate more knowledge through research; (iii) to decrease 
the number of infections through prevention measures; (iv) to limit the use of antibiotics to 
sensible cases in human and animal health and (v) to increase investment in research towards 
new medicines, diagnostic tools, vaccines and other interventions. 
It takes a global effort to advance each of these objectives and step by step realize this action 
plan. I decided to take a little step towards the second objective (ii) during my PhD project and 
investigated non-ribosomal peptide synthetases (NRPSs), the assembly lines of many antibiotics 
and other bioactive compounds. They naturally occur in many bacteria and fungi and their 
products are among our “most important antibacterial, antifungal, antiviral, 
immunosuppressant, and anticancer drugs”4. Much research has been done towards finding, 
understanding and manipulating these mega-enzymes, the advances of which I will introduce in 
the first part of this thesis. At the same time, many aspects remain elusive. In this work I focus 
on the development of an NRPS tagging procedure for a visual readout of NRPS engineering 
suitable for high-throughput screening. In addition, I investigated the intramolecular 
cooperation within a native but truncated NRPS, in its original form and upon different local 
disruptions. My results contribute to a better understanding of NRPSs while at the same time 
raising more questions about these fascinating molecular machines.  
With my PhD thesis, I take a tiny step towards finding out how NRPSs work in more detail. Of 
course, it is a tiny step, a little dent in what is already known about NRPSs and a tiny dent in the 
humongous circle of human knowledge, much like Matt Might nicely put it in his “illustrated 
guide to a Ph.D”5. Nonetheless, every tiny dent contributes to enlarging this circle of knowledge 
and may one day lead to, in our case, new medicines. 
1.2 Non-ribosomal peptide synthetases and their natural products 
Non-ribosomal peptide synthetases (NRPSs) produce, as their name implies, peptides. They are 
not the ribosome; hence they synthesize non-ribosomal peptides (NRPs). In contrast to the 
ribosome, which is the main peptide and protein producer across all forms of life, NRPSs 
synthesize their peptides independently from a DNA sequence-derived blueprint. This approach 
has the advantage that NRPSs are not limited to the 22 L-amino acids encoded by DNA but can 
choose from a tremendous pool of building blocks to form their peptides. Additionally, they 
cannot only form linear peptides, but can make them circular, branched or intertwined resulting 
in a vast variety of shapes that the peptides can adopt. With this variety of constituents and 
shapes, NRPs often have useful chemical properties and/or interfere with biological processes, 
such as cell-wall biosynthesis or enzyme activity. In addition, they are less vulnerable to 
degradation, e.g. by peptidases, than linear peptides. For this reason, many bacteria and fungi 
Linear NRPSs 
14 
 
afford to produce the large NRPSs to have an evolutionary advantage through the production of 
an NRP with a certain, helpful characteristic. 
Of course, being enzymes, NRPSs and their products are not completely independent from the 
ribosome. As for every other enzyme, the ribosome builds NRPSs according to the genetic code. 
Thus, to ultimately change the sequence of an NRP, one needs to change the DNA that encodes 
its synthetase. What evolution has mastered resulting in the large diversity of NRPs that we find 
in nature today is much more complicated in the laboratory setting. While the genetic code has 
been deciphered and we exactly know the effect that changing the DNA sequence will have on 
the amino acid sequence, the non-ribosomal code has only been partially cracked.  
It is known by now, how the molecular arrangement of NRPSs is linked to the sequence of their 
final product. Their modular setup and the contribution of each domain within these modules 
have largely been uncovered. However, despite these great advances, it remains difficult to 
predict which effect the change of individual amino acids or the rearrangement of whole 
domains within NRPSs have on the sequence of the NRP they produce. Thus, it remains difficult 
to rationally engineer NRPSs to produce custom peptides with changed bioactivity.  
Alternative natural product producers 
NRPSs are not the only bioactive natural product producers: Polyketide Synthetases (PKSs) 
equally contribute to natural bioactive compound production, following a similar pattern of 
modular substrate elongation. The elongation reaction is similar to fatty acid synthetases with 
the basic building blocks being actyl- and malonyl-CoA. NRPSs and PKSs can form complexes with 
each other. There are plenty of very comprehensive review articles featuring PKSs6–9. Another 
alternative route to bioactive natural peptides is represented by the ribosomally synthesized and 
post-translationally modified peptides (RiPPs)10. However, in this work I am covering and using 
primarily NRPSs, which I will introduce in more detail in the following sections, starting with 
basic, linear NRPSs.  
 Linear NRPSs  1.2.1
A basic, linear NRPS consists of an initiation module, followed by one or more elongation 
modules and is completed by a termination module. Each module is in charge of adding a 
specific building block to the growing natural product11, the non-ribosomal peptide, NRP. Thus, 
the size and sequence of an NRP is dictated by the number and order of modules within the 
NRPS that produces it. Linear NRPSs can range in size from two12 to 2213 modules. These can be 
distributed across several distinct enzymes, which cooperate via communication domains 
(section 1.2.9). The building blocks they incorporate include the standard proteinogenic L-amino 
acids, but also fatty acids (FAs)14–16 and non-proteinogenic AAs17,18. Through internal and external 
auxiliary domains (section 1.2.7), the structural and chemical variety of NRPs is further increased 
resulting in up to 500 different monomers found in natural products19. This great variety has 
evolved over millions of years to produce bioactive NRPs providing its host organism protection 
against e.g. other microbes4,20. However, in modern medicine, many NRPs have also been 
discovered to be anti-fungal, anti-viral, anti-cancer and immunosuppressant4,20–24. A particularly 
comprehensive overview of different NRPs, their structures, their host organism(s), their 
function and mode of action is provided by Süssmuth and Mainz25.  
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Besides linear NRPSs, more complex versions exist, such as iterative and non-linear NRPSs 
(section 1.2.10)23. In the following sections, I will give an example of a well-studied linear NRPS 
and then introduce the general biosynthetic cycle of NRP formation before describing the 
obligatory and auxiliary domains and their roles in more detail. 
 A well-studied example of a linear NRPS: the tyrocidine synthetase 1.2.2
Here I want to highlight one example of a linear NRPS: the tyrocidine synthetase (Figure 1A), 
which produces the antimicrobial cyclic NRP tyrocidine (Figure 1B) in many Bacillus species26. 
In 1963, the tyrocidine synthetase was the first NRPS to be discovered. Tatum and coworkers 
found that the cellular production of the cyclic peptide tyrocidine26,27 was not affected after the 
addition of a ribosome inhibitor and thus an alternative synthesis pathway was inevitable28. 
Purification and in vitro study of the polyenzyme responsible for tyrocidine synthesis was 
reported in 197029,30. Further analysis contributed to the concept of a modular setup of the NRPS 
with the number of modules matching the number of residues of tyrocidine11. In 1997, the 
complete DNA sequence of the tyrocidine biosynthesis gene cluster of Brevibacillus Brevis (ATCC 
8185) and detailed biochemical analysis of each of its components was reported by Mootz and 
Marahiel31 and extended by others32–36. In my thesis, I used parts of the tyrocidine synthetase for 
engineering an AA-pigment synthetase, namely modules 5 and 6 specific for asparagine and 
glutamine, and for the analysis of native NRPS modules in vitro, namely modules 8, 9 and 10 
specific for valine, ornithine and leucine, highlighted in different colors (Figure 1). 
 Biosynthetic cycle of NRP formation 1.2.3
The very basic scheme of a linear NRPS is shown in Figure 2, including the initiation module, 
elongation module(s) and the termination module. 
Figure 1 | The tyrocidine synthetase produces the antimicrobial cyclic peptide tyrocidine.  (A) 
Schematic depiction of the three enzymes that make up the tyrocidine synthetase. Numbers 
refer to the modules. Modules used in this study are number 5 and 6, shown in gray and 
modules 8, 9 and 10, shown in color. Amino acids are depicted attached to the PPant arms. (B) 
Chemical structure of tyrocidine.  
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Each NRPS module is composed of multiple domains that cooperate to incorporate a specific 
building block into the growing peptide chain. A basic initiation module consists of an 
adenylation (A) domain, that specifically recognizes its substrate amino acid (here called X) and 
activates it via adenylation (Figure 2, 1.) of the carboxyl group while simultaneously releasing a 
pyrophosphate (PPi). The second crucial domain within an initiation module is the peptide 
carrier protein (PCP) domain, also termed thiolation (T) domain. This domain requires a 
posttranslational modification to be functional. Specifically, a 4′-phosphopantetheine “arm” 
(PPant) is attached to a conserved serine within the PCP domain (Figure 2, 0.) by an external 
4’-phosphopantetheinyl transferase (PPtase). This PPant arm serves as the point of attachment 
for the activated substrate via thiolation (Figure 2, 2.), which is shuttled to the elongation 
domain. In addition to the A and PCP domain, the elongation module also contains a 
condensation (C) domain, which facilitates peptide bond formation (Figure 2, 3.) between the 
upstream substrate (“donor”, here X) and the downstream substrate (“acceptor”, here Y), 
forming the intermediate product “XY”. This cycle of activation, thiolation and condensation is 
repeated N times, adding one building block per elongation module. The last building block is 
added by the termination module producing the peptide “XY[N]Z”, before it reaches the 
thioesterase (TE) domain. The TE domain cleaves the thioester bond between the intermediate 
substrate and the upstream PCP domain and temporarily binds it at a conserved serine residue 
via an acyl-O-TE intermediate. Release of the final product is facilitated through a nucleophilic 
attack either by water or an intramolecular nucleophile resulting in either a linear or a cyclic 
NRP, respectively (Figure 2, 4.). In the following sections each basic and several additional 
domains will be described in more detail. 
Figure 2 | The biosynthetic cycle of NRP formation.  A standard NRPS consists of an initiation, 
one or more elongation and a final termination module. Each module again consists of various 
domains, each playing a crucial role in the NRP formation process. AX, Y, Z - Adenylation domains 
specific for amino acids with sides chains X, Y and Z; PCP - Peptide Carrier Protein (= Thiolation 
domain - T); C - Condensation domain; TE - Thioesterase domain. Conserved serine residues 
within PCP and TE domains are highlighted as little grey dots. This figure was modified from 
Süssmuth and Mainz23 with permission of the publisher. 
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 Adenylation (A) domains 1.2.4
A domains recognize and activate their substrates via adenylation 
A domains, the adenylation domains of NRPSs, belong to a large family of adenylate forming 
enzymes: the ANL (Acyl‐CoA synthetases, NRPS adenylation domains, and Luciferase enzymes) 
superfamily37. Other members of this family include acyl- or aryl CoA synthetases and luciferase 
oxidoreductases. On average, NRPS A domains are comprised of about 500 residues summed up 
to a size of about 55 kDa. Like all members of the ANL family, NRPS A domains catalyze a two-
step adenylation reaction37: In the first step adenosine triphosphate (ATP) and the substrate are 
bound and adenosine monophosphate (AMP) is attached to the carboxyl group of the substrate 
resulting in the activated substrate-adenylate and release of pyrophosphate (PPi). In the second 
step a nucleophile, here the thiol group of the PPant arm, attacks the reactive intermediate to 
release the final product and AMP from the A domain. 
The first correlations between peptide elongation and substrate activation were made in the 
gramicidin S38,39 and the tyrocidine synthetase29,30 in 1969 and 1970. Verification that indeed 
A domains of an NRPS specifically recognize and activate their substrates could only be provided 
25 years later, once individual A domains were purified and analyzed in vitro using an ATP/PPi 
exchange assay40–42. With the elucidation of the structure of the Phe activating first A domain of 
the gramicidin S synthetase in 199743 and other A domains44–46, also in conjunction with their 
cognate PCP domain47,48, further insights into the substrate recognition and adenylation process 
were gained. It became clear that the A domain is divided into two subdomains, a large, 
N-terminal core domain Acore of about 400 residues and a small, C-terminal subdomain Asub of 
about 100 residues. The two domains are linked via a hinge loop49,50. The active site, where the 
amino acid and Mg⋅ATP are joined together, is located in the Acore close to the interface between 
the two subunits. 
Furthermore, ten conserved signature sequences (A1 - 10) could be identified and assigned 
specific roles in substrate binding, structural arrangement or catalysis51–53 (Table 1). The Acore 
domain contains regions A1 - A7 while A8 - A10 are located on the Asub domain. An extended 
post A10 motif (LPxP) has been recognized to play a role in correct positioning of a lysine within 
the active site of A10 and in A domain PCP interaction54.  
Table 1 | A domain signature sequences and their roles in substrate binding and activation. Φ 
represents an aromatic amino acid residue, while x stands for any residue. Table modified from 
Labby et al.55 with permission from the publisher. 
core consensus sequence role 
A1 L(T/S)YxEL N-terminus of domain, caps an α-helix53 [structural] 
A2 LKAGxAYL(V/L)P(L/I)D properly aligns Gly7853 [structural] 
A3 LAYxxYTSG(S/T)TGxPKG 
acts as a loop and positions the β,γ-phosphates correctly53  
[substrate binding] 
A4 ΦDxS 
aromatic residue terminates an α-helix that forms side of 
acyl-binding pocket53 [substrate binding]  
A5 NxYGPTE 
invariant glutamic acid coordinates Mg2+ ion; adenine ring 
of ATP is stacked against aromatic residue53 [structural and 
substrate binding] 
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A6 GELxIGx(V/L)ARGYL 
stabilizes distorted β-sheets in the N-terminal domain53 
[structural] 
A7 Y(R/K)TGDL 
aspartic acid residue is 100% conserved and hydrogen 
bonds with ATP through the ribose hydroxyls53 [substrate 
binding and catalytic] 
A8 GRx[D/K]xxxKxxGxxxELxxxE 
arginine stabilizes the ribose through its hydroxyls; a hinge 
is formed at aspartic acid residue; in the thioester-forming 
conformation, the glycine forms part of the PPant tunnel53 
[structural and substrate binding] 
A9 (L/V)PxΦM(L/V/I)P 
stabilizes thioester-forming conformation by properly 
positioning residues to interact with PCP domain56 
[catalytic] 
A10 NGK(V/L)DR 
in the adenylate-forming conformation, lysine is within the 
active site53  [catalytic] 
 
A domain specificity is regulated by amino acids lining the active site pocket 
With the structures of substrate-bound A domains, the active site pocket and the specificity 
conferring residues could be identified57,58 and refined59. This enables the prediction of substrate 
specificity from the DNA sequence of an unknown A domain60–62.  
A domain activity is accompanied by conformational rearrangements 
For single modules, the A domain was reported to adopt three different conformations:  (i) an 
open (O) conformation, where no ligand is bound, (ii) an adenylation conformation, where the 
small C terminal Asub domain is turned by ~48° to complex Mg
2+, ATP and the amino acid 
substrate to perform the adenylation reaction and finally (iii) a thiolation (T) state, in which the 
Asub domain is rotated by ~140° around the large N terminal Acore to tether the activated amino 
acid to the PPant arm of the PCP domain45,49,63,64. This A domain alternation mechanism is 
expected to contribute most to the conformational rearrangements that are necessary for the 
growing peptide chain to travel along the enzyme. 
Some A domains require MbtH-like proteins to support their fold and function 
MbtH-like proteins (MLPs) are small proteins of about 70 amino acids named after their first 
discovery in the mycobactin biosynthesis gene cluster65 in M. tuberculosis. They are required by 
some A domains for activity66,67 or increase solubility and product formation68–71. From their 
consensus sequence (NXEXQXSXWPX[5]PXGWX[13]LX[7]WTDXRP)
72 the tryptophan residues have 
been identified to contribute critically to the interaction with the A domain73,74. Several crystal 
structures capturing A domains and MLPs in complex73,75,76 suggest that MLPs interact mainly 
with the Acore domain but do not have direct contact with the substrate or the small Asub domain. 
A gel filtration experiment showed that in complex, the A domain has a slightly lower apparent 
molecular weight than without the MLP thus indicating a more rigid conformation of the MLP 
bound A domain76. Note that for some NRPSs, MLPs are completely dispensable77.  
Promiscuous A domains lead to a variety of different peptides formed by the same NRPS 
While the A domain normally determines the building block that is incorporated via its specificity 
conferring residues as described above, there are examples of promiscuous A domains, which 
add to the diversity of NRPs produced by one NRPS.  
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The nostopeptolide A synthetase features an A domain that accepts three different branched 
hydrophobic amino acids (Ile, Leu and Val)78 and is thus able to synthesize three versions of 
nostopeptolide A. Another example is the anabaenopeptin synthetase, where the initial A 
domain is even capable of activating two structurally different amino acids: arginine and 
tyrosine. The crystal structure revealed that this promiscuity is possible due to arginine adopting 
the same conformation as the tyrosine in the active site pocket of the A domain 79. Despite the 
fact that we know how A domains recognize their substrates and thereby control the NRP 
sequence, there are exceptions and influences by neighboring domains which cannot be 
predicted yet. In vitro, A domain specificity was shown to be dependent on what type and how 
much of the upstream C domain was present in the analyzed construct 80,81. 
Assays for analyzing A domain activity 
During the adenylation reaction catalyzed by the A domains, ATP is consumed while PPi and AMP 
are released. The change in each reactant over time can be used as a measure to study A domain 
activity in vitro. In Figure 3, different assays are summarized according to the reactant they 
detect.  
ATP/PPi exchange assays (Figure 3A) measure the reverse adenylation reaction through the 
incorporation of [32P]-PPi into ATP
82–84. They exhibit a high sensitivity but require radiolabeled 
ATP. A recently presented assay uses [18O] labeled ATP and thus is non-radioactive85. The 
hydroxylamine‐trapping assay (Figure 3B) detects the amino acid-AMP intermediate, from which 
AMP is cleaved yielding a signal at 540 nm. This assay is useful for A domains that bind PPi 
tightly86. The commercial kit AMP-GloTM (Promega) detects AMP (Figure 3C) by first depleting 
ATP from the reaction and then turning the AMP back to ADP and ATP followed by a luciferase 
assay. Colorimetric phosphate assays (Figure 3D) detect PPi release by cleaving PPi into two 
monophosphates Pi that react with either Malachite Green or MesG to form a colorful product 
that can be quantified87–90. Another type of PPi release assay is coupled to the decrease of NADH 
via an enzymatic cascade taking PPi as a starting substrate
91 (Figure 3E) and has been recently 
adapted to the study of NRPSs70. In this assay, A domain activity is ultimately measured via 
quantification of the decrease in absorption at 340 nm, the absorption maximum of NADH92.  
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In this work, I use the coupled PPi release assay described last for the in vitro investigation of 
NRPS A domains, because it does not require radioactivity, it is suitable to study A domains also 
within a larger NRPS complex70 and can be performed in a photospectrometer to detect one 
distinct round of activation or in a plate reader for higher throughput measurement of repeated 
activation cycles.  
 Peptidyl carrier protein domains and their activation through PPtases 1.2.5
PCP domains, also called thiolation (T) domains, are small domains of less than 100 amino acids 
or about 10 kDa arranged in a 4-5 helix bundle structure as identified in X-ray93–95 and NMR96–99 
studies. They are located downstream of the A domains in an NRPS to take on the adenylated 
substrate and present it to adjacent C (and other auxiliary) domains. To do so, PCP domains need 
a posttranslational modification: a 4′-phosphopantetheine (PPant) moiety with a length of 18 Å 
is transferred from a Coenzyme A (CoASH) precursor onto a conserved serine 
([I/L]GG[D/H]S[L/I])100,101 by an external PPtase102 (Figure 2, 0.). The thiol (-SH) group at the 
terminus of the PPant arm serves as the nucleophile to attack the activated carboxy group of the 
adenylated substrate and thereby tethers it covalently to the PCP domain via a thioester bond 
(Figure 2, 2.).   
Figure 3 | Overview of A domain activity assays. The two step adenylation 
reaction catalyzed by A domains uses ATP and produces PPi and AMP. 
(A) ATP–PPi exchange assays; (B) hydroxylamine‐trapping assay 
(C) AMP-GloTM (Promega) (D) Colorimetric phosphate assays (PPiase: 
pyrophosphatase; PNP: purine nucleoside phosphorylase: MesG: 
2-amino-6‐mercapto‐7‐methylpurine ribonucleoside). (E) NADH coupled 
PPi release assay (F6P: d‐fructose‐6‐ phosphate; F1,6P: fructose‐1,6‐
diphosphate; PPi-PFK: phosphofructokinase (pyrophosphate dependent); 
GAP: glyceraldehyde‐3‐phosphate; DHAP: dihydroxyacetone phosphate; 
TPI: triosephosphate isomerase; GDH: glycererophosphate 
dehydrogenase). Figure modified from Kittilä et al.71 with permission from 
the publisher. 
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PPtases are crucial for NRPS activity103 and can block efficient substrate elongation when 
accepting and transferring e.g. acetyl-CoA. Mis-primed PCP domains can be liberated again by 
TE type II domains, present in many NRPS encoding gene clusters (section 0). This laxness of 
PPtases towards their substrate can also be exploited to bypass A domain selection by loading 
amino acid-thioesters directly onto the PCP domain104–106 or evolve a PPtase to introduce non-
native compounds107. PPtases are promiscuous with regards to which NRPS they attach the 
PPant arm to108. Sfp, a PPtase from the surfactin Srf gene cluster in Bacillus subtilis105, is a 
well-studied promiscuous PPtase, often used to phosphopantetheinylate NRPS in vitro and in 
vivo109–111. 
The PPant arm is used by PCP domains to shuttle the intermediate products between adjacent 
domains 
As described before, NRPSs undergo large conformational changes during their biosynthetic 
cycles. One might expect the peptide carrier protein domain with its PPant arm to be involved in 
these movements to a great extent, however, in contrast to previous findings in an NMR study96, 
PCP domains seem to be quite rigid. According to several X-ray structures and structural 
alignments, they do not change their conformation, neither upon phosphopantetheinylation, 
nor dependent on their neighboring domains94,95,112. These findings support the notion that A 
domains are the major driving force of the conformational changes in NRPSs, which then re-
orient the PCP domains to fulfill their task. Though, an additional layer of regulation and 
elasticity might be imposed by the PCP domain loading state as proposed recently64,113,114. 
In general, PCP domains need to shuttle intermediate substrates between adjacent domains and 
must thus engage in transient contacts with them. Hydrophobic and ionic interactions between 
the A domain and its PCP domain could be attributed to helix 2 of the PCP domain and helix 11 
of the Acore
50. Further, the loop connecting helix 1 and 2 of the PCP domain (at the end of which, 
the conserved serine is located) interacts with the last structural motif of the Asub domain via a 
network of charged residues98. In addition, the A-PCP linker region has been discovered to 
contain a conserved motif (LPxP) shared among ~70% of linkers, where a mutation of the Leu in 
the enterobactin synthetase greatly reduced product formation54.  
In the downstream direction, the PCP interacts with and discriminates between C or TE domains. 
The exchange of an elongation with a termination PCP domain prevented product formation115. 
Point mutations in the C-terminal part of the exchanged PCP domain could rescue product 
formation in this engineered NRPS hinting at specific interaction of these residues with the 
downstream domain.  
The importance of the linker regions between the PCP and its adjacent domains in both 
directions has also been shown in an earlier publication from the Di Ventura lab116. In this study, 
the native PCP domain of an indigoidine synthetase was replaced by external or artificial PCP 
domain. Successful product formation of the engineered NRPS largely depended on how much 
of the native linker region was included in the exchanged part. 
Assays to monitor successful substrate transfer to PCP domains 
A frequently used method is a thiolation assay117, in which a radiolabeled substrate is presented 
to the NRPS module(s) of interest. Upon thiolation the enzyme gets precipitated and excess 
substrate is removed by washing. The radioactivity of the remaining enzyme is measured by a 
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scintillation counter indicating the amount of radioactively labeled substrate covalently bound to 
the PCP domain. A more direct way of assessing substrates bound to the PCP domain is mass 
spectrometry of attached substrates118–122. The NRPS fraction is subjected to LC-MS either as a 
whole or after enzymatic digest. The fractions containing the PPant arm can be traced back to 
previous fractionation states and the mass of the substrate attached can be assessed.  
 Condensation domains 1.2.6
Condensation (C) domains have a size of about 450 amino acids or 50 kDa and have been first 
recognized in 1995 due to their conserved HHxxxDG motif123. They form a V shaped124 pseudo-
dimer reminiscent of the chloramphenicol acetyl transferase125. The two legs of the V can be 
separated into an N-terminal and a C-terminal lobe, forming a tunnel for the connection of the 
donor and acceptor substrates. The conserved motif is located within the N-terminal lobe, close 
to the center of the tunnel.  
C domains form a peptide bond between the donor and the acceptor substrates 
Condensation domains catalyze the peptide bond (amide bond) formation between donor 
(upstream) and acceptor (downstream) amino acids32 presented to them through the PPant arm. 
Formation of the peptide bond is facilitated by a nucleophilic attack of the acceptor amino group 
on the donor carbon engaged in the thioester bond (Figure 2, 3.), which is resolved in the 
process. 
Although, the conserved HHxxxDG motif is crucial for catalysis its exact nature is ambiguous: 
Mutations of the second histidine, for example, can lead to (almost) complete obstruction32,126 
or to an only two-fold reduction of peptide bond formation127, which points towards a catalytic 
role of the second His. The same mutation can also render an NRPS module (here part of TycB of 
the tyrocidine synthetase) insoluble, hinting at a structural function35. Mutation of aspartate (D) 
within the catalytic motif inactivates the enzyme35,128.  
Overall, the catalytic process of peptide bond formation by C domains is thought to be driven by 
stabilization of catalytic intermediates rather than acid-base catalysis. However, more crystal 
structures with one or both substrates bound are needed to fully recapitulate the catalytic 
mechanism23. 
The C domain acts as a checkpoint for correct directionality and specificity of the reaction 
partners 
The condensation reaction is the one that ultimately drives product elongation. Consequently, 
C domains control proper directionality of this elongation process129. A recent crystal structure 
of the first condensation domain of a calcium-dependent antibiotic (CDA) synthetase can adopt 
two different states, a more closed and a more open state130. It is hypothesized that this minor 
conformational change aides the proper directionality of the reaction, e.g. opening only after the 
desired acceptor amino acid has entered the tunnel130. Interestingly, this acceptor amino acid 
bound conformation is also adopted by the C domain during donor substrate activation by the 
upstream A domain. Hence it is likely that during the condensation reaction, the proximate 
donor substrate is already prepared for thiolation to improve the overall enzyme efficiency50.  
C domains act as an additional gatekeeper ensuring that the correct substrates are condensed. 
This feature is more pronounced at the acceptor than at the donor side33,129,131, though the 
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donor side was also shown to be size- and stereo-selective with regards to the immediate donor 
residue and other upstream building blocks132,133. Thus, likely there is a substrate recognition 
step as well, but in contrast to A domains, no specificity conferring residues could be identified 
in a large phylogenetic analysis of C domains134. However, and this is also in contrast to 
A domains, this phylogenetic analysis could identify individual residues within the conserved 
sequences51 from which you can distinguish if a C domain is a starter or an elongation C domain. 
Sequence analysis can furthermore predict whether elongation C domains catalyze a 
condensation reaction between two L-amino acids (LCL) or between a D- and an L-amino acid 
(DCL)
134. How L-amino acids can be epimerized prior to condensation within the NPRS will be 
discussed in the next section. 
Starter C domains have been first identified in Daptomycin135 and a CDA136 synthetases as part of 
the initiation modules and are responsible for condensing a fatty acid onto the acceptor amino 
acid51. Functional evidence of this type of condensation reaction was produced by the 
examination of the surfactin lipoinitiation module15. The starter C domain indeed catalyzed the 
amide bond formation between 3-hydroxymyristic acid-S-CoA, activated by an external fatty acyl 
CoA ligase, with the PPant tethered substrate activated by the initiation module A domain, 
glutamate (Glu)15. 
Alternative roles of (evolved) C domains 
Condensation domains have evolved over time to form structurally homologous domains with 
the ability to accomplish other relevant functions within NRPSs137, such as epimerization138, 
cyclization139, b-lactam formation140, or recruitment141 of auxiliary enzymes. Mainly in fungal 
NRPS complexes, C domains can also replace the TE domain and promote macrocyclic release of 
the final product142,143. This is also the only example to date of any type of C domain crystal 
structure represented with the donor substrate oriented in a catalytically competent state143.  
 Auxiliary domains in cis and trans 1.2.7
Auxiliary (or tailoring) domains expand the basic NRPS domains and add an additional 
opportunity for NRP diversification in cis, as part of the NRPS, or in trans, as a separate enzyme. 
Accordingly, these additional modifications are either introduced along with NRP elongation, 
prior to or following the production process. Here are few examples of auxiliary domains23 and 
the reactions they perform to modify their substrates, some of which will be described in more 
detail in the paragraphs below: cyclization (Cy), epimerization (E), formulation (F), ketoreduction 
(KR), methyl transfer (M), oxidation (Ox), and reduction (R). This list is by no means complete 
and new tailoring domains are still being identified. For a very detailed update and overview on 
auxiliary domains, please see23. 
Larger auxiliary domains such as E, F and Cy domains act as a discrete domains located in the 
beginning or rationally along the NRPS (assembly) line. Smaller auxiliary domains, like M, Ox and 
R domains are often embedded within A domains, preferably between core sequences A2 and 
A3 or between A8 and A955 (Table 1). 
Epimerization domains 
Epimerization (E) domains epimerize L-amino acids to D-amino acids in trans144,145 or more 
commonly in cis51,146. Therefore, they are usually embedded in the NRPS complex, downstream 
of the PCP domain, on which the PPant tethered substrate is then presented for epimerization. 
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E domains display a C domain-like structure, however, there are critical differences between the 
two: (i) the C domain binding site for acceptor substrate is blocked in E domains, e.g. by eleven 
additional residues in TycA138; (ii) the floor loop between the N- and C-lobe is expanded by at 
least 5 residues in E domains, which enable specific interactions with the PCP domain138; (iii) the 
linker region between PCP and E domain of the gramicidin synthetase GrsA PCP-E di-domain was 
found to align in a structured interaction along the E domain surface leading to correct 
positioning of the rigid PCP domain and thus of the PPant bound substrate towards the active 
site147. In contrast to PCP-C domain linkers, the connection between PCP and E domains plays a 
prominent role in enzymatic recognition and binding. 
Methylation domains 
Methyltransferases or methylation (M) domains use S-adenosylmethinonine (SAM) as a 
co-substrate to perform backbone N-methylation of NRPs148. Other attachment sites like O-, S-, 
and C-methylation as well as N,N-dimethylation have also been reported23,149,150. The 
methyltransferase domains have a size of about 45 kDa and are usually embedded within the A 
domain core sequences A2-A3 or A8-A955. They can also be located between two domains151 or 
act in trans as a standalone enzyme152. Bioinformatic comparison of M domains has identified 
conserved signature motifs from which the type of methylation can be predicted to a certain 
degree153. Very recently, the structure of an M domain embedded in TioS AVal(A8-9) domain in 
complex with its MbtH-like protein partner TioT was solved154. This is the first available structure 
of an interrupted A domain and could pave the way to better understand how integration of 
auxiliary into A domains can yield a functional collaboration between the two. 
Oxidation domains 
Likewise, Oxidation (Ox) domains are generally embedded within A domains of the substrate 
they oxidize. The position between A8 and A9 core motifs seems to be an evolutionary favorable 
insertion point of auxiliary domains55, even though Ox domains can also locate at other positions 
such as downstream of the PCP domain as observed for MtaC of the myxothiazol PK/NRP 
synthetase 155. 
Three conserved signature motifs for Ox domains have been identified55 (Table 2). Sequences 
Ox1 and Ox2 allow the classification of NRPS integral Ox domains to a larger group of 
FMN-dependent oxidoreductases found as distinct enzymes. The contribution of each conserved 
motif on the oxidation reaction remains unknown. 
Table 2 | Conserved motifs of NRPS integrated FMN dependent Ox domains. 
core consensus sequence 
Ox1 KYxYxSxGxxY(P/G)VQ 
Ox2 GxxxG(L/V)xxGxYYY(H/D)P 
Ox3 IxxxYG 
 
Examples of PKS/NPRS complexes harboring Ox domains are EpoB and MtaD of the epothilone 
and myxothiazol biosynthesis pathways, respectively155,156. The Ox domain-integrated A domains 
accept L-cysteine, cyclize it to form a thiazoline and subsequently perform the oxidation to 
create a thiazol moiety157. Another example of an Ox domain integrated in a glutamine specific 
A domain can be found in the indigoidine synthetase, which will be discussed in section 1.2.11.  
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 Thioesterase domains 1.2.8
Thioesterase (TE) domains (~280 aa) release the final peptide product formed by the upstream 
modules158,159 most commonly in form of a cyclic or a linear product. They comprise a high 
sequence variety, contain very few conserved sequence stretches160 and are able to facilitate a 
vast number of reactions. Unlike for e.g. A domains, the substrate they accept and reaction they 
catalyze cannot be predicted from conserved motif sequences or phylogenic analysis161. More 
detailed information about different types of TE domains are covered in comprehensive review 
articles162,163. In addition, reductase or condensation domains can also account for product 
release in some cases162. In the following I will focus on the aspects of TE domains that are key 
for this work.   
TE domains feature a catalytic pocket and a flexible lid-like structure 
As described above, thioesterase domains can differ largely in their protein sequence, the 
confirmation they adopt and in the reaction they catalyze. However, some features are common 
to most of them, as established by crystal structures of different TE domains164–169: (i) an active 
site pocket harboring the catalytic triad Ser-His-Asp, where the serine is embedded in a GXSXG 
motif. (ii) an alpha/beta fold, where alpha helices and beta sheets are alternating in a rather 
conserved order and finally (iii) a flexible lid region, which consists of one or more alpha-helices 
and is located between beta sheets 6 and 7170.  
Thioesterase domains release the final NRP as a linear or a cyclic product  
The general release mechanism of TE domains occurs in two successive steps, very similar to 
other hydrolases171,172. In short, the intermediate peptide chain is transferred from the last PCP 
domain PPant arm onto the active site serine of the TE domain from where it is released through 
and intra-, or intermolecular nucleophilic attack. 
In the first step, the intermediate substrate is loaded onto the active site serine. For this 
purpose, the His-Asp dyad draws a proton from the alcohol of the serine side chain making it 
more nucleophilic. The intermediate NRP is presented to the TE domain linked to the PPant arm 
of the PCP domain. The linking thioester bond is then attacked by the negatively charged serine 
side chain forming the acyl-O-TE intermediate and releasing the PPant thiolate. 
In the second step, the substrate is offloaded from the TE domain as the final product. To that 
end, an intramolecular or external nucleophile approaches the scene. It is activated by either the 
active site histidine after deprotonation by the leaving thiolate as proposed by Townsend173,174 
or by another external cue. The nucleophile attacks the carbonyl of the acyl-O-TE intermediate, 
releasing the final NRP and a seryl alkoxide, which requires immediate reprotonation. If the 
nucleophile was a water molecule, hydrolysis of a linear peptide product occurs. If the 
nucleophile was the N-terminus of the NRP, a (macro-) cyclic product is released.  
The latter case is the most common scenario, since cyclic peptides can adopt specific, 
entropically favored conformations needed for the interaction with target structures. In 
addition, cyclic peptides are less susceptible to degradation by peptidases thus making them 
more stable175. In addition, there is a range of exceptional NRPSs, which also require more 
exceptional product release strategies. Some of these will be shortly discussed in sections 1.2.10.  
Conformational rearrangements of the TE domain during product release 
Iterative and non-linear NRPSs 
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The core region of thioesterase domains does not undergo any larger rearrangements to 
facilitate product release. In their native conformation, they provide an oxyanion hole through 
hydrogen bonding from two backbone amide NH groups, which stabilizes the acyl-O-TE 
intermediate during formation and breakdown169 without any further conformational switch 
required. However, the aforementioned lid region has been shown to exist in two different 
states, an open and a closed one169. In an NMR study it could be additionally confirmed that this 
lid is moving from one state to the other during substrate processing176 suggesting that it does 
have a role during this process. Potentially, it excludes intrusive molecules like water from the 
active site pocket. Yet, the active site pockets of different TE domains can have different 
volumes and in addition differently sized lids can limit this volume without stringent implications 
for substrate specificity163.  
Variations from the catalytic triad sequence motif can be found in natural NRPSs 
For the catalytic triad there are examples of natural deviations from the Ser-His-Asp sequence, 
which have been long known for other alpha/beta hydrolases172,177. For example, instead of the 
serine there is a cysteine serving the same purpose in few NRPSs163. The histidine has also been 
found replaced by proline in the mycolactone TE178. Finally, aspartate can also be substituted by 
glutamate or serine163.  
Thioesterase type II domains regulate a variety of reactions in trans including regeneration of 
misprimed PCP domains 
In addition to the thioesterase type I described above, in many NRPS gene clusters a second type 
of thioesterase can be found, termed type II (in short TEII)158. They mostly act in trans and 
remove mis-primed PPant arms of NRPSs thus regenerating the enzyme for another futile cycle 
of NRP production167,179. In rare cases, they can also participate in substrate selection or 
(intermediate) product release180. In this way, they can improve the NRP yield from 
heterologously expressed NRPSs180,181. 
 Communication domains 1.2.9
Communication (Com) domains mediate the intermolecular communication and directionality 
between two adjacent NRPS modules which are expressed as separate proteins to ensure proper 
peptide propagation along the enzymatic complex182. They are short regions located at the 
C-terminal end of the donor module and the N-terminus of the acceptor module. Structural 
analysis revealed that their contact is facilitated by anti-parallel helix-hand interactions183,184. 
Communication domains can be found in the tyrocidine, plipastatin, surfactin, gramicidin S and 
lichenysin Synthetases182. Note that there are also NRPS complexes, e.g. the andrimid PKS/NRPS 
synthetase, that lack communication or other docking domains, suggesting that alternative 
interaction mechanisms might exist185.  
 Iterative and non-linear NRPSs 1.2.10
Besides linear NRPSs, other types of NRP producing enzymes have been identified: iterative and 
non-linear NRPSs. Iterative NRPSs produce their NRPs by iteratively adding up the basic 
monomer or peptide sequence that is defined by the specificity of their modules23. In this way 
the NRPS machinery can be much smaller and still produce a longer NRP. Cyclo-oligomerization 
catalyzed by iterative NRPS has been shown for the bacterial gramicidin S186 and enterobactin 
synthetase, as well as the fungal beauvericin and enniatin synthetases187. This oligomerization 
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can be achieved by temporarily storing the intermediate components on the terminal PCP 
domain and the active site serine of the TE domain before oligomerization.  
For non-linear NRPSs, the sequence of the NRP is not reflected by the module specificity or 
arrangement of their synthetase188. A recent study suggests that they might be more common 
than initially expected189. An example of an NRP produced by non-linear NRPS is fungisporin and 
related cyclic tetrapeptides in Penicillium chrysogenum190. 
  Special cases: Pigment synthetases with focus on indigoidine and dodecylindigoidine 1.2.11
synthetases 
A large variety of natural pigments produced in bacteria, fungi and archaea191–194have been 
discovered and many of them originate from NRPSs and PKSs. Some compoundsare currently 
applied as antifungal, antibacterial and antitumor agents or as natural dyes for food or 
clothing193. A recent review article focusses on natural blue pigments195, including indigoidine 
and a derivative, N,N-dodecylindigoidine.  
These two blue pigments are produced by extraordinary NRPSs of the possibly iterative kind, 
which will be described in greater detail below.    
Indigoidine and its proposed synthesis mechanism 
The blue pigment indigoidine was noted to be produced in Pseudomonas indigofera196 in 1890, 
isolated from the Spree river in Germany. Many chemical properties of indigoidine were also 
described then already, e.g. its insolubility in water and many organic solvents, its 
decomposition in sodium hydroxide (NaOH), the transformation into a yellow-brown substance 
in concentrated hydrochloric acid (HCl). 
The chemical structure of indigoidine (5,5′-diamino-4,4′-dihydroxy-3,3′-diazadiphenoquinone-
(2,2′)) was solved in 1965197 by the Heidelberg based Nobel-Prize Laureate Richard Kuhn and a 
chemical synthesis pathway was presented198. Other solvents for indigoidine were identified to 
be dimethylsulfoxide (DMSO), dimethylformamide (DMF) and pyridine. The molar extinction 
coefficient in DMF was determined to be ε (Indigoidine in DMF) = 23 442 M-1 cm–1 198. During and 
following the chemical synthesis process, other derivatives of indigoidine were also identified, 
e.g. the colorless but fluorescent reduced leuco-indigoidine197,199. 
The biosynthetic gene cluster harboring the indigoidine synthetase gene was first discovered in 
blue pigment producing200 plant pathogen Erwinia chrysanthemi201 (Figure 4A). Homologues 
indigoidine synthetase genes have been found across the bacterial kingdom, within the genus of 
Streptomyces (e.g. lavendulae ATCC 11924202), Pseudomonas (e.g. flourescens203 and 
indigofera204), Photorhabdus (e.g. luminescens205, where the expression was silenced, but could 
be triggered by promotor exchange), Microbispora and Dickeya strains and others. The two 
indigoidine synthetases I will investigate further and use in this work are IndC from 
Photorhabdus luminescens205 and BpsA from Streptomyces lavendulae ATCC 11924199,202.  
The indigoidine synthetase is a single module NRPS of about 1280 amino acids, which consists of 
an A domain (accession number cd05930) specific for L-glutamine, followed by a PCP domain 
(CL0314) and a final TE (alpha/beta hydrolase, cl21494) domain. The A domain is interrupted by 
a mcbC type nitro-reductase domain (cd02142), which binds the cofactor FMN to reduce it to 
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FMNH2 and concomitantly oxidize the glutamine substrate (Figure 4A). The FMNH2 is 
autocatalytically recovered via oxidation with molecular oxygen206. 
The indigoidine synthetase is schematically depicted in Figure 4B and converts two L-glutamine 
molecules into the blue pigment indigoidine. The proposed synthesis mechanism is shown in 
Figure 4C. Glutamine is recognized and activated by the A domain and thiolated to the PCP 
domain. Either before or after thiolation, the oxidation domain introduces a double bond in the 
glutamine side chain, whereupon the amino group of this side chain executes a nucleophilic 
attack on the thioester bond. Thus, the oxidized cyclic glutamine is proposed to be released from 
the enzyme and undergo a tautomerization, where the double bond shifts within the cyclic 
molecule to the neighboring C-C bond. The second isomer is suggested to non-enzymatically 
dimerize into the blue pigment indigoidine55,201.  
It remains unknown at which step exactly the oxidation reaction occurs. Furthermore, in this 
proposed mechanism, the function of the TE domain is unclear and seems neglectable, which is 
unlikely given that evolution put it there. 
Figure 4 | Indigoidine and its proposed synthesis mechanism by the indigoidine synthetase. (A) 
Domain representation of the indigoidine synthetase. The A domain is interrupted by a mcbC 
like nitro-FMN-reductase and followed by a PCP and TE domain (alpha/beta hydrolase). (B) 
Schematic depiction of the indigoidine synthetase. The A domain is specific for glutamine and 
ultimately converts two L-glutamine molecules into one indigoidine, that has an intense blue 
color. (C) Proposed mechanism of indigoidine production. Upon thiolation, the glutamine is 
suggested to be oxidized and released from the enzyme via an internal nucleophilic attack. The 
oxidized and circularized intermediate undergoes isomerization and is hypothesized to non-
enzymatically dimerize to form indigoidine. 
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The natural role of indigoidine is not finally resolved 
The role of indigoidine in the natural context is ambiguous. Its presence has been investigated in 
various organisms and contexts, some of which will be described below to give an overview of 
possible roles that indigoidine plays in nature. 
In Streptomyces lavendulae, indigoidine production is controlled via the SARP (Streptomyces 
antibiotic regulatory protein) regulatory cascade including IM-2 and its receptor FarA207,208, 
which is also responsible for the production of antibiotics D-cycloserine and different nucleoside 
antibiotics. In Roseobacter Phaeobacter sp. Strain Y4I, indigoidine production was linked to the 
inhibition of Vibrio fischeri on agar plates209. Another Roseaobacter strain (Leisingera sp. JC1) 
resides in the reproductive system of the Hawaiian bobtail squid (Euprymna scolopes) and is 
partly deposited into the jelly coat of their eggs, to protect them from Vibrio fischeri 
colonization210. On the other hand, indigoidine synthetase null mutant Roseobacter strains were 
less motile and faster to colonize an artificial surface209, which reveals the pleiotropic effects of 
indigoidine. Indigoidine exerts pleiotropic effects on oxidative stress as well. Indigoidine 
synthetase null mutant Roseobacter were more resistant to hydrogen peroxide209 while for 
Erwinia the presence of indigoidine lead to an increased resistance toward oxidative stress201. 
For Vogesella sp. strain EB indigoidine might be a precursor for an indigoidine-derived pigment 
termed cryo-indigoidine, which prevents freezing of the bacterium in low temperatures and 
increases survival in the cold, iron-oxidizing environment of Andean Patagonia211.  
Overall, we can summarize that indigoidine seems to have a mild antimicrobial effect on other 
bacterial entities and is involved in surface colonization and oxidative stress response, however 
with strains-specific outcomes. 
Indigoidine as a reporter molecule 
Indigoidine has a dark blue color and is synthesized by a single, post-translationally modified 
enzyme from a widely available, non-absorbing, non-toxic substrate (L-glutamine). This 
combination makes indigoidine an ideal reporter molecule, which has been exploited in various 
applications. 
It has been used as an alternative reporter molecule for blue/white screening of successful 
cloning in bacteria212. In mammalian cells, indigoidine could also be produced and was 
subsequently reduced to the fluorescent leuco-indigoidine serving as a selection marker in 
FACS199. Since a PPtase has to add a PPant arm to the PCP domain of the indigoidine synthetase 
for proper function, indigoidine formation has been used to validate characteristics of known 
PPtases in vivo and in vitro108. When placed upstream of an indigoidine synthetase gene, the 
strength of engineered promotors and other regulatory sequences could be investigated213. The 
same principle was applied to explore naturally occurring metabolite-sensitive repressors in 
bacteria214. Once purified, an indigoidine synthetase was employed to measure glutamine 
concentration in vitro from different biological samples215. 
In the examples described above, the indigoidine synthetase remained unaltered to produce the 
blue pigment as a reporter molecule for testing PPtases, regulatory sequences and glutamine 
concentrations. In contrast, indigoidine synthetase has also been used to monitor the success of 
domain and in particular PCP engineering of the single module NRPS itself, by us116 and others216, 
as illustrated in more detail in section 1.2.5. 
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N,N-dodecylindigoidine and its proposed synthetase in Shewanella violacea DSS12 
Another exceptional but less well studied pigment is N,N-dodecylindigoidine. It consists of an 
indigoidine core with two dodecanoic (=lauric) acid side chains attached to the N-terminal amino 
group via a peptide bond (Figure 5B). It has a purple color with an absorption maximum at 
636 nm in chloroform217.  
The source of this pigment is Shewanella violacea DSS12, which is a marine bacterium that was 
found in the Ryukyu Trench near Japan at a depth of 5 110 m218. Cultivated on Marine Agar 
plates it produces a violet pigment in the form of long crystals, which turned out to be 
N,N-dodecylindigoidine217. The genome of Shewanella violacea has been sequenced 
completely219 and searched for potential genes related to its pigmented phenotype using a 
Bidirectional Best Hits (BBH) approach in comparison to the pigment producing Rheinheimera 
baltica DSMZ 14885220,221. Among others, a putative N,N- dodecylindigoidine synthetase 
(WP 013053246.1), hereafter referred to as “dIndS”, as well as an Sfp type PPtase 
(WP_013050488.1) have been identified221.  
According to the Conserved Domain Database222, dIndS consists of the following domains (Figure 
5A): FAAL = fatty acyl AMP ligase (accession number cd05931), PCP = phosphopantetheine 
attachment site (pfam00550), SDR = short-chain dehydrogenases/reductases with a Rossman 
fold for NAD(P) binding (cl25409), A = adenylation domain of NRPSs (cd05930) and A/B H = 
alpha/beta hydrolases (cl21494). Deduced from the potential product formation process of 
indigoidine, I proposed a similar process for N,N-dodecylindigoidine (Figure 5B). The domain 
order and function suggest that the FAAL recognizes and activates dodecanoic acid, which is 
then transferred to the PPant arm attached to the first PCP domain. The second A domain likely 
has a specificity for glutamine, which is transferred to the PPant arm of the second PCP domain. 
Figure 5 | Predicted conserved domains of the putative N,N-dodecylindigoidine synthetase 
“dIndS”. (A) Conserved domains of the protein WP 013053246.1 in Shewanella violacea 
according to the Conserved Domain Database. FAAL = fatty acyl AMP ligase, 
PCP = phosphopantetheine attachment site, SDR = short-chain dehydrogenases/reductases, 
Rossman fold for NAD(P) binding, A = adenylation domain of NRPSs and A/B H = alpha/beta 
hydrolases. (B) Possible domain arrangement and product formation. 
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The two A domains are connected via a NAD(P) binding domain, which could condense the fatty 
acid and the amino acid to a secondary amine by reductive amination. How glutamine is oxidized 
and cyclized to ultimately form the indigoidine core remains unknown. None of the other 
Bidirectional Best Hits matched an external oxidation domain221. The exact role of the final TE 
domain (alpha/beta hydrolase) also remained unclear, similar to the indigoidine synthetase TE 
domain, which is of the same type. 
 Interactions and interfaces between NRPS domains 1.2.12
A number of crystal structures and cryo-electron micrographs of multi-domain NRPSs trapped by 
mechanistic inhibitors, have become available to study the conformation in certain states of the 
NRP synthetic cycle53,47,104,50. Yet, the complete picture remains elusive: Do complex NRPSs adopt 
a conformational pattern along which the growing peptide chain travels in an orderly manner, 
like suggested by Marahiel223? Or do they exist in an disorganized state and find their reaction 
partners if present rather by chance - a hypothesis based on work by the Gulick lab104,224? 
Either way, the synthesis process must be very efficient to avoid mis-initiation or premature 
product release, both ultimately leading to truncated NRPs futile to the NRPS host organism. 
How the modules communicate with each other in the larger context to ensure this efficiency to 
date remains a secret. 
1.3 Ways of expanding and harnessing the toolbox of NRPSs to find and 
engineer novel drugs based on natural products 
Now that I have summarized what we know about NRPSs, their setup, their mode of function 
and the great diversity and importance of their products, I want to focus on how to expand and 
use that knowledge for the discovery and development of novel antibiotics or other drugs. In 
this second part of the introduction, I want to present current approaches to find novel natural 
products and their synthetases. These findings contribute to expanding the natural toolbox of 
known NRPSs to be used for engineering novel, custom NRPs. However, there are still some 
problems to be overcome before we can fully exploit that toolbox. I will introduce the problems 
and show successful examples of NRPS engineering.    
 The search of novel antibiotics in (un-)cultivatable organisms 1.3.1
The great advances of high throughput sequencing, (mass) spectrometry, bioinformatical 
analysis and integrated approaches enable large screens of potential NRP producer organisms225, 
of which an estimated 99% of which are uncultivatable. Many of them are marine organisms226–
228 or live in the soil229,230 or on plants231,232. Recently, several new (potential) natural product 
producers have been identified via genome mining233–235 or improved mass spectrometry 
approaches120,236. In a particularly successful approach, Ling et al. first obtained single colonies of 
uncultivatable bacteria from soil using a new device named iChip, then identified colonies with 
antimicrobial potential via co-culture and finally discovered teixobactin229, a novel antibiotic that 
“kills pathogens without detectable resistance”229. 
New information about NRPS or NRP discoveries can be added to comprehensive databases that 
have already been established for NRPSs and PKSs, such as Norine237, Clustermine360160 and 
antiSMASH238,239 database.  
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 Aspects of NRP production by fermentation  1.3.2
To date, most marketed natural products are fermented in their original producer organism and 
purified further to be formulated into an administrable product23. Chemical total- or 
semisynthesis have been reported for a variety of natural products, however, often the 
fermentation process is less expensive, better scalable and possibly more environmentally 
friendly since no or less hazardous chemicals are employed in the production process.  
Besides the original producer, also heterologous hosts have been successfully established to 
express complete NRPS gene clusters.  In this way, the whole production pathway of e.g. anti-
bacterial240 or anti-tumor241,242 natural products was reconstituted in E. coli. Expression of 
orphan NRPSs under the control of an inducible promotor has led to the identification of natural 
products silenced in their native producer strain205,243. Other hosts like yeast and Aspergillus 
strains have been engineered to process fungal NRPSs244,245. 
For heterologous expression of NRPS gene clusters, a couple of problems also have to be taken 
into account: The sheer size of these gene clusters can cause difficulties in handling and cloning. 
Though, novel DNA recombination strategies like Gibson assembly246 and recombination in 
yeast247,248 have provided remedy for this problem. Another aspect is the difference in codon use 
by many of the original producer strains. Codon optimization might be necessary prior to 
successful expression in a different host strain. Since (commercial) gene synthesis is advancing 
rapidly to be more accurate, more efficient and less expensive, producing complete codon 
optimized genes for heterologous expression will be more commonly used. 
 NRPS engineering has the potential to generate novel drugs 1.3.3
What we know about the mode of action of NRPSs and the pharmaceutical impact of their 
products has become evident so far. How to use this knowledge to engineer artificial systems to 
generate custom NRPs and thus potentially novel drugs will be described in the coming sections.  
Different routes can be taken to make NRPSs synthesize different products. One route is 
precursor-directed biosynthesis, in which alternative substrates are presented to the enzymes 
while the supply of the original substrate is limited eventually forcing the NRPS to accept and 
incorporate the alternative precursor. This approach can be paired with mutasynthesis that 
takes a mutated strain incapable of producing the original product without external supplement 
of at least one of the precursors which is then exchanged by the alternative substrate249,250. In 
my thesis, I focus on a different route, namely design engineering and combinatorial 
biosynthesis, where NRPSs are engineered and recombined based on previous knowledge to 
achieve the predefined outcome. This concept was first introduced by Marahiel and co-workers 
in 1995251. In some cases, design engineering is complemented by precursor directed or 
mutasynthesis to improve the results.    
The strategies of design NRPS engineering reach from the introduction of point mutations and 
subdomain modifications to whole module alterations or even the reconstitution of 
new-to-nature NRPSs from scratch. The more complex the modifications become, the higher 
their potential to produce truly custom peptides. On the other hand, the expected and 
unexpected problems also increase with higher complexity. I will now summarize the successful 
examples of NRPS engineering and the problems that arise even in successful instances. These 
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problems might be the reason why despite a lot of effort, engineered NRPS still fall short of the 
expectations that many scientists had upon their discovery. 
 Examples of successful engineering approaches of NRPSs and their limitations 1.3.4
Successful is a relative term in NRPS engineering. In a perfect world scenario, “successful” would 
mean that the engineered version of the enzyme is just as active as the wild type version, also in 
vivo, and that the substrate and reaction specificity is retained, just towards the altered 
substrate. This is certainly not the case for most engineered NRPS. In some cases, a comparison 
with the original NRPS in vitro and in vivo is hard to assess, so the effect of engineering cannot 
be expressed in numbers. Thus, I will describe examples, which are considered successful if an 
alternative product of the engineered NRPS was detected. When the levels of modified product 
or enzyme activity are only a fraction of those of the wild type, reasons for this shortcoming will 
be discussed.  Usually these shortcomings provide an insight to the limitations still encountered 
in NRPS engineering and demonstrate what to consider for the following engineering 
approaches.  
 Point mutations 1.3.5
As the most prominent substrate selector in NRPSs, A domains are logical targets of small-scale 
manipulations like point mutations to alter their specificity towards a desired substrate. In 
addition, the introduction of point mutations does presumably not perturb the native intra-, and 
intermodular interfaces of the NRPS.  
Following the proposal of the specificity conferring code of A domain substrate binding 
pockets57, the second module of the surfactin synthetase (SrfB AAsp) was mutated to change 
substrate specificity from L-Asp to L-Asn252. According to the code, three residues should have 
been changed, but the biochemical analysis revealed, that a single point mutation was enough 
(H322E). When the original AAsp  domain of the surfactin gene cluster was replaced by the 
modified AAsn domain, the modified surfactin [Asn(5)] was detected in Bacillus subtilis, however, 
at lower levels and only along with the original surfactin. In addition, the specificity change 
recognized in vitro was accompanied by a drastic drop in catalytic activity252. These results 
suggest, that engineering A domain specificity is possible via the introduction of point mutations. 
However, they also underline the great impact of the C domain acceptor side, which in this case 
allows the unnatural substrate Asn to pass through, but at the same time uses A domain 
mis-initiation of Asp to form the original product, overruling A domain specificity. A similar 
problem arose when mutating the seventh A domain specific for Asp (A7Asp) of a calcium 
dependent antibiotic (CDA) synthetase to match the specificity conferring code of Asn, so the 
converse case of the first example253. While in vitro the change in specificity was demonstrated, 
replacing the original by the mutated A domain in Streptomyces mainly led to the production of 
a hexapeptidyl intermediate. This premature product release is likely caused by the upstream 
C domain at the acceptor side, which recognizes the modified substrate Asn only weakly stalling 
the production process and releasing the hexapeptide by unintended hydrolyzation253.  
Other approaches of successfully altering the A domain specificity via point mutations have been 
described. For example, alternative andrimids were produced in vivo after site-directed 
mutagenesis followed by a mutasynthesis approach switching the substrate specificity of an 
A domain from L-Val to L-Ile or L-Leu254. While the most functional versions yielded near wild 
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type levels of the alternative products, other versions (specificity altered to L-Ala and L-Phe) only 
reached up to 1.3% of the production level of the unmodified enzyme254. In another example, 
yeast cell surface display was employed to alter the substrate specificity of DhbE. In vitro a 
switch in substrate preference of 200-fold was reached. However, all top selected variants that 
were reintroduced into the native gene cluster, were unable to load the alternative substrate 
onto its partner aryl carrier protein (ArCP-) domain because of a substrate specificity 
independent mutation in the active site (H234W)255. A directed evolution approach via 
successive saturation mutagenesis (SM) of the eight non-conserved residues lining the substrate 
binding pocket of, in this case, TycA yielded a mutant where the switch in substrate preference 
from L-Phe to L-Ala was 105 in total256. An L-Phe accepting A domain in the gramicidin synthetase 
that was mutated to accept non-natural aromatic substrates modified with azide and alkyne 
groups for subsequent chemical modifications via click reactions257. A single point mutation was 
sufficient to achieve a 105‐fold specificity switch towards the non-native substrate, without a 
great loss in catalytic efficiency. The alternative substrates were incorporated in vitro and in vivo 
into a diketopiperazine, even in the presence of the native substrate phenylalanine257. 
The most comprehensive and eventually also one of the most successful A domain engineering 
experiments combined several methods to make TycA accept (S)-β-Phe instead of the native 
L-Phe258. TycA was subjected to random mutagenesis of several residues of the active side in 
combination with rational shortening of a loop connecting β-sheets 13 and 14 based on the 
structure of VinN, an A domain naturally incorporating β-Phe. The resulting library of about 106 
variants was expressed and displayed on the cell surface of yeast. Successful variants of TycA 
that could activate and thiolate a clickable β-Phe were detected via an immunofluorescence 
labelling strategy and were identified in a FACS screen. When the most efficient variants were 
complemented with the downstream modules TycB and C, β-Phe-containing peptides were 
produced at a high level in vitro (~1 mmol) and yielded high titers in E. coli (~100 mg l–1). 
Engineering efforts of A domain specificity can also reduce the promiscuity of an NRPS: The 
fusaricin synhetase, for example, naturally produces a mixture of peptides by incorporating 
L-Tyr, L-Val, L-Ile, L-allo-Ile, or L-Phe at the third position. The peptide featuring L-Phe at this 
position is the most favorable for it has the highest antimicrobial activity. Thus to shift the 
equilibrium, the A3 domain was successfully mutated to match more stringent L-Phe 
incorporating A domains259. 
In conclusion, NRPS engineering via point mutations has the largest effect when mutating the 
specificity conferring code of the A domain, which is why these residues represent the most 
common target. An apparent advantage of this kind of NRPS engineering is the evasion of 
interfering with the native inter- and intramolecular cooperation of the assembly line. However, 
with the increasing number of studies using this approach, it became evident, that the A domain 
is not the only domain that determines which building block is incorporated. Instead, the 
acceptor side of C domains also governs this process to different extents. Moreover, the 
successful substrate specificity switch of an A domain usually comprised the exchange of 
standard amino acids of similar size and/or polarity. Thus, mutating the A domain binding pocket 
alone is not sufficient in many cases and further modifications e.g. through mutasynthesis, are 
helpful to ensure the altered A domain could also be re-integrated into the native cluster in vivo 
to produce the modified product. 
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 Subdomain modifications 1.3.6
Subdomain modifications are also targeted at A domains of NRPSs, for the same reasons and 
anticipated advantages as point mutations. However, for this type of modification, it is less 
obvious, what part of the domain to change, hence, there are fewer examples. 
In two different studies, the successful swap of the substrate binding pocket between A domains 
within the hormaomycin260 and the gramicidin261 synthetases were reported. In both studies, 
less conserved regions within the A domain were identified and used as integration sites for the 
heterologous substrate binding pocket. In the gramicidin synthetase, the subdomain (≠Asub) of 
the initiation module GrsAPhe was exchanged with nine different subdomains encoding various 
specificities. All chimeras could be purified, however only the integration of a Val specific binding 
pocket lead to adenylation activity and the formation of a Val-Pro diketopiperazine (cyclic 
dipeptide) when the downstream module GrsB was supplemented261. Note that also for this type 
of A domain modification, the reaction rate for the chimera was 300-fold slower than for native 
GrsA and the demonstration of in vivo activity is missing.  
Another A subdomain modification is the addition of a heterologous auxiliary domain into the 
naturally rather conserved site between A8 and A9 motifs. Two different methylation 
M domains, from KtzH(MH) and TioS(M3S), were inserted into the naturally uninterrupted 
A domain of Ecm6 from a Streptomyces strain262. In both versions, the A domain retained its 
activity in vitro and in addition the site-specific methylation patterns of the integrated M 
domains could be observed on the native substrate. From the engineering point of view, this was 
a great achievement. However, it remains questionable, whether the methylated substrate can 
be accepted and processed in the native context of the other Ecm modules. A previous attempt 
to exchange a complete uninterrupted A domain by an A(M) domain in a bimodular actinomycin 
NRPS caused a drastic decrease in the catalytic efficiency of the upstream C domain263.  
As for the point mutations, the success of A subdomain modifications largely depends on how 
well the modified domain can still interact with - and if the altered substrate can be processed 
by - the surrounding domains. If these two prerequisites are met, also for unknown reasons, 
even fusion sites within otherwise conserved domains can yield a functional chimeric enzyme. 
 Whole domain and module rearrangements  1.3.7
When rearranging whole domains and modules, an important aspect is finding the right fusion 
site between the non-cognate neighbors. Two different strategies are often employed: The first 
strategy is to find non-conserved regions for the fusion. The reasoning behind this strategy is 
that in un-conserved regions, changes have been tolerated during evolution, so an engineered 
fusion is unlikely to perturb an important function. The same strategy was also employed in the 
subdomain exchange described before261. The second strategy is based on the opposite 
assumption: a fusion site is searched in highly conserved regions, if both future neighbor 
domains share the same conserved sequence. Thus, the conserved sequence is supposed to 
maintain its role in the fused enzyme. The advantage of the second strategy is that fusion sites in 
conserved sequences can be located precisely within many NRPSs and therefore permit to fuse 
different NRPSs in the same position.  
For whole module rearrangements alongside the fusion sites between the individual domains, 
another aspect to consider is the composition of a module. Naturally, a C-A-PCP module 
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structure is assumed, however, a A-PCP-C module has also been successfully reengined264,265. 
Even a CC-term.-A-PCP-CN-term. module was reported very recently to serve as a general exchange 
module266. The anticipated advantage of exchanging whole modules is the functional 
cooperation within the native module to e.g. circumvent the problem of the C domain acceptor 
side gatekeeper function, if the C-A domains naturally belong together. On the downside, the 
native linker or interface between two adjacent domains is interrupted at the fusion site, which 
could lead to additional complications. Here I will summarize the engineering approaches 
starting with the exchange of individual domains, followed by di-domains and conclude with 
whole module rearrangements. 
A very early exchange of A domains of tyrocidine and bacitracin synthetases to produce custom 
dipeptides in vitro resulted in a product yield similar to the native excised dipeptide synthetase 
in vitro267. This result nurtured the hope that through A domain exchange any custom NRPS 
could be produced. However, this hope was soon damped. In a different study, the pyoverdine 
Pvd synthetase producing a fluorescent compound was used as a model NRPS. Substitution of 
the native PvdD A domain specific for threonine with different synonymous A domains produced 
high levels of wild type pyoverdine in vivo216,268. When substituting with non-synonymous 
A domains, however, the modified Pvd synthetase failed to produce any modified product, 
instead trace amounts of the original pyoverdine were detected216,268. This effect was attributed 
to the C domain again, condensing the native substrate which has been falsely activated by the 
substituted A domain, as described before252.  
PCP domains have been the target of domain exchanges as well. The Heidelberg team of the 
iGEM (international Genetically Engineered Machine) competition in 2013, supervised by 
Barbara DiVentura and Roland Eils, substituted the PCP domain of the indigoidine synthetase 
IndC (section 1.2.11) with PCP domains of other NRPSs and several synthetic PCP domains that 
have been rationally engineered from a multiple sequence alignment116. They found that most 
substituted PCP domains did not lead to the production of indigoidine, not even the PCP domain 
of the homologous BpsA could restore pigment production. However, one of the synthetic PCP 
domains successfully replaced the native one and was further investigated with regards to the 
substitution borders. The highest titer of indigoidine production was reached when the insertion 
was on the left side directly downstream of the A domain (A-PCP linker provided by the inserted 
PCP domain) and on the right side at the end of the PCP domain (native PCP-TE linker provided 
by IndC)116. These results suggest that also the linker regions play an important role for NRPS 
engineering. Another PCP domain exchange specifically investigated the switch between 
elongation and termination module PCP domains115. They found that substituting one for the 
other kind was not successful. A random mutagenesis of the unfunctional inserted PCP domain 
generated functional variants. Rescue of substrate production was particularly attributed to 
mutations at positions +4 and +24 from the active site serine. And indeed, in a multiple 
sequence alignment, these two positions showed a discrimination between PCPs interacting 
with downstream C domains in contrast to PCP domains passing on the substrate to 
TE domains115. A di-domain exchange study replacing the A, A-PCP, or PCP-E domains of TycA 
(Figure 1A) with variants from the bacitracin synthetase showed that engineered versions could 
epimerize the alternative substrates Trp, Ile, and Val in vitro at reduced efficiency269. The success 
of these di-domain substitutions also largely depended on the PCP domain substituted, which 
needed to be naturally followed by an E domain to yield an epimerized alternative product. 
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Thus, the PCP domain does not only discriminate between downstream C and TE domains, but 
also E domains269.  
Instead of exchanging (part of) modules of a large NPRS enzyme, communication domain 
relocation was also successfully used to change the order of NRP synthesis and thus the 
sequence of the peptide product. In this way, three modules of the surfactin, bacitracin and 
surfactin synthetases could be reconfigured with matching communication domains and indeed 
they produced the expected tri-peptides183, also in vivo270. Introduction of point mutations into 
the Com domains of the plipastatin synthetase changed their affinity for each other and thus the 
sequence of substrate incorporation. This resulted in the production of a variety of differently 
sized and arranged permutations of plipastatin271. While the modification or translocation of 
Com domains is a promising approach to NRPS engineering, it does not circumvent the problems 
such as interfering C domain specificity.  
Deletion of modules or translocation of the TE domain within an NRPS was shown to produce 
the expected cyclic NRP of decreased ring size for the surfactin synthetase272,273 and shorter 
cyclic as well as linear products of the plipastatin synthetase274. However, deletion of single 
domains or whole modules of plipastatin synthetase causes a module skipping process and 
thereby to an unexpected decrease of the product ring size by two building blocks instead of 
only the one that was deleted275, a phenomenon that was also observed in a natural NRPS276. A 
successful case of module addition to the balhimycin synthetase to turn the native heptamer 
into an octamer was accompanied by the loss of a P450 tailoring function and thus also provides 
the disadvantage of this engineering approach277. 
A very comprehensive set of studies with the aim to re-engineer the calcium dependent 
antibiotic (CDA) daptomycin synthetase135 to acquire improved variants included C-A di-domain, 
C-A-PCP module substitutions as well as deletion of auxiliary enzymes. Overall, about 120 
modified daptomycin synthetases were generated, 42 of which were produced in vivo at levels 
between 3-100% of the wild type and thus sufficient for purification and in vitro characterization 
of the antimicrobial efficiency278–281. In this way, one of the few examples of a modified antibiotic 
with improved characteristics actually produced by an engineered NRPS could be presented279.  
Whole module exchanges of the C-A-PCP unit were successful in the lichenysin synthetase282,283. 
The first, Gln specific module was exchanged for a Glu specific one to produce a modified 
lipocyclopeptide in Bacillus close to wild type levels282. Through the recombination of C-A-PCP 
units of the enniatin, beauvericin, and PF1022 fungal NRPSs, chimeric synthetases were created 
which produced the expected peptides in Aspergillus284. The latter example indicates that fungal 
NRPS modules might be less problematic to reengineer than the bacterial ones, which have been 
used in most studies to date.  
Choosing a different unit for the whole module exchange is another strategy that was 
introduced as a “XU” concept and used A-PCP-C units for the rearrangement. The basis for a new 
exchange unit was the discovery of a conserved motif within the C-A domain linker (WNATE) 
chosen as the fusion site, which lies within a flexible loop that is not otherwise responsible for 
interacting with its neighboring domains265. Based on this system, an exchange unit can only be 
followed by an alternative unit, where the A domain specificity matches the specificity of the 
natural downstream module, to ensure proper functioning of the C domain at the acceptor 
side265. Following these rules of using the conserved fusion sites and matching specificities, Bode 
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and co-workers successfully combined up to five modules of seven different NRPSs via 
homologous recombination in yeast and expressed them in E. coli. Several GameXPeptide285 (a 
cyclopentapeptide) derivatives as well as completely novel peptides were produced by these 
recombinant NRPSs in the one to two digit mg/l range265. An even more independent type of 
exchange unit is represented by CC-term.-A-PCP-CN-term., where the fusion site is located in the 
flexible hinge loop between the N- and C-terminal lobe of the C domain266. This second-
generation exchange unit (XU2.0) was reported to allow the free recombination of modules, 
quasi-independent from their native up- and downstream partner, because the C domain 
acceptor and donor side are always presented with their cognate substrate. In this way, different 
XU2.0 could be combined in yeast
247 to give rise to a NRPS library for GameXPeptide derivative 
production266. Finally, it was tested whether and how an elongation A domain can be turned into 
an initiation one for in vivo NRP production and found that in order to achieve this conversion, 
either the complete or at least the C-terminal lobe of the native upstream C domain needs to be 
present. When only the C-A domain linker was left at the N-terminus, no product was detected 
after expression in E. coli266. While in vitro neither the use of an elongation A domain as an 
initiation domain264 nor the combination of (C-A-PCP) modules of non-matching specificities34 
has caused the inactivity of the rearranged NRPS, this is the first time these achievements were 
reported in in vivo.   
 Open questions and problems of NRPS re-engineering 1.3.8
Nature has been very successful in exchanging NRPSs between species, reengineering them to 
produce novel and more potent bioactive molecules and even inserting external domains to add 
to the diversity of their products. We are not yet able to take advantage of the same strategies 
in the laboratory environment. The original hope in NRPS engineering was to elucidate general 
design rules to reliably modify these natural assembly lines to produce custom peptides and test 
them for enhanced bioactivity. If this is ever possible, as in evolution, only time can tell. 
Research up until now has identified diverse characteristics of NRPSs which can turn into pitfalls 
when trying to modify them as described in the previous sections. Among them are C domain 
specificity at donor and acceptor side, boundaries between the rearranged domains, turning 
elongation into initiation A domains, a discrepancy between results observed in vitro and in vivo, 
unforeseeable effects of neighboring domains, their interfaces and interdomain linkers. Some of 
these issues can be prevented by smart design engineering. Others can be resolved by directed 
evolution286, a process for which the 2018 Nobel Prize in chemistry was awarded to Frances 
Arnold, George Smith and Gregory Winter287. Following either strategy, a great number of 
variants need to be screened in order to find the active ones.  
Structural guidance for domain and module rearrangements has been provided by crystal 
structures of individual domains as well as multi-domain constructs trapped in a specific state by 
point mutations168 or mechanism-based inhibitors48,50,76,104. Each structure represents a staged 
snapshot of the synthesis process, but the overall movie has yet to be shot. One step in this 
direction was recently taken by comparing the crystal structure and negative stain electron 
microscopy (EM) images of a A-PCP-C tri-domain construct in complex with an MbtH-like 
protein76. The EM images supported the idea that domains within an NRPS module adopt many 
conformations and do not seem to exist in a set of well-defined states224. NMR studies provided 
insights into conformational changes in solution, but are limited to relatively small proteins and 
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therefore only individual PCP and TE domains or PCP-TE di-domains have been analyzed96,165,288. 
Thus, it is still unclear how individual modules are structurally and functionally embedded within 
the context of full-length or at least multi-modular truncated NRPSs. 
To sum up, a successful NRPS engineering approach according to the current state of the art 
includes a series of complementary considerations and experiments: (i) consider functional and 
structural knowledge for design engineering where possible; (ii) compensate unforeseen errors 
in the design using directed evolution; (iii) screen a sufficiently large number of engineered 
variants for activity at best in vivo. Using a combination of these approaches, maybe it is possible 
to come one step closer to generating NRPs with enhanced bioactivity via NRPS engineering. 
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2. Aims of the study 
The easiest readout for any kind of assay is color. Color can be detected by the bare human eye 
even quantitatively to a certain degree. Using relatively basic equipment, the amount of pigment 
causing the coloration of the cells or the medium can be precisely quantified. In this work I 
explore the possibility to append a unimodular NRPS that produces a blue pigment (Figure 6) at 
the end of any NRPS, be it engineered or natural. The idea is to use the color to easily monitor 
the production of the peptide in vivo, which would represent a break-through in projects aimed 
at engineering large libraries of novel NRPSs. The underlying assumption is that the pigment 
would be produced only if the upstream modules work together and the engineered peptide is 
made. The peptide would be tagged with the pigment. I, therefore, further assume that the 
pigment would not lose, but possibly change, its color once fused to other AAs. 
To achieve this goal, I set myself the following tasks: 
Analyze the blue pigment indigoidine and its synthetase 
As a pigment I chose indigoidine, which is produced by a standalone unimodular NRPS from two 
glutamine molecules. I aim to investigate two indigoidine synthetases, namely IndC and BpsA, in 
vivo and in vitro. Further I want to test whether I can assess the effects of modifications on the 
indigoidine synthetase via pigment quantification. In addition, I want to explore a putative 
synthetase of dodecylindigoidine (a naturally tagged-version of indigoidine) to see whether this 
enzyme could also serve our purpose. 
Construct fusions of single NRPS modules to the indigoidine synthetases IndC and BpsA to test if 
the tagging works  
In the second part, I aim to put 
the idea of tagging to the test. I 
will construct fusions between a 
module incorporating a certain AA 
and IndC/BpsA. To increase the 
chances of success, I selected a 
module from the tyrocidine 
synthetase incorporating 
asparagine that is naturally 
followed by a glutamine-
incorporating module. This part of 
the project will help me tackle 
open questions in NRPS 
engineering, such as (i) where to 
best fuse the two non-cognate 
NRPSs, (ii) how to turn elongation 
into initiation modules and vice 
versa and (iii) how mutations 
directed to a specific module 
affect this module and its neighboring modules. 
Figure 6 | Concept of tagging NRPSs with an indigoidine 
synthetase to monitor NRPS manipulations using an easy, 
visual readout.  
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Analyze inter- and intramodular communication 
Finally, beyond the tagging approach, I wish to address the question of how different modules 
interact with each other using constructs consisting of either one, two or three modules 
extracted from the same natural NRPS, in this case the tyrocidine synthetase. I aim at 
introducing point mutations on the A and PCP domains on a certain module and study their 
effects when the module is alone or connected with other modules. In this way I hope to gain 
further insights into the inter-, and intra-modular communication between NRPS modules which 
could be very important for future engineering approaches. 
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3. Materials and Methods 
3.1 Materials 
 Chemicals 3.1.1
Unless otherwise indicated, chemicals were purchased from Sigma-Aldrich (St. Louis, Missouri, 
USA) or Carl Roth (Karlsruhe, Germany). Kits for plasmid purification, DNA gel-extraction and PCR 
clean-up as well as the corresponding vacuum manifold were purchased from Qiagen (Hilden, 
Germany). For bacterial genomic DNA extraction, GenElute Bacterial Genomic DNA Kit (Sigma 
Aldrich) was used. Custom peptides were produced by PSL Peptide Specialty Laboratories 
(Heidelberg, Germany). Dansyl-L-glutamine was ordered from Santa-Cruz Biotechnology (Dallas, 
Texas, USA). Short, single-stranded custom DNA oligos (primers) were ordered from Sigma-
Aldrich. Long, double stranded custom DNA oligos were ordered as gBlocks® from IDT Integrated 
DNA Technologies (Coralville, Iowa, USA). As DNA vectors for replication and protein expression 
in E. coli I used pTrc99A289, pSB1C3290, pCDFDuetTM and pET-28(a)+ (both Merck, Darmstadt, 
Germany). For more details on the expression vectors, please see Table 3. Ni-NTA beads from 
Bio-Rad (Hercules, California, USA) were used for immobilized metal affinity chromatography in 
Poly-Prep® chromatography columns (also Bio-Rad).  
Table 3 | Vectors and their characteristics. 
Vector:  Resistant to: Other features: 
pTrc99A ampicillin 
Hybrid trp/lac promoter; IPTG inducible; pBR322 origin of 
replication 
pCDFDuet spectinomycin 
Two multiple cloning sites (MCS) each with an upstream 
T7 promoter, lac operator, and ribosome binding site 
(rbs); CDF origin of replication; lacI gene; IPTG inducible 
pET-28(a)+ kanamycin T7 promoter; IPTG inducible; pBR322 origin of replication 
pSB1C3 chloramphenicol 
pUC19-derived pMB1 origin of replication; IPTG inducible; 
T7 promoter 
pMiniHimar-
Rb1 
kanamycin 
Transposase under Plac promotor; R6K origin of 
replication; inverted repeats flanking “transposon” 
 
 Labware 3.1.2
Graduated Pipette Tips TipOne® in sizes of 10 µl, 200 µl and 1000 µl were ordered as re-fill packs 
from Starlab (Hamburg, Germany). Serological Pipettes Costar® Stripettes® in sizes 5 ml, 10 ml 
and 25 ml were purchased from Corning® (New York, USA). Single use polypropylene 14 ml tubes 
were bought from Greiner Bio-One (Frickenhausen, Austria). Reusable glass 14 ml tubes were 
provided by Schott Duran (DWK Life Sciences, Wertheim, Germany). Before each usage, 
glassware was cleaned and autoclaved. Glass bottles and flasks were provided by Schott Duran 
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as well. Micro reaction tubes with a safe lock lid in the volume of 1.5 ml and 2 ml were bought 
from Eppendorf (Hamburg, Germany). Micro reaction tubes with a volume of 0.2 µl were 
purchased as individual tubes and as 8-well tube strips from Starlab. BRAND® 1.5 ml PP screw 
cap tubes with an attached lid were purchased from Sigma-Aldrich. 15 ml and 50 ml reaction 
tubes were purchased from Greiner Bio-One (Cellstar®) or Corning (Falcon®). Clear 96 well plates 
(PlateOne, flat bottom) were bought from Greiner Bio-One as well. 
 Equipment 3.1.3
A set of mechanical pipettes (Tacta by Sartorius, Göttingen, Germany) to transfer small amounts 
of liquids were used in combination with graduated pipette tips for volumes between 0.5 µl to 
1 ml. An electric pipette boy (pipetboy comfort by Fisher Scientific) was used in combination 
with serological pipette tips to transfer volumes of 5 to 25 ml. Thermo Cyclers for DNA 
amplification were used from Bioyzym (LifeTouch Thermal Cycler) and Eppendorf (Mastercycler 
Nexus Gradient GSX1 Thermal Cycler). Separated DNA fragments in an agarose gel stained with 
GelRed were visualized in a UV chamber with attached CCD camera (both Intas Science Imaging 
Instruments, Göttingen, Germany). Tabletop centrifuges for 24 samples up to a volume of 2 ml 
were used from Beckman Coulter (Brea, USA), Microfuge 22R and 20R. For larger samples, the 
Allegra 25R and Avanti J-26XP also from Beckman Coulter were used. The tabletop thermo 
shaker PHMT was fabricated by Grant Instruments (Cambridge, UK). DNA and protein 
concentrations were measured on a NanoDropTM 2000c (Thermo Fisher Scientific). The pH of 
solutions was measured with a 50+ series bench pH meter by Chromservis (Prague, Czech 
Republic). Bacterial cells were lysed using a Sonopuls HD 2070 with ultrasound transducer 
UW 2070 with a MS 73 micro tip by BANDELIN electronic (Berlin, Germany). To remove water 
from samples to complete dryness, they were frozen in liquid nitrogen and dried in an Alpha 1-2 
LD plus lyophilizer by Christ (Osterode am Harz, Germany) attached to a chemistry hybrid pump 
by Vacuumbrand (Wertheim, Germany). Small molecule MS was performed on a micrOTOF II 
(Bruker: Billerica, Massachusetts, USA) by Heiko Rudy, IPMB. LC-MS of small molecules were 
performed on an Agilent 6100 Series (single Quadrupole, electrospray atmospheric pressure 
ionization) instrument with a Kinetex 2.6 m C18 column (Phenomenex, 50 x 2.1 mm). NMR 
spectra were recorded on a Varian Mercury Plus 500 MHz spectrometer and a Varian Mercury 
Plus 300 MHz spectrometer by Tobias Timmermann at the IPMB.    
 Enzymes   3.1.4
Restriction endonucleases, CutSmart buffer and the Gibson Assembly Master Mix were 
purchased from New England Biolabs NEB (Ipswich, Massachusetts, USA). The high fidelity DNA 
polymerase Phusion Flash High-Fidelity was used as the 2X PCR Master Mix from Thermo Fisher 
Scientific (Waltham, Massachusetts, USA). Lower fidelity Taq polymerase OneTaq® was used as 
the 2X Master Mix in standard buffer including loading dye from NEB. Random mutagenesis was 
reached using an error-prone Taq DNA polymerase and PCR conditions that favor the 
introduction of point mutations, all provided in the error-prone PCR reaction kit by Jena 
Bioscience (Jena, Germany). In vitro protein expression was tested with the PURExpress® Protein 
Synthesis Kit by NEB.  
Enzymes (and substrates) for the online pyrophosphate assay were all purchased from Sigma-
Aldrich. The reduced NADH powder was ordered from GERBU Biotechnik (Heidelberg, Germany). 
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 Bacterial strains 3.1.5
One Shot™ TOP10 Chemically Competent Escherichia coli were purchased from Thermo Fisher 
Scientific and used to prepare chemically competent E. coli in house. Lei Fang from the Pfeifer 
Lab (Prof. Blaine Pfeifer, Department of Chemical and Biological Engineering, University of 
Buffalo, USA) kindly provided the iGem team Heidelberg 2013 with the E. coli BAP1 strain109 
engineered from E. coli BL21(DE3) with a stably integrated PPtase (Sfp from Bacillus subtilis105). 
BAP1 cells were also made chemically competent in house. We used TOP10 cells for plasmid 
amplification and BAP1 cells for protein expression. 
Shewanella violacea DSS12 was provided by Institute Pasteur, Paris, France. E. coli EC100 pir+ is 
a cloning strain for plasmids with an R6K ori and was purchased from Epicentre Technologies 
(Madison, Wisconsin, USA). Both were used to experimentally validate the putative 
N,N-dodecylindigoidine synthetase dIndS. 
Photorhabdus laumondii luminescens (DSM 15139) and Streptomyces lavendulae lavendulae 
(DSM 40708) were ordered from DSMZ (Deutsche Sammlung von Mikroorganismen und 
Zellkulturen, Leibzig, Germany) as glycerol stocks. Bacillus amyloliquefaciens (DSM 7) genomic 
DNA was also ordered from DSMZ. Brevibacillus parabrevis (ATCC 8185) was kindly provided to 
the iGem team Heidelberg 2013 by Prof. Mohamed A. Mahariel (University of Marburg, 
Marburg, Germany). Bacillus subtilis 168 was generously provided by Dr. Ilka Bischofs-Pfeifer, 
MPI for Terrestrial Microbiology, Marburg, Germany. Prof. Dr. Erhard Bremer, Laboratory for 
Microbiology, Faculty of Biology, University of Marburg kindly provided us with Bacillus 
licheniformis DSM 13. Prof. Fussenegger sent us the expression plasmids for bpsA codon 
optimized for bacterial cells pMM6419. These strains and their genomic DNA served as 
templates to extract NRPS genes of interest.  
 Buffers, media and antibiotics 3.1.6
For DNA separation, TEA buffer (AppliChem) was bought as 10x stock solution. To prepare 
running buffer and 1 % agarose gels (LE agarose, Biozym, Hessisch Oldendorf, Germany), it was 
diluted to 0.5 % in deionized water. DNA was visualized using 1 % GelRed® (Biotum, Fremont, 
CA, USA) in the 6x DNA loading dye (TriTrack, Thermo Fisher Scientific) and in the DNA ladder 
(GeneRuler Ladder Mix, also Thermo Fisher Scientific).  
For protein separation, SDS-PAGE was performed using NuPAGE (Thermo Fisher Scientific) gels 
and 20x buffers. Depending on protein size, 10 % Bis-Tris, 4-12 % Bis-Tris or 3-8 % TA gels were 
utilized (1 mm thick) in combination with MES, MOPS or TA buffer diluted to 1x in deionized 
water.  
LB-Miller (lysogeny broth according to Miller) medium was prepared by dissolving 5 g/l Bacto™ 
yeast extract (Bacto Biosciences, Franklin Lakes, New Jersey, USA), 10 g/l Bacto™ Tryptone 
(Bacto Biosciences) and 10 g/l sodium chloride in ultrapure water (GenPure, TKA 
Wasseraufbereitungssysteme, Niederelbert, Germany). For LB agar plates, 12 g/l bacteriology 
grade agar (AppliChem, Darmstadt, Germany) was added. Before use, the medium was 
autoclaved at 121 °C for 20 minutes. Once cooled to below 40 °C, the desired antibiotic can be 
added to the medium. For agar plates, the medium was poured into petri dishes (Greiner Bio-
One) and allowed to harden at room temperature. Once the antibiotic is added, the medium is 
stored at 4 °C. 
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Antibiotics are used in the following concentrations (Table 4):  
Table 4 | Antibiotics concentrations in stock and working solutions. 
Antibiotic Stock solution  
[mg/ml] 
Dilution factor Working 
concentration  
[µg/ml] 
Ampicillin (AppliChem) 100  1:1000 100 
Chloramphenicol (AppliChem) 30 1:1000 30 
Kanamycin (AppliChem) 50 1:1000 50 
Spectinomycin (AppliChem) 100 1:1000 100 
 
Supplemented Difco Marine Broth 2216 (MB), pH 7.6, contains 5 g/l peptone, 5 g/l yeast extract 
(e.g. BD BactoI Yeast Extract, 212750), 2 g/l casamino acids and 100 ml 10x MB salt concentrate 
(1 g/L ferric citrate, 194.5 g/l sodium chloride, 59 g/l magnesium chloride, 61.6 g/l magnesium 
sulfate hexahydrate, 36 g/l calcium chloride hexahydrate, 5.5 g/l potassium chloride, 1.6 g/l 
sodium bicarbonate, 0.8 g/l potassium bromide, 0.571 g/l strontium chloride hexahydrate, 
0.22 g/l boric acid, 0.04 g/l sodium silicate, 0.024 g/l sodiumfluoride, 0.016 g/l ammonium 
nitrate and 0.100 g/l disodium phosphate 46ehydrate). For supplemented MB agar plates, 12 g/l 
bacteriology grade agar was added. 
M9 minimal medium was modified from the original recipe by Miller291. Our optimized version 
for NRPS production and pigment absorption measurements contained 1x M9 salts (M9-Minimal 
salts 5x, powder, SERVA, Heidelberg, Germany), 1 mM MgSO4, 0.5 % casamino acids (OmniPur®, 
Merck, Darmstadt, Germany) and 2 mg/ml Glucose. Antibiotics were added according to Table 4. 
The final M9 minimal medium was filtered prior to use.   
 Informatics tools 3.1.7
DNA sequences were handled with ApE, A plasmid Editor292, for gene and domain annotation, 
plasmid map construction, cloning strategies, sequencing result alignments and DNA sequence 
translation. Primer design for site directed mutagenesis was assisted by PrimerX293 according to 
the parameters described by Edelheit et al294. Protein sequences were aligned using Clustal 
Omega295 and protein parameters were estimated based on their sequence with ExPASy 
ProtParam296,297. Protein structures were downloaded from PDB298 or predicted in RaptorX299 and 
visualized in UCSF Chimera300. NRPS protein sequences were accessed from online databases 
Norine237, ClusterMine360160 and in general from NCBI301. NRPS A domain specificity prediction 
was predicted with NRPSsp61.  
The plate reader was programed, and data was recorded via the MagellanTM software (also 
provided by TECAN). Data analysis was performed in Excel (Microsoft, Redmond, Washington, 
USA). Graphics were created in InkScape302 and PowerPoint (Microsoft). Protein Alignments 
were made pretty in JalView303. NMR data was analyzed in the ACD/Labs (Toronto, Ontario, 
Canada) NMR Processor Academic Edition 12.0. The bibliography was created in Zotero304 and 
this Thesis was drafted in Word (Microsoft). 
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3.2 Methods  
 Prepare chemically competent E. coli 3.2.1
To prepare chemically competent E. coli, the desired strain was plated on an LB agar plate 
(without antibiotic if not otherwise indicated) and grown over night at 37 °C. Over the following 
day, the plate was stored at 4 °C before an individual colony was picked, transferred into 50 ml 
LB medium in a 200 ml glass flask and incubated overnight at 37 °C, shaking at 180 rpm. In the 
morning, 400 ml LB medium were inoculated with 4 ml overnight culture and grown at 37 °C and 
180 rpm to an OD600 of 0.5-0.6. In the meantime, 200 ml 100 mM CaCl2 and 20 ml 10 % glycerol 
in 100 mM CaCl2 were chilled on ice. About 200 1.5 ml micro reaction tubes were also precooled 
on large metal racks on ice and covered with aluminum foil to prevent contamination. Once the 
bacterial culture has reached the desired OD600, cells were pelleted in 50 ml reaction tubes for 
20 minutes at 4100 rpm at 4 °C. The supernatant was discarded and a washing step followed. On 
that account pellets were re-suspended in 5 ml ice cold 100 mM CaCl2 solution. After combining 
two pellet re-suspensions each per reaction tube, the volume was filled up to 50 ml with 
100 mM CaCl2 solution and incubated for 30 minutes on ice. Cells were then pelleted again at 
3500 rpm for 15 minutes at 4 °C and the supernatant discarded. All pellets were then combined 
in 10 ml 10 % glycerol in 100 mM CaCl2 and pipetted up and down until homogeneous. Another 
10 ml 10 % glycerol in 100 mM CaCl2 was added to the cell re-suspension up to a total volume of 
20 ml. Finally, 100 µl cell aliquots were dispensed in the pre-cooled micro reaction tubes with a 
multistep pipette (Multipette® plus, Eppendorf), frozen in liquid nitrogen and stored at -80 °C. 
 DNA amplification via PCR and purification 3.2.2
DNA fragments for molecular cloning were amplified using the Phusion Flash high fidelity DNA 
polymerase in a 2X reaction mixture. Primers (listed in section 6.1), template, ultrapure water 
and up to 3 % DMSO were combined according to the manufacturer’s instructions prior to 
adding the Master Mix in a 1:1 volume ratio. Samples were then placed in a thermal cycler 
running the following temperature cycles (Table 5). 
Table 5 | Temperature cycles for DNA amplification using 
high fidelity Phusion Flash DNA polymerase. 
 Temperature 
[°C] 
Time 
[s] 
1 - Initial Denaturing 98 10 
2 - Denaturing  98  1 
3 - Primer Annealing 49 - 72, 
primer 
dependent 
5 
4 - Elongation 72 15/kb 
5 - Final Elongation 72 20/kb 
 
Steps 2 to 4 were repeated 30 times. 
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Amplified DNA fragments were separated on a 1 % agarose gel stained with GelRed for 30 
minutes at 135 Volts in 0.5 % TAE buffer. A DNA ladder was run in parallel on each gel to 
estimate the DNA fragment size and bands were visualized in a UV chamber. DNA fragments of 
the expected size were excised from the gel using a scalpel and purified using a gel-extraction kit 
according to the manufacturer’s instructions. Purified DNA fragments were stored at -20 °C in 
ultrapure water. 
 Cloning via Gibson Assembly 3.2.3
Gibson Assembly is an isothermal reaction joining DNA fragments that contain an overlapping 
sequence  of minimum 16 bp with their adjacent piece of DNA246. We used a commercial 2X 
Gibson Assembly Master Mix to join purified DNA fragments. The necessary overlap was created 
by performing a PCR with primers that have the desired overlap as a non-complementary 
attachment at their 5` end. Vector backbones were obtained either via PCR or by classical 
restriction enzyme digest. The reaction itself was performed according to the manufacturer’s 
recommendations, with small adjustments. In short, all DNA fragments including the backbone 
were added in a micro reaction tube at a concentration of 0.01 pmol (the smaller the fragment, 
the higher the applied molar concentration) to a volume of 5 µl. To the DNA mix, the 2X Gibson 
Assembly Master Mix was added in a 1:1 volume ratio and the reaction mix was incubated at 
50 °C for 15 minutes to 1 hour, depending on the amount of DNA fragments to be joined. Finally, 
the reaction mix was diluted 1:4 in ultrapure water and transformed into chemically competent 
TOP10 cells.  
 Transformation 3.2.4
First, the desired plasmid was transformed into chemically competent bacterial cells. For that, 
0.5-4 µl purified plasmid DNA was combined with 25-100 µl thawed competent cells on ice and 
incubated for 5-30 minutes. The amount of DNA and cells as well as the initial incubation step on 
ice depend on the state of the DNA: For a retransformation of purified DNA plasmid, less 
DNA/cells and shorter incubation times were chosen while for a transformation of a DNA mix 
after Gibson assembly more DNA/cells were combined and a longer incubation time was 
allowed. Cell-DNA suspension was then heat shocked for 30 seconds at 42 °C, followed by 
incubation on ice for 2 min. For Ampicillin resistant plasmids, transformed cells were 
immediately plated out on a pre-heated LB agar plate containing ampicillin and incubated o/n at 
37 °C. For plasmids featuring a different resistance gene, 900 µl LB medium without antibiotic 
was added to the transformed cells and they were grown at 37 °C shaking at 180-200 rpm for 
one hour prior to being plated on the pre heated LB agar plate plus matching antibiotic and 
incubated at 37 C° o/n. Colonies on LB agar plates can be stored for up to 5 days at 4 °C. For long 
term storage, a glycerol stock was prepared and stored at -80 °C. 
 Colony PCR and plasmid extraction from positive clones 3.2.5
To check whether an E. coli colony contained the desired plasmid, we performed a colony PCR. 
Individual colonies were resuspended in 50 µl ultrapure water and 1 µl of this resuspension was 
used as a template for PCR. Primers were chosen to bind on two different fragments of the 
Gibson Assembly and amplify a sequence no longer than 4 000 bp. 0.5 µl of 10 µM forward and 
reverse primer were added to the template as well as 3 µl ultrapure water. As a DNA 
polymerase, we used OneTaq polymerase as a 2X Master Mix, which was added to the reaction 
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mix in a 1:1 ratio and run in a thermal cycler according to the manufacturer’s instructions (Table 
6). Steps 2 to 4 were repeated 30 times. Expected fragment size was checked on a 1 % agarose 
gel. 
Table 6 | Temperature cycles for DNA amplification 
using Taq polymerase. 
 
 
Temperature 
 [°C] 
Time 
[s] 
1 - Initial Denaturing 95 300 
2 - Denaturing  95  15 
3 - Primer Annealing 49 - 68, 
primer dependent 
15 
4 - Elongation 68 60/kb 
5 - Final Elongation 68 60/kb 
 
Positive clones were picked and used to inoculate a 4 ml overnight culture in LB medium plus the 
appropriate antibiotic. The desired plasmid was then extracted from the bacterial cells using the 
QIAprep Spin Miniprep Kit (Qiagen). DNA sequence was verified via Sanger sequencing at GATC 
(Konstanz, Germany). Purified DNA plasmids were stored at -20 °C in ultrapure water. A list of 
plasmids which were used or generated in this work is provided in section 6.2. 
 Cultivation of Shewanella violacea and whole genome extraction 3.2.6
Untargeted gene disruption of Shewanella violacea was performed by Konrad Herbst as 
described before305. Conjugation of S. violacea with the disruptive pMiniHimar-RB1 plasmid was 
performed at 8, 12 and 18°C and plated out with a dilution factor of 1:10, 1:10 and 1:100 
respectively as described in the internship protocol of Konrad Herbst221.  S. violacea with 
disrupted genomes were incubated on kanamycin containing supplemented marine broth (MB) 
agar plates for 2 weeks at 8°C. Subsequent storage of these plates at 4 °C for several weeks lead 
to darker pigmentation of some of the colonies. To identify the disrupted genes, four pigmented 
and four non-pigmented colonies were picked and grown in supplemented MB medium plus 
kanamycin to an OD of minimum 0.6 at 180 rpm and 8 °C. The cells were harvested and whole 
genome extraction was performed using the GenElute Bacterial Genomic DNA Kit (Sigma Aldrich) 
according to the manufacturer’s instructions. To identify the disrupted genes, two approaches 
were chosen: Firstly, the extracted genomic DNA was digested with BamHI, religated and 
transformed into electro-competent E. coli EC100 pir+ to recover DNA fragments which have the 
transposon construct integrated. Secondly, I was specifically looking for an integration event 
within the putative dIndS gene, so I performed a PCR across the putative gene using three 
primer pairs spanning whole sequence. In case transposon integration happened, the PCR 
product should be longer (~4.5 kbp instead of 2 kbp). 
 Site-directed mutagenesis 3.2.7
For site-directed mutagenesis, I modified a protocol developed by Edelheit et al.294 Forward and 
reverse primers containing the desired mutation were designed according to the conditions 
proposed in their publication. Two separate PCR reactions were set up in a total of 10 µl each, 
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both containing the template plasmid, one with the forward primer and one with the reverse 
primer. DNA plasmids containing the mutation were thus amplified linearly as a single stranded 
DNA fragment by the Phusion Flash polymerase master mix. After the PCR, both reactions were 
combined, denatured and slowly re-annealed to favor the annealing of forward and reverse 
strands containing the mutation. The reaction was then digested over night with DpnI according 
to the manufacturer’s recommendations to eliminate the template plasmids. Finally, the 
reaction mix was transformed into TOP10 cells and mutations were verified by Sanger 
sequencing.  
 Random mutagenesis via error-prone PCR 3.2.8
To perform directed evolution, I chose error-prone PCR to randomly introduce mutations solely 
into a desired DNA sequence. I used the error-prone PCR kit by Jena Bioscience and followed the 
manufacturer’s instructions. Since the maximum optimal length for random mutagenesis with 
the polymerase provided in this kit is 4 000 bp (oral communication from Jena Biosciences), 
longer PCRs were split up into two reactions using overlapping primers for Gibson Assembly. 
Mutated DNA fragments were then purified like described before and inserted into a non-
mutated backbone via Gibson Assembly.  
 Bacterial glycerol stock  3.2.9
To prepare a glycerol stock, an individual colony of the bacterial cells transformed with the 
desired plasmid(s) was used to inoculate 4 µl LB medium plus suitable antibiotic. The bacterial 
culture was grown o/n at 37 °C shaking at 180-200 rpm. After 16-18 hours, 800 µl o/n culture 
were combined with 200 µl 100 % Glycerol, transferred by a trimmed 1000 µl pipette tip, into a 
1.5 ml tube with screw cap. The glycerol stock was then stored at -80 °C. 
 Small scale protein expression and absorption measurement 3.2.10
Small scale protein expression was mainly performed to screen new fusion NRPSs for their ability 
to produce the blue pigment indigoidine. I found the colorless M9 minimal medium to be best 
suited for protein expression as well as detecting the produced pigment via absorption 
measurement afterwards. Thus, a starter culture consisting of 4 ml LB medium plus antibiotic 
was inoculated with a single colony of plasmid transformed into the expression cells BAP1 and 
grown o/n at 37 °C shaking at 180-200 rpm.  
After 16 to 18 hours, 3 ml M9 minimal medium plus suitable antibiotic were inoculated with 6 µl 
of the overnight culture and grown at 37 °C and 200 rpm to an OD600 of 0.8-1.0. Cultures were 
then cooled down on ice for 5 minutes before inducing protein expression by adding 0.5 mM 
IPTG. Further, proteins were expressed at 18 °C and 200 rpm for 18-24 hours. The absorption of 
200 µl overnight culture in a clear 96 well plate was then measured in the plate reader from 300 
to 800 nm.  
 Calculation of indigoidine production from absorption of  the overnight culture 3.2.11
In a smallscale overnight expression culture, (engineered) NRPSs are expressed, post-
translationally modified with a PPant arm on a specific serine within each T domain and thus 
potentially active in the expression strain.  Since the project aimed to easily identify functional 
engineered NRPSs via a blue pigment tag, the readout of indigoidine synthesis should be easy as 
well. Therefore, I measured the absorption of the overnight expression culture and calculated 
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the relative amount of blue pigment according to Myers et al306. The absorption maximum of 
indigoidine lies at 600 nm, which is the same absorption at which you typically measure bacterial 
cell density. Thus, to assess the amount of pigment independently from the cell density, I 
measured the absorption of 200 µl overnight expression culture in a clear 96 well plate in the 
TECAN plate reader at both, 600 and 800 nm. The ratio δ between OD600 and OD800 of a 
negative control sample (e.g. no blue pigment expression or an un-induced sample) was 
calculated and used to infer the relative amount of indigoidine in the samples of interest as 
follows: 
                                                              
Each construct was expressed in triplicate, induced from the same overnight culture, and 
relative pigment production was calculated. For IndC or BpsA wild type the OD800 was elevated 
due to the high absorption at 600 nm and thus the OD800 of the respective negative control was 
assumed for relative pigment amount calculation. Finally, the relative pigment production of all 
samples was normalized to the wt indigoidine synthetase. In order to take small changes in the 
procedure into account, like cell density of the overnight culture or duration of expression, one 
negative and one positive control were expressed in parallel for each batch of small-scale 
protein expression. In that way, distinct calculation of pigment production per experiment could 
be performed. 
 Calculation of indigoidine concentration from absorption values 3.2.12
The molecular extinction coefficient of indigoidine195 in DMF is ε = 23400 M–1 cm–1 and can be 
used to calculate the approximate indigoidine concentration from an absorption measurement. 
                 
     
       
 
 Large scale protein expression 3.2.13
Large scale expression cultures were set up to purify the NRPSs of interest. In this case, an 
overnight culture was set up from an individual colony like previously described and 800 µl 
overnight culture was used to inoculate a 400 ml LB medium in a 1 l flask. The expression culture 
was grown at 37 °C shaking at 180-200 rpm for about 3 h to an OD600 of 0.8-1. Once this OD 
was reached, the incubator was cooled to 18 °C for about 30 minutes. Once this temperature 
was reached, protein expression was induced with 0.5 mM IPTG. Proteins were expressed for 18 
to 20 hours before being harvested in 400 ml centrifuge tubes at 4000 g and 4 °C for 30 minutes. 
Supernatant was discarded and the cell pellet was frozen (either plain or re-suspended in buffer) 
at -80 °C.  
 His-tag based affinity protein purification 3.2.14
Proteins were all equipped with a hexa-histidine tag (His6-tag) and purified via immobilized 
metal affinity chromatography using Ni-NTA beads. The cell pellet of a 400 ml overnight 
expression culture of the desired protein was resuspended in 12 ml lysis buffer (50 mM TRIS or 
HEPES, pH at 4 °C adjusted to 7.5, 5 mM imidazole, 500 mM NaCl and 12.5 % glycerol) and frozen 
at -80 °C for a minimum of 12 hours. Resuspended pellets were then thawed at room 
temperature (about 25 °C) shaking lightly until the solution was almost free of ice crystals. All 
further steps were performed on ice or at 4 °C. Thawed samples were lysed via sonication 
(100 % power, 3 min, 30 s intervals, 6/10s pulses) and cleared for 35 minutes at 15 000 rpm and 
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4 °C. The supernatant containing the desired protein was added to 1.5 ml to 2 ml of Ni-NTA 
beads in 50 % water (so 0.75 to 1 ml of pure beads) and incubated for 2 h gently shaking at 4 °C 
for the proteins to bind to the beads. The bead slurry was added to chromatography columns 
and the supernatant was eluted via gravity flow. The beads were washed twice with 3-4 column 
volumes of lysis buffer. Finally, the protein was eluted in two steps with 1.5 column volumes 
elution buffer (50 mM TRIS or HEPES, pH at 4 °C adjusted to 7.5, 250 mM imidazole, 500 mM 
NaCl and 12.5 % glycerol). Different fractions of the eluate were collected manually and 0.75 µl 
were spotted onto a nitrocellulose membrane (Thermo Fisher Scientific). The membrane was 
then stained for 5 minutes in Ponceau S solution to identify the fractions with the highest 
protein concentration. Those fractions were pooled and added onto Amicon® Ultra 0.5 ml spin 
columns with a 100, 50 or 10 kDa MWCO, depending on protein size (Merck). Purified proteins 
were then concentrated and buffer exchanged to storage buffer (50 mM sodium phosphate 
buffer, 20 % glycerol, pH 7.25 at 4 °C) five to ten times at 14 000 rpm for 7 minutes at 4 °C. In 
this way, smaller protein contaminations were also reduced. Proteins were then either stored at 
4 °C for immediate use in an in vitro assay or glycerol content was increased to a total of 40 % 
and proteins were stored at -20 °C. Protein amount was measured via absorption at 280 nm and 
molar concentrations were calculated through division by the molecular weight of the respective 
protein.   
 Protein separation via SDS-PAGE 3.2.15
Size analysis of proteins of interest was performed via SDS-PAGE. For a quick expression check, 
400 µl of overnight expression culture were pelleted at 13 000 g for 2 minutes. The supernatant 
was discarded and the pellet was resuspended in 30 µl 1x FastBreak™ Cell Lysis Reagent 
(Promega, Madison, Wisconsin, USA) to lyse the cells. 10 µl 4x NuPAGE™ LDS Sample Buffer 
(Thermo Fisher Scientific) were added to each sample before denaturing the proteins for 
10 minutes at 95 °C. Before loading into the gel’s wells, samples were spun down at 19 000 g for 
10 minutes to pellet the DNA and only load the protein containing solution. For size comparison, 
one lane with Precision Plus Protein™ Dual Color Standards (Bio-Rad) was run in parallel to all 
samples. For 15 well gels, 10 µl sample was loaded per pocket, for 10 well gels, 20 µl sample was 
loaded into each pocket. The type of gel was determined by the predicted protein sizes to be 
separated. Gels were run in the matching 1x buffer in the electrophoresis chamber at a constant 
180 Volts for one hour. The plastic support around the gel was then removed and the gel stained 
in a Coomassie staining solution (0.1% Coomassie Brilliant Blue G-250 (Thermo Fisher Scientific), 
50 % methanol and 10 % glacial acetic acid) for 30 minutes to 1 hour, shaking lightly. Protein 
bands became visible after destaining the gel overnight in deionized water. Gel bands were 
documented with a CCD camera (iPhone 5, Apple, Cupertino, California, USA) against a white 
background.  
For SDS-PAGE of purified proteins, the procedure was very similar. A small sample was diluted in 
50 mM TRIS buffer, loading dye was added to 1x final concentration before denaturing the 
proteins at 95 °C. The DNA pelleting step could be omitted and the remaining steps were 
performed as described above. 
All proteins in this work, from small scale expression to purified proteins were checked for 
expression and the correct size on an SDS-PAGE. Only in cases where it added particular 
information did I show these gels.  
Materials and Methods 
53 
 
 In vitro NRP formation by purified enzymes 3.2.16
After successful purification, BpsA and its TycC:BpsA fusion constructs were used to form their 
products in vitro. The basic components needed include the reaction buffer (TRIS, pH 7.5-7.9 or 
sodium phosphate buffer, pH 8), ATP (between 0.5 – 5 mM), MgCl2 (between 2 – 20 mM), 
substrate (between 0.1 – 1 mM) and enzyme (between 0.1 – 3 µM). For the formation of 
indigoidine, a higher pH of around 8 is beneficial, possibly to aid the autocatalytic re-oxidation of 
FMNH2 to FMN.  
 Coupled online Pyrophosphate release assay and kcat calculation 3.2.17
The coupled online pyrophosphate release assay was performed to measure A domain activity of 
purified NRPSs under different conditions and with different substrates70. In short, successful 
substrate activation by the NRPS A domain leads to the release of one pyrophosphate PPi, which 
is the first substrate in a cascade of enzymatic reactions ultimately leading to the oxidation of 2 
β-NADH to 2 NAD+. Since NADH absorbs strongly at 340 nm while NAD+ does not, amino acid 
activation by NRPS A domains can indirectly be assessed by measuring the decrease of 
absorption at 340 nm in the online pyrophosphate assay. 
Enzymes and substrates for the online PPi release assay were purchased from Sigma-Aldrich 
followed by dilution or resuspension in 50 mM TRIS-HCl (Table 7). All amino acids were 
dissolved in water. 
Table 7 | Components for the online pyrophosphate assay, their amount, volume of TRIS, 
pH 7.5, needed to prepare the stock solution, stock concentration and final concentration. 
Component amount V [ml] Cstock Cfinal 
D-Fructose 6-phosphate disodium salt 
hydrate 
100 mg 1.1 300 mM 3 mM 
Fructose-6-phosphate Kinase,  
Pyrophosphate-dependent  
from Propionibacterium freudenreichii 
(shermanii) 
10 UN 0.5 20 U/ml 0.1 U/ml 
Aldolase from rabbit muscle 100.29 U 1 100 U/ml  1 U/ml 
Triosephosphate Isomerase  
from rabbit muscle 
33 651 U/ml        3.7 2 500 U/ml 5 U/ml 
α-Glycerophosphate Dehydrogenase  
from rabbit muscle 
200 UN 0.29 500 U/ml 5 U/ml 
ATP (pH ~6.5) 5 g  0.1 M 0.5 mM 
MgCl2   100 mM 2 mM 
Amino acid(s): N, Q, V, O, K, L,  
Dipeptides: NQ, AQ, GQ, dansylQ 
(in100 % DMSO) 
Tripeptide: dFNQ 
  0.1 M 1 mM  
ß-NADH (Gerbu Biotechnik) 1 g   0.1 mM 0.8 mM 
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The online PPi release assay itself was performed in a total volume of 100 µl in 50 mM TRIS-HCl 
buffer, pH 7.5 at 30 °C in a 96 well plate. Per NRPS to be analyzed, a master mix was created by 
adding the buffer first, followed by other components except the NADH, amino acids and 
enzyme. The amino acids were dispensed in the individual wells of the 96 well plate in a volume 
of 5 µl (to be 1 mM in the total reaction volume). Finally, NADH and the enzyme of interest (to 
final concentrations between 0.5 µM and 3 µM) were added. The master mix was mixed by 
inverting the tube and 95 µl were dispensed in each well of the plate. After combining the 
master mix with the substrate, the reaction is started and the 96 well plate is placed in the plate 
reader, where the absorption at 340 nm is measured over time. Each enzyme-substrate 
combination and the respective negative control (without amino acid) were measured in 
triplicate. kcat values were calculated like described by Kittilä et al
70 in Excel. The decrease in 
absorption at 340 nm was fitted in the linear range (ΔOD340 min
-1) and divided by the arithmetic 
product of the molar extinction coefficient of NADH92 (ε340(NADH) = 6 220 M
-1 cm-1), the path 
length d (100 µl per well in a flat bottom 96 well plate ~0.2 cm), the enzyme concentration 
cenzyme (in µM) and the factor 2, due to two NADH being converted per PPi release.  
     (
         
  
                      
) 
For each enzyme-substrate combination, the mean kcat value of three measurements was 
calculated and background subtracted by the mean value of the negative control. The error was 
determined by subtracting the negative control standard deviation SD from the sample SD, 
including error propagation (             √            
          
  ).  
 Thiolation assay using radiolabelled amino acids  3.2.18
(Experiments were performed by Florian Meyerthaler, Mootz lab, Institute for Biochemistry, 
WWU Münster) 
Thioester formation of radiolabelled leucine was investigated according to a modified protocol7. 
Enzymes were mixed at 0.5 µM in a total volume of 100 µL TRIS HCl (pH 7.5) together with 10 
mM MgCl2, 2 mM TCEP, 2 mM L-Val and/or L-Orn, 10 µM L-Leu (980 pmol of non-labelled and 
20 pmol of [3H]-L-Leu (Hartmann Analytics, Braunschweig, Germany)). The reaction was started 
by adding 5 mM ATP and quenched after 1 min with ice-cold 800 µL TCA (10 % trichloroacetic 
acid solution). Proteins were coprecipitated with 15 µL ice-cold BSA (25 mg-1ml-1 solution) and 
pelleted for 30 min at 13 000 rpm. The pellets were washed twice with 800 µL ice-cold TCA and 
resuspended in FA (10 % formic acid solution). After addition to 3 mL scintillator liquid, the 
amount of radiolabelled leucine covalently attached to the PPant arm of the respective enzyme 
was measured in a scintillation counter (Beckman Coulter LS 6500 Liquid Scintillation Counter). 
 Indigoidine extraction from E. coli  3.2.19
Indigoidine extraction from an E. coli overnight culture co-expressing an indigoidine synthetase, 
IndC or BpsA, and a PPtase (Sfp) was performed according to a modified protocol described by 
Yu et al307. The fermentation broth was centrifuged for 30 minutes at 4 000 g resulting in a pellet 
consisting of indigoidine and bacterial cells. The pellet was lyophilized in vacuo. The dried pellet 
was resuspended in pure DMSO causing the indigoidine to dissolve, in contrast to the cell debris. 
In another round of centrifugation for 30 minutes at 4 000 g, the solution was cleared of the 
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non-dissolvable components and the indigoidine containing supernatant was passed through a 
0.45 µM Durapore® PVDF membrane spin filter (Merck).  
 Identification of indigoidine via MS and NMR spectroscopy 3.2.20
Indigoidine, dissolved in 100 % DMSO either extracted from bacterial expression culture or 
pelleted after an in vitro reaction, was diluted with 100 % methanol in a 1:1 ratio before applying 
the sample on a micrOTOF-Q II mass spectrometer. Mass to charge ratios (m/z) were scanned 
between 50 to 1 200 in positive or negative ion mode. The nebulizer was set to 0.4 bar, the dry 
heater at 200 °C and the dry gas at 4 l/min.  
For 1H NMR measurement, the pelleted indigoidine was dissolved in deuterated DMSO-[D6] 
(VWR chemicals, Radnor, Pennsylvania, USA) and subjected to a frequency of 300 or 500 MHz at 
25 °C by Tobias Timmermann at the IPMB. The resulting spectrum was analyzed in the NMR 
Processor Academic Edition 12.0 by ACD/Labs.  
 Identification of substrate intermediate on PPant arm of NRPS mutants 3.2.21
In order to elucidate the mechanistic details of indigoidine formation by the respective 
synthetase or one of its fusion constructs with TycC, we sought to identify intermediate 
substrates stuck on the PPant arm or the active site Serine of the TE domain via mass 
spectrometry (Thomas Ruppert, ZMBH, Core facility for Mass Spectrometry and Proteomics). We 
followed a modified protocol described by Henderson et al122. In detail, we purified the protein 
of interest as described in section 3.2.13 followed by a buffer exchange of 1 µM protein into 
100 µl of 50 mM TEAB and 6 M Urea, pH 7.3. At 25 °C, the protein was first digested with 1 % 
Lys-C for 4 h. The solution was then diluted 1:5 in 50 mM TEAB (pH 7.3) and digested with 1 % 
Trypsin at 25 °C overnight. A last digestion step using 1 % Glu-C was performed after another 1:5 
dilution with 50 mM TEAB (pH 7.3) for 4 h at 25 °C. The resulting peptides were subjected to an 
LC-MS and peptide identification was performed by Thomas Ruppert.  
 BpsA and TycC5-6:BpsA product formation followed by liquid-chromatography coupled 3.2.22
mass spectrometry (LC-MS) 
(Experiments were performed with Aubry Miller, Cancer Drug Development Group Leader, DKFZ, 
Heidelberg) 
The formation of the respective products was analyzed by LC-MS. Enzymes (3 µM) were mixed in 
sodium phosphate buffer (pH 8, final volume of 50 µL) with 20 mM MgCl2, 1 mM L-Asn and 
1 mM L-Gln and incubated at 25 °C. With the addition of 5 mM ATP the reaction was started and 
after 16 h stopped by removing the enzyme in a 10 kDa MWCO spin filter. The samples were 
pelleted (14 000 rpm, 10 min). For enzymes producing a blue pigment, the supernatant was 
discarded and the pigment was redissolved in 100 % DMSO to load on the LC-MS. For enzymes 
expected to form a peptide, the supernatant was injected onto the LC-MS. 10 µL were subjected 
to the LC-ES-API-MS (Agilent 6100 series, Single Quadrupole, electronspray atmospheric 
pressure ionization). The MS was used in negative mode together with a Kinetex 2.6 m C18 
column (30 °C). For indigoidine, the gradient ran from 0 to 6 min from 99 % A and 1 % B to 
10 % A and 90 % B at a flow rate of 0.6 min-1. For the expected Asn-Gln dipeptide, the solvent 
composition ran for 1 min at 99 % A and 1 % B followed by a wash of 100 % B within 3 min at a 
flow rate of 0.6 min-1. Solvent A contained H2O with 0.01 % FA (formic acid) and B 100 % 
acetonitrile with 0.01 % FA. Extracted ion traces of the small molecule masses were recorded. 
TycC 8-, 9-, 10 product formation followed by liquid-chromatography coupled mass 
spectrometry 
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 TycC 8-, 9-, 10 product formation followed by liquid-chromatography coupled mass 3.2.23
spectrometry  
(Experiments were performed by Florian Meyerthaler, Mootz lab, Institute for Biochemistry, 
WWU Münster) 
The formation of the respective peptide products was analyzed by LC/MS. Enzymes (3 µM) were 
mixed in TRIS-HCl buffer (pH 7.5, final volume of 20 µL) with 10 mM MgCl2, 2 mM TCEP, 100 µM 
L-Val, 100 µM L-Orn and 100 µM L-Leu and incubated at 37 °C. With the addition of 5 mM ATP 
the reaction was started and after 1 h quenched with 10 µL of formic acid. The samples were 
pelleted (13 000 rpm, 5 min), the supernatant mixed with 20 µL acetonitrile and 10 µL were 
subjected to the LC-ESI-MS (Agilent 6130B Single Quadrupole). The MS was used in positive 
mode together with a NUCLEODUR® HILIC column (27 °C, gradient from 0 to 3 min of 95% B, 3 to 
23 min of 95% to 50% B, from 23 to 25 min of 50% B and from 25 to 28 min of 50% to 95% B). 
Solvent A contained H2O, 0.15% FA and 10 mM ammonium formate and B H20, 95% acetonitrile, 
0.15% FA and 10 mM ammonium formate. Extracted ion traces of the peptide masses were 
recorded.
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4. Results 
In this chapter I will show the experimental results I have obtained. I will start with the 
investigation of two homologous indigoidine synthetases to shed more light on how they 
produce the blue pigment with special emphasis on how modifications influence this process in 
vivo and in vitro. I will focus on how I used the pigment synthetase(s) to tag a module extracted 
from the tyrocidine synthetase and fine-tune this system to link upstream NRPS modifications to 
the level of pigment production in E. coli and pyrophosphate release in vitro. In the third part of 
the results, I will present further NRP-indigoidine fusion synthetase engineering approaches, also 
using modules of other NRPSs to be tagged and testing a dodecylindigoidine synthetase for its 
use as a tag. Finally, I will present results obtained by studying constructs of increasing size and 
complexity consisting of one, two or three modules extracted from the tyrocidine synthetase to 
which point mutations have been applied on A and PCP domains. 
4.1 Analysis of two homologous indigoidine synthetases  
The two homologous indigoidine synthetases I investigated are IndC from Photorhabdus 
luminescens and BpsA from Streptomyces lavendulae ATCC 11924. They share 49.1% sequence 
identity and 64.5% similarity on the protein level. Yet, their domain composition is the same 
(Figure 4A). One major difference is that IndC features 23 cysteines, while BpsA only has 
6 cysteines in total. I amplified the indC gene directly from the genomic DNA of Photorhabdus 
luminescens and inserted it into the bacterial expression vectors pCDFDuet and pTrc99a. The 
DNA sequence of BpsA was provided as a codon optimized version for expression in bacterial 
cells (with 25.6% base pairs changed in comparison to the genomic DNA) by the Fussenegger lab. 
I changed the backbone for BpsA expression to pTrc99a.   
 IndC and BpsA produce the blue pigment indigoidine in E. coli and in vitro 4.1.1
The expression of IndC in BAP1 cells, which have the promiscuous PPtase Sfp stably integrated in 
their genome, leads to the formation of the functional holo-enzyme that produces the blue 
pigment indigoidine (Figure 7B, C). I verified that the pigment is indigoidine by measuring its 
mass via ESI-MS with the help of Heiko Rudy (IPMB, Heidelberg) (Figure S 1) and its composition 
via 1H NMR with the help of Tobias Timmermann (IPMB, Heidelberg) (Figure S 2). Both were as 
expected for indigoidine202. 
For in vitro analysis of the indigoidine synthetases, I optimized the purification procedure based 
on existing protocols108,202. In contrast to BpsA, IndC has not been purified before. Since it 
harbors almost four times as many cysteine residues as BpsA, the addition of 5 mM 
dithiothreitol (DTT) as a reducing agent was necessary to prevent intramolecular disulfide bond 
formation leading to a locked conformation of the enzyme and thus inactivation. I purified both 
indigoidine synthetases in their holo-version from BAP1 cells. Both formed the blue pigment in 
vitro upon addition of the substrate glutamine, ATP and MgCl2 (Figure 7D). The correct 
composition of indigoidine was verified via 1H NMR (Figure S 3). Since BpsA has been more 
frequently used for in vitro studies, does not require reducing agent for purification and was 
reported to withstand storage at -20 °C215, this homologue was used for further in vitro studies. 
For analysis of pigment production in vivo, IndC is equally suited, since the cytoplasm of E. coli 
naturally is a reducing environment308,309 and is thus able to keep IndC in the active state. 
Effects of mutations to the indigoidine synthetase can be evaluated by pigment production 
levels in E. coli 
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 Effects of mutations to the indigoidine synthetase can be evaluated by pigment 4.1.2
production levels in E. coli 
With the aim in mind to use the indigoidine synthetase as a C-terminal tag for an NRPS to 
monitor the outcome of its re-engineering, I examined whether I could monitor the effects of 
mutations to the pigment synthetase itself via indigoidine relative quantification upon 
expression of the mutated enzyme in BAP1 cells. 
In order to evoke a change in pigment production and, at the same time, gain insights into the 
indigoidine production mechanism, I chose to mutate key residues of IndC and BpsA. Some of 
the residues are crucial to all NRPSs; others are conserved only among indigoidine synthetases 
and are thus interesting for my purposes (Table 8). I introduced all mutations via an established 
protocol294 that I adapted using overlapping forward and reverse primers that carry the desired 
mutation. I expressed the mutated constructs in BAP1 cells overnight and quantified pigment 
production relative to a negative control and normalized to the wild type level (Figure 8).  
All mutations within the A domain core motifs completely prevented pigment production, which 
is what I expected given the crucial roles of the mutated residues (Table 1). The mutation of the 
conserved serine of the PCP domain, which cannot be PPantylated anymore, also lead to a 
complete abrogation of indigoidine formation in both homologues. For the oxidation domain, 
some of the point mutants did not lead to color formation (N571S in IndC), while others did not 
have a significant impact (Y603A/F in BpsA) despite being part of the conserved Ox1 sequence. 
Contrary to what was expected, the mutation of the conserved lysine from the Ox1 motif did not 
completely abrogate indigoidine formation in IndC (K605E), even less so when the positively 
charged lysine (K) was mutated to the neutral alanine (A) instead of to the negatively charged 
Figure 7 | Indigoidine produced in E. coli and in vitro. (A) Indigoidine 
synthetases convert two glutamine molecules into the blue pigment 
indigoidine. (B,C) Expression of IndC in E. coli BAP1 cells leads to blue 
pigment production on LB-agar plates and in liquid culture, respectively. 
(D) Indigoidine production followed in vitro via the increase in absorption 
at 600 nm over time. Enzymes were added at 1 µM, Q at 100 µM in 
50 mM TRIS, pH 8, with 20 mM MgCl2 and 5 mM ATP. For the purification 
of IndC, 5 mM DTT was added to each buffer. 
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glutamic acid (E). Only in combination with another point mutation within the same motif 
(Y615A) did it inhibit indigoidine production in IndC. In BpsA, however, K600E did have the 
destructive effect as previously reported202.  
Table 8 | Overview of the mutations introduced into IndC and BpsA. Amino acids (AA) are 
represented by their one letter code. Mutations are described in the format AAwtpositionAAmut. 
domain  consensus sequence Mutation in IndC Mutation in BpsA 
A  A3: LAYxxYTSG(S/T)TGxPKG T179A/S180A  
A  A7: Y(R/K)TGDL D414A D410L 
Ox  conserved222 N571S  
Ox  Ox1: KYxYxSxGxxY(P/G)VQ K605E/A K600E 
Ox  Ox1: KYxYxSxGxxY(P/G)VQ K6005-Y615  
Ox  Ox1: KYxYxSxGxxY(P/G)VQ  Y603A/F 
A  A10: NGK(V/L)DR K922A  
PCP  [I/L]GG[D/H]SL S980A S974A 
TE  GXSXG S1108A/C S1103A/C 
TE 
 
conserved 
A1135D 
A1135D/P1136A/G1137E 
A1131D/G 
 
In the TE domain, mutation of the conserved serine to either alanine or cysteine again eliminates 
pigment production. This observation was unexpected since this serine is not involved in the 
suggested synthesis mechanism of indigoidine (Figure 4C), despite being part of the catalytic 
triad found in many NRPSs. In addition, it does not serve a structural role, so I deduce that in fact 
it might be involved in the synthesis, possibly even in the tranditional role of transiently storing 
the intermediate substrate before its release (as described in section 0). The alanine which was 
mutated within the TE domain is conserved among all indigoidine synthetases. Other NRPSs and 
the putative dIndS feature an aspartate in this position, as part of the catalytic triad S-H-D. In 
IndC, mutating this alanine to aspartate abrogated indigoidine formation. Additionally, replacing 
the following two residues P and G by A and E to match this part of dIndS had the same effect 
(Figure 8). In BpsA, the same A1131 to D mutation decreased indigoidine production by 81% but 
did not prevent it completely. When I replaced the neutral alanine by the neutral glycine instead 
of the negatively charged aspartate, the decrease in pigment formation compared to the wt was 
even less (Figure 8). This indicates that a small, neutral amino acid might be required in this 
position for indigoidine production, while the residue found most often in this position, 
aspartate, partially or even completely prevented product formation. For BpsA, an SDS-PAGE of 
an overnight expression sample of the wt and all mutants is shown in Figure S 4. Note that the 
wild type BpsA and all mutants that still produced close-to-wt indigoidine levels exhibited a 
lower enzyme expression level. This is possibly due to a mild antimicrobial effect of 
indigoidine209 leading to slower cell growth of the expressing cells and thus to a lower enzyme 
level.  
Effects of mutations to the indigoidine synthetase can be evaluated by pigment production 
levels in E. coli 
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The slightly negative values of the absorption at 600 nm can be attributed to the formula I used 
to quantify the pigment306 (section 3.2.11) where the ratio δ between OD600 and OD800 is 
calculated for the negative control (here, two empty plasmids), multiplied with the OD800 of the 
sample of interest and subtracted from OD600, where the potentially produced pigment would 
absorb. Thus, the negative control, which does not express any proteins, can proliferate more 
quickly than the samples expressing the large enzymes. The overall absorption of the negative 
control as well as the ratio δ are higher than for un-pigmented sample cells of a lower density 
and thus the overall calculated absorption at the pigment maximum can be below zero. 
In conclusion, it is possible to investigate the effect of point mutations on indigoidine 
synthetases through quantification of the pigment produced by the respective variant in vivo. 
Analysis of corresponding mutations to IndC and BpsA revealed that even two homologue NRPSs 
do not necessarily react in the same way to the same perturbation. 
 
Figure 8 | Effects of point mutations in IndC 
and BpsA on pigment production. Bar graphs 
show the background-subtracted absorption at 
600 nm of the indicated mutants after 
overnight expression in BAP1 cells normalized 
to the wild type synthetase. n = 3 +SD.  
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 Analysis of BpsA mutants in vitro reveals which mutants are still capable of continuous 4.1.3
substrate activation 
Having observed the differences in pigment production of two indigoidine synthetases in vivo 
based on absorption measurements, I further investigated BpsA and its mutants in vitro. kcat 
values for glutamine activation were calculated from the online PPi release assay and 
summarized in Figure 9.  
In Figure 9A, the averaged raw data of the absorption of 1 µM BpsA wt converting 0 (grey), 
0.1 (red), 0.5 (green), or 1 mM glutamine (blue) from triplicate measurements at 340 and 
600 nm is shown. The absorption at 340 nm (circles) illustrates the decrease in NADH, which is 
coupled to the release of PPi via an enzymatic cascade (Figure 3E). This measurement serves as 
the basis to fit the steady PPi release per minute in the linear range, subtract the background 
signal (Q = 0, grey) from the samples and then calculate the kcat values (Figure 9B). Absorption at 
600 nm (triangles) illustrates the pigment formation, which can be measured in parallel (Figure 
9A). From the molecular extinction coefficient of indigoidine (though given in DMF) I calculated 
the production rate, which was 6.05 indigoidine min-1 for 1 mM glutamine converted by 1 µM 
BpsA. Thus, according to product formation, 12.10 glutamine molecules were activated per 
minute, which is about three (2.97) times less than the activation rate according to the PPi 
release assay (35.98 min-1).  
As forecasted from the in vivo absorption measurement (Figure 8), BpsA wt had the highest 
activation rate when fed with the substrate glutamine, which amounted to 35.98 min-1. The 
mutation of the ATP binding residue in the A7 motif (D410 to leucine (L)) indeed prevented ATP 
Figure 9 | A domain activity of BpsA wt and mutants in presence of glutamine. (A) Absorption 
at 340 nm (circles) and 600 nm (triangles) of 0 mM (grey), 0.1 mM (red), 0.5 mM (green) and 
1 mM (blue) glutamine and 1 µM BpsA wt over time. Curves represent the mean of three 
replicates in 100 µl, ±SD in matching transparent color. The absorption at 340 nm was taken as 
the basis to calculate the kcat for BpsA wt. (B) The bar graph shows the kcat values of the indicated 
BpsA variants after background (no Q) subtraction calculated from the online PPi release assay. 
Enzymes were added at 1 µM, glutamine (Q) at 1 mM. The inlay shows a zoom into the lower 
value bars. n = 3 +SD. 
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binding and set the kcat value to zero (Figure 9B, inlay). The oxidation domain mutant, which in 
vivo showed no pigment formation, is in vitro still able to activate glutamine at the rate of 
14.02 min-1, corresponding to about 38% of the wt. This finding suggests that activation comes 
before oxidation during indigoidine production. If thiolation also occurs before the oxidation 
step would need to be assessed in a separate thiolation assay. PCP and TE domain mutations led 
to a drastic decrease in substrate activation. For other NRPSs it was shown that they can also 
activate their substrates without the presence of the PCP domain, but for BpsA, this domain 
seems to have an influence also on the substrate activation rate. The same is true for the TE 
domain. While it is not assigned any responsibility in the proposed indigoidine production 
process, a mutation of the conserved serine in the TE domain prohibited pigment formation in 
vivo and repeated substrate activation in vitro, highlighting it as essential. The A1131 to D 
mutation in the TE domain did not completely abrogate pigment formation in vivo (Figure 8), 
which is supported by the in vitro kcat value of 1.17 min
-1 and a retained but strongly affected 
product formation ability leading to a maximum absorption at 600 nm of 0.012±0.001 au in 
100 µl (not shown) in comparison to 0.281±0.002 au for wt BpsA (Figure 9A, 1 mM, background 
subtracted). 
Overall, the online PPi release assay can provide additional information about the ability of 
modified NRPSs to repeatedly activate their substrate. Thus, for engineered or mutated 
indigoidine synthetases  this assay adds to the understanding of the functionality gained from 
the visible pigment production.  
 Activation of dipeptide substrates by BpsA and its mutants 4.1.4
Since I want to create an NRP-indigoidine fusion synthetase possibly producing indigoidine-
tagged amino acid(s), I explored the option of creating such a molecule by feeding a di- or 
tripeptide with glutamine (Q) at its C-terminus (Figure 10A) to BpsA.  
In comparison to the native substrate Q, dipeptides glycine-glutamine (GQ), alanine-glutamine 
(AQ) and the fluorescently labelled dansyl-glutamine (dansylQ) were activated by wt BpsA in 
vitro at significantly lower rates (Figure 10B). For GQ and AQ, even a slight increase in absorption 
at 600 nm was detected indicating that a pigment was formed. The amount of pigment was too 
low to be purifed for further analysis. Increasing the incubation time and the reaction volume 
did not improve the yield. Thus, I was unable to identify the pigment that was produced by BpsA 
from the dipeptide substrates. In an early attempt to produce indigoidine-tagged amino acids, 
NQ was fed to IndC and incubated for 72 hours at 25 °C. The blue pigment produced was 
identified via MS as pure indigoidine (m/z [M-H]- 247.0) without asparagine attached. In the 
supernatant, the substrate dipeptide NQ (m/z [M-H]- 259.0) as well as the individual fragments, 
Q (m/z [M-H]- 145.1) and N (m/z [M-H]-  131.0), were detected. Thus, I could not yet clarify 
whether the substrate dipeptide NQ decomposed on its own over time and IndC converted the 
Q fragment to indigoidine, or the NQ fragmentation was enzymatically induced by IndC, actively 
splitting N from Q to produce pure indigoidine. BpsA did not activate the dipeptide NQ (or only 
to a very low degree within the large standard deviation) or the tripeptide dFNQ 
(D-phenylalanine-NQ, Figure 10B), again uncovering a difference between the two indigoidine 
synthetases.  
Dipeptides AQ and dansylQ were then presented to one BpsA mutant of the Ox domain (K600E) 
and two of the TE domain (S1103A and A1131D) and their activation rate was assessed from the 
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PPi release assay (Figure 10C) and compared to the activation of Q. The TE domain mutants 
activated the dipeptides at similar rates as the native substrate Q. The Ox domain mutant 
activity towards the dipeptides however was greatly reduced, from 12.9 min-1 to almost zero for 
AQ (Figure 10C). This indicates that the Ox domain might be involved in modifying a XQ (where X 
stands for any amino acid) dipeptide to be accepted by BpsA, e.g. through detachment of the 
upstream amino acid from Q.  
Taken together, these results suggest that indigoidine synthetases cannot form indigoidine-
tagged amino acids from dipeptide substrates, because the N-terminal amino acid is split off 
either non-enzymatically or through an enzymatic process likely involving the Ox domain.     
Figure 10 | Activation of different dipeptides by BpsA wt and mutants. (A) 
Scheme of an example dipeptide XQ serving as a substrate for BpsA to produce 
indigoidine-tagged X, where X stands for any amino acid. (B) Bar graphs show the 
activation rate of BpsA wt and (C) BpsA mutants towards the indicated di- and 
tripeptides in comparison to the native substrate Q (Figure 9B) as calculated from 
the online PPi release assay. Substrates were added at 1 mM, BpsA and its mutants 
at 1 µM. n = 3 ±SD.   
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4.2 Development of an asparagine-indigoidine fusion synthetase to 
monitor the effects of upstream module manipulation with a visual 
readout 
In the following part of the thesis, I will describe how I created a novel fusion enzyme between 
the asparagine incorporating module of TycC and an indigoidine synthetase (IndC or BpsA). 
Further, I evaluated and improved the fusion enzyme(s) to find the best version to investigate 
the effects of upstream module modifications, such as point mutations or different N-terminal 
start sites, on the downstream pigment synthesis through absorption measurements. In order to 
be able to link the upstream module modifications to pigment production levels, there is one 
major prerequisite that needs to be fulfilled: the pigment needs to be produced exclusively if the 
upstream module is functional. Ultimately, with these experiments I intend to test if an 
indigoidine synthetase can be genetically fused to any multimodular engineered or native NRPS 
to monitor the functionality of the upstream NRPS modules via pigment formation. 
In the following sections I will describe the different fusion sites and other engineering aspects I 
followed while creating the asparagine-indigoidine fusion synthetase. Therefore, I will give a 
quick overview of how I annotated these fusion constructs, because there is no general 
annotation agreed upon in the field of NRPS research yet. Residues are represented by the single 
letter amino acid code. I numbered the AAs in the unimodular enzymes, namely IndC, BpsA and 
dIndS, starting from the first methionine (M1). For the tyrocidine synthetase and other larger 
NRPSs, the numbering starts at the position where the beginning of the domain is predicted to 
be (by Pfam310) and is, therefore, domain-dependent. Residues before or after the domain 
border are annotated by “+” for downstream or “-“ for upstream. The name of the NRPS that is 
used in a fusion construct is written as normal text. The individual domains of the NRPS, which 
are part of the fusion enzyme, are given in parenthesis and connected with hyphens. The last 
residue of a domain, the so-called fusion site, is separated by an underscore “_”. Protein fusion 
sites are represented by a colon “:”. The asparagine-indigoidine fusion synthetases without any 
fusion site specifications will be called TycC(AAsn-PCP-C-AGln):IndC/BpsA or TycC5-6:IndC/BpsA. 
 Expression of different TycC5-6:IndC fusions leads to fusion-site-dependent pigment 4.2.1
production 
In the search of a good starting point for a prototype NRP-indigoidine fusion synthetase, I turned 
to the well-studied tyrocidine synthetase (Figure 1). I tried to circumvent the complications 
arising when two modules, which do not naturally belong together, are fused, e.g. the additional 
proofreading activity of the C domain. Thus, I decided to use the modules TycC5, specific for 
asparagine (N), and TycC6, specific for glutamine (Q) (Figure 1). The indigoidine synthetase does 
not feature an N-terminal C domain. For this reason, in the fusion synthetase, the C domain is 
contributed by TycC6, naturally condensing N and Q and thus possibly able to cooperate with 
the indigoidine synthetase, also processing glutamine.  
For an initial screen, I generated ten different TycC5-6:IndC constructs fused together at 
different residues within the AGln of TycC6 and IndC, where the N-terminal part is still 
contributed by TycC6 and the C-terminal part by the indigoidine synthetase (Figure 11A). I 
amplified the desired gene fragments from the genomic DNA of Brevibacillus Brevis and 
Photorhabdus luminescens and assembled them without scars using Gibson Cloning311 into the 
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pCDFDuet(MCS2) expression vector. As an N-terminal start site for all constructs, I chose the 
“Q-167”, 167 AA upstream of the TycC5 AAsn domain. This start site was originally suggested by 
the Heidelberg iGem team in 2013312. For most fusion constructs, I generated the PCP domain 
mutant of module TycC5 (PCPAsn S28A), mutating the conserved serine to an alanine as described 
before for IndC and BpsA (Table 8). This mutant serves as a control, to try to ensure from the 
beginning that I select for fusions, which only produce a pigment if the upstream module is 
working. I expressed the different fusion constructs and their respective PCPAsn mutants in E. coli 
BAP1 cells overnight, calculated the background (= IndC PCP mutant)-subtracted absorption of 
each variant at 600 nm according to Myers et al.306 and normalized all values to IndC wt pigment 
levels (Figure 11B).  
In general, the more of IndC is left intact within the TycC5-6:IndC fusion, i.e. the less of the AGln 
domain of TycC6 is included, the more pigment is produced. For the iGem fusion, where IndC is 
left complete and added directly after the TycC6 condensation domain, the pigment production 
level is just as high as for wt IndC. While pigment production of the NRP-indigoidine synthetase 
is necessary to use it as readout for NRPS engineering, it also needs to be ensured that no 
pigment is produced, in case the upstream module does not work. However, for the first three 
fusion sites, Asn module inactivation through the mutation of the PCP domain does not result in 
a drastic decrease of pigment production. This leads me to the conclusion that if the indigoidine 
synthetase, which is naturally a standalone NRPS, is left intact, it can produce indigoidine much 
faster than any potential asparagine-indigoidine fusion, which is why the upstream PCP domain 
mutation does not have much of an effect on pigment production. I confirmed this assumption 
by purifying and analyzing the produced pigment of the TycC(AGln_T-161):(M1) and 
TycC(AGln_V-37):(N3)IndC fusion enzymes via ESI-MS. Instead of indigoidine-tagged asparagine 
(calculated exact mass of C18H20N8O8: 476.14), I identified pure indigoidine (calculated exact 
mass for C10H8N4O4: 248.05, found in ESI
-: [M-H]- 247.0) for both. 
Fusion sites closer to the middle of the two AGln domains, which were partially inspired by the 
successful A subdomain swap by Kries et al.261 (section 1.3.6), did not produce any pigment when 
used as a TycC5-6:IndC fusion site. Thus, I also did not create the corresponding PCPAsn mutants 
for comparison. Moving the fusion site further towards the A domain C-terminus, incorporating 
more of the TycC AGln and less of the IndC AGln, namely into the A7 core motif (“D372:L415”) and 
upstream of the large Acore domain, between A7 and A8 (“R395:G438”), did lead to a pigment 
production level above the background (Figure 11B, inlay). These levels amounted to 2-3 % of 
those obtained by wild type IndC. However, for these two fusion constructs, the inactivation of 
the upstream Asn-incorporating module through PCP domain mutation resulted in a substantial 
decrease in pigment formation. This characteristic makes these two TycC5-6:IndC fusions the 
best candidates for the development of an artificial NRP-indigoidine synthetase suitable for 
high-throughput screening of upstream NRPS engineering approaches monitored via absorption 
at  600 nm. Fusion sites even further downstream, on the Asub domain, post A8 core motif and 
within the Asub-Ox domain linker did not produce any pigment suggesting that these fusion sites 
lead to inactive enzymes (Figure 11B, inlay). 
Overall, I identified several TycC5-6:IndC fusion constructs which can produce a blue pigment, 
two of which have the desired characteristic of showing less pigment formation upon upstream 
PCP domain mutation. 
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 The N-terminal start site can have (minor) effects on pigment production 4.2.2
Another critical point in NRPS engineering, next to the fusion site of two recombined modules, is 
the new artificial start site. Since there is no apparent difference in the sequence of initiation 
and elongation A domains, it is hard to estimate how to turn the second into the first266. I 
Figure 11 | Pigment production of TycC5-6:IndC constructs fused together at different sites 
within the AGln domain and their respective PCPAsn mutants. (A) Scheme of a TycC5-6:IndC 
synthetase including the position of the fusion site within the AGln domain, where X indicates the  
C-terminal position of TycC AGln and Y the N-terminal position of IndC AGln, and explanations why 
they were chosen. (B) Absorption at 600 nm measured after overnight expression of the 
indicated fusion constructs and their PCPAsn mutants from pCDFDuet(MCS2). The background 
was subtracted, and values are normalized to the absorption of IndC wt. The inlay shows the 
absorption of the last five fusion constructs enlarged. The start site of all constructs is the same 
(TycC(Q-167_AAsn). n = 3 +SD. 
Results 
67 
 
addressed this question using the two most promising TycC5-6:IndC constructs described above 
(section 4.2.1, fusion sites “D372:L415” and “R395:G438”, in pCDFDuet(MCS2)): I exchanged the 
original start site ((Q-167)TycC5) with other start sites and measured the absorption at 600 nm 
after overnight expression in BAP1 cells, relative to the negative control (IndC PCP mutant, 
S980A) (Figure 12).  
Including the native upstream C domain (M1) and artificially adding the first 28 amino acids from 
the tyrocidine initiation module (TycA(M1-S28):(I-5_AAsn)TycC) increased pigment production 
about two fold for the “D372:L415” fusion site (Figure 12A), but only slightly for the 
“R395:G438” fusion construct (Figure 12B), in comparison to the “Q-167” start site, which is 
located directly downstream from the TycC5 C domain, including the complete linker region. 
Start site “I-30” mimics the length of the TycA N-terminus and reached a similar pigment 
production level for the “R395:G438” fusion (Figure 12B). I did not test it for the “D372:L415” 
fusion. Conversely, I tested start sites “Y-18” and “MLA:Y-18”, where residues L and A were 
added upstream of “Y-18”, both resembling the IndC N-terminus, solely for fusion site 
“D372:L415”. Both do not differ much in pigment production level from the “Q-167“ start. 
Neither does the fusion construct starting at “I-5”, without the TycA part added (Figure 12A). 
With this screen I showed that one can indeed evaluate the influence of the N-terminal start site 
of an upstream module on the downstream module pigment production of an artificial 
dimodular TycC5-6:IndC fusion construct. It seems that keeping a native start site, either by 
leaving the upstream C domain in place or by adding the sequence of the native initiation 
module TycA, can improve pigment production. However, this was only observed for one of the 
two fusion constructs questioning whether it is a general concept. What this screen cannot tell, 
is if the TycC5 A domain is indeed functional in vivo with the tested start sites, or wether it rather 
Figure 12 | Different N-terminal start sites can influence pigment production 
of TycC5-6:IndC fusion constructs in E. coli. TycC5-6:IndC fused together at (A) 
D372:L415 and (B) R395:G438, featuring different artificial N-terminal start 
sites, were expressed in E. coli BAP1 from pCDFDuet(MCS2). Bar graphs show 
their relative absorption at 600 nm in comparison to the background (empty 
vector). n = 3 +SD. 
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provides a stable N-terminus for the indigoidine producting module, since I am lacking the proof 
of product formation or substrate activation. For this reason, I recreated a sole indigoidine 
synthetase by fusing only the TycC6 AGln part to IndC and testing different A domain start sites 
(section 4.2.3).  
 A TycC6(AGln):IndC fusion can recreate an indigoidine synthetase  4.2.3
For the reconstitution of an indigoidine synthetase consisting of the N-terminal part of the TycC 
module 6 AGln domain and the C-terminal part of IndC, I used the same internal fusion site that 
was successful for the TycC5-6:IndC hybrid enzyme: TycC6(AGln_D372):(L415)IndC. Different start 
sites for this fusion construct were then created and the chimeras were expressed in BAP1 cells 
overnight. Absorption at 600 nm for the different constructs were calculated relative to the 
background set by the IndC PCP domain mutant S980A (Figure 13). The hybrid TycC6:IndC did 
not yield much pigment when it started at “Q-167”, which worked well for the TycC5-6:IndC 
fusion construct. Start sites “S-42”, “A-7” and “V1”, which is the first residue of the AGln domain 
according to Pfam, did not drastically increase pigment production (Figure 13). Adding the IndC 
N-terminus (M1-M27) or setting the start to the corresponding amino acid “L-19” of the native 
C-AGln linker did result in an increase of more than 0.1 au relative to the other start sites. Note 
that the TycC6:IndC hybrid indigoidine synthetase starting at “Q-167” does not produce much 
pigment, while shortening the N-terminus to start at “L-19” (corresponding to TycC5(AAsn_Y-18), 
Figure 12A) leads to a remarkable increase in pigment production. Both observations are in 
contrast to the TycC5-6:IndC fusion construct and the effects on pigment production of the 
corresponding start sites (Figure 12), again indicating that discoveries about one NRPS module 
are not generalizable to others, not even within the same NRPS. Adding a native N-terminus, this 
time from IndC, also increases pigment production. To find out whether this N-terminus indeed 
serves a role in IndC, I removed the first 20 amino acids (start site “A21”, corresponding to “A-7” 
of TycC AGln) or the first 26 amino acids (start site “M27”, corresponding to “V1” of TycC AGln) of 
IndC and compared the pigment production levels to those of IndC wt (Figure S 5). Both 
truncations did not lead to a decrease in pigment production in comparison to the wt IndC 
(Figure S 5), indicating that this sequence does not play a crucial role, neither for IndC stability 
nor activity. 
Figure 13 | Pigment production 
of a reconstituted indigoidine 
synthetase TycC6:IndC largely 
depends on the N-terminal start 
site. Absorption at 600 nm of an 
overnight expression culture of 
the indicated hybrid enzymes 
relative to the negative control 
(IndC PCP mutant, S980A) from 
pCDFDuet-MCS2. X indicates the 
tested start site. n = 3 +SD. 
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These TycC6:IndC hybrid enzymes are a reconstruction of a native indigoidine synthtase. Thus, it 
is clear that if the TycC AGln module could be successfully turned into an initiation module, this 
fusion enzyme produces the blue pigment. Therefore, all start sites of constructs for which 
indigoidine production was observed, are suitable to turn this natural elongation A domain into 
a starter A domain in vivo. In contrast, for the TycC5-6:IndC start sites (section 4.2.2), I could not 
draw the same conclusion, since from the in vivo pigment production it is not clear whether the 
TycC5 AAsn domain successfully acted as an initiation A domain. We cannot support the finding of 
the Bode group that a natural elongation A domain needs part of or the whole native C domain 
upstream to function as an initiation A domain in vivo266.  
 Changing the expression backbone and indigoidine synthetase used in the fusion 4.2.4
improves its properties 
The best candidate for a fusion enzyme so far is TycC(Q-167_AAsn-PCP-C-AGln_R395):(G438)IndC, 
since it is able to produce a detectable amount of pigment, which is abolished upon upstream 
PCPAsn domain mutation. However, this construct also suffers from the very low pigment 
production of about 3% of the IndC wild type (Figure 11B, inlay). Thus, I aimed to improve these 
aspects of the most promising hybrid enzyme using various approaches, some of which will be 
presented later (section 4.3).  Here I show the improvement obtained when changing expression 
backbone (from pCDFDuet(MCS2) to pTrc99) and indigoidine synthetase (from IndC to BpsA). 
TyccC(Q-167_AAsn-PCP-C-AGln_R395) was fused to (G438)IndC or to (G434)BpsA and expressed 
from either pCDFDuet(MCS2) or pTrc99 in BAP1 cells. Absorption at 600 nm of the overnight 
expression culture was measured and calculated in relation to the negative control (Figure 14). 
The original TycC(Q-167_AAsn-PCP-C-AGln_R395):(G438)IndC expressed from pTrc99 produced 
more pigment than when expressed from pCDFDuet. However, pigment production of the PCPAsn 
mutant also increased when expressed from pTrc99, though it is still only about half of the wt 
production level. Using BpsA in the hybrid enzyme resulted in an even higher pigment level, 
while at the same time decreasing the absorption at 600 nm for the PCPAsn mutant. This makes 
TycC(Q-167_AAsn-PCP-C-AGln_R395):(G434)BpsA the perfect candidate for further investigations. 
Figure 14 | Influence of the indigoidine 
synthetase homologue and the expression 
backbone on pigment production of 
TycC5-6:indigoidine synthetase fusion 
constructs and their PCPAsn mutants. Bar 
graphs show the absorption at 600 nm of the 
indicated hybrid enzyme in the indicated 
vector relative to the negative control 
(PCPGln domain mutant of the respective 
indigoidine synthetase in the respective 
backbone). n = 3 +SD. 
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 Mutational analysis of TycC5-6:BpsA fusion reveals different effects of Asn-4.2.5
incorporating module inactivation on pigment production in vivo and in vitro 
I further investigated the most promising fusion construct for asparagine-indigoidine tagging, 
TycC(Q-167_AAsn-PCP-C-AGln_R395):(G434)BpsA, by analyzing the effects of different point 
mutations in the different parts of the chimeric enzyme on pigment production in vivo (Figure 
15A, B). 
To inactivate the Asn incorporating module 5 of TycC, I mutated the aspartate of the core motif 
A7 to alanine (AAsn D370A) and the conserved serine of the PCP domain to alanine (PCPAsn S28A), 
as described before (Figure 14). Surprisingly, the AAsn domain mutant produced similar levels of 
pigment as the “wt”, in contrast to the PCP domain mutant that produced very little indigoidine 
(Figure 15B). From the analysis of the corresponding A domain mutations in IndC and BpsA, I 
expect the A domain activity of this mutant to be abrogated; however this does not seem to 
influence the downstream pigment producing module. I confirmed this observation by mutating 
other residues within the core motifs A3, A7 and A10 of the TycC5-6:IndC hybrid enzyme (Figure 
S 6). To ensure this difference of TycC5 inactivation via A domain versus PCP domain mutation is 
not due to an unintended additional mutation, I sequenced the complete insert of the three 
variants and did not detect any difference in the sequence other than the intended point 
mutations. Further I checked the overnight expression cultures via SDS-PAGE for large 
differences in protein expression level or mutant solubility but did not detect any anomaly 
(Figure 15C). Consequently, I conclude that this distinct effect of TycC5 inactivation on 
downstream pigment production is indeed accounted for by the intrinsic behavior of the 
TycC5-6:BpsA/IndC fusion enzyme. 
Mutation of the second histidine of the conserved C domain motif HHxxxDG to an alanine 
(CAsn-Gln-H129A) leads only to a minor decrease in pigment production which might indicate that 
it is not crucial in the condensation reaction between Asn and Gln or that condensation reaction 
does not occur. Opposed to the corresponding mutation in TycB (section 1.2.9), this mutant is 
not insoluble, indicating that in TycC5-6 C domain, the second His of this conserved motif does 
not play a structural role. To inactivate the Gln-incorporating module via A domain mutation, the 
core motif A7 was chosen again which is located on the TycC6 part of the fusion construct. 
D372 to A mutation of the hybrid AGln leads to a complete abrogation of pigment formation 
revealing that the fusion between TycC6 and BpsA is functional and cooperates with the 
downstream PCP and TE domains towards product formation, which is inhibited upon A7 motif 
mutation. Almost all mutations of the BpsA part of the hybrid enzyme also resulted in loss of 
pigment production as expected from the analysis of the corresponding mutations in wild type 
BpsA (Figure 8). Only the TE-A1131D mutation behaved differently in that it also completely 
lacked pigment production, while in wild type BpsA it still produced indigoidine to a lower 
degree. 
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Overall, it seems that despite the observation that the N-terminus and PCP domain mutation of 
TycC5 do influence pigment formation of the TycC5-6:BpsA fusion construct, it is not clear 
whether this tagging approach works. Most data collected so far rather suggests, that the 
TycC6:BpsA part is able to produce indigoigine per se and without the input of the upstream 
TycC5 module. 
In vitro analysis of TycC5-6:BpsA mutants shows a discrepancy between in vitro and in vivo 
behavior 
To analyse the TycC5-6:BpsA wild type and mutant fusion proteins in vitro, I expressed and 
purified them from E. coli BAP1 cells, which should result in the holo-version of the enzymes 
with the PPant arm attached to the PCP domain due to the co-expressed PPtase Sfp. I then used 
them in an online PPi release assay and calculated the kcat values upon feeding no substrate 
(negative control), only asparagine (N), only glutamine (Q) or a combination of the two (N & Q). 
The results are presented in Figure 16.  
In theory, if the TycC5-6:BpsA fusion construct produced indigoidine-tagged asparagine, similar 
to the structure presented in Figure 10A, one would expect similar kcat for N and Q and about 
twice their value if both substrates were added. However, from this PPi release assay, I 
Figure 15 | Influence of point mutations on pigment production by a TycC5-6:BpsA fusion 
construct. (A) Scheme of the TycC5-6:BpsA hybrid enzyme to conceptually localize the mutations 
analyzed in (B). (B) The bar graph shows absorption at 600 nm of indicated mutants of the “wild 
type” TycC(Q-167_AAsn-PCP-C-AGln_R395):(G434)BpsA after overnight expression in BAP1 cells 
from the pTrc99 vector relative to the negative control (BpsA PCP mutant, S974A). n = 3 +SD.  (C) 
Overnight expression of BpsA “wt”, AAsn-D370A and PCPAsn-S28A mutants (in triplicate) visualized 
via SDS-PAGE run on a 3-8% TRIS-acetate gel stained with Coomassie. The position of the hybrid 
enzymes is indicated by the arrowhead. They run at an expected size of above 250 kDa 
(calculated size is 274 kDa).  
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calculated a very low kcat of the “wt” hybrid enzyme when adding N as the only substrate (~ 0.12 
min-1) and a relatively high activation rate for Q alone (~1.4 min-1), which was only slightly 
increased by adding both substrates. The product formation rate was assessed by measuring the 
increase in absorption at 600 nm in the linear range. 
The “wt” TycC5-6:BpsA analyzed in vitro formed no pigment from Asn alone, but Gln was 
converted into indigoidine at a rate of about 0.63 min-1 (corresponding to the conversion of 1.27 
Gln min-1), which is very close to the released PPi (Figure 16). For the AAsn-D370A mutant, which 
produced close to wild type pigment levels in vivo, the activation of N was abrogated as 
expected (no significant difference in comparison to the background, p=0.42 in a two-sample 
student’s T-test), whereas the activation of Q, also in the presence of N, was boosted in 
comparison to “wt” TycC5-6:BpsA (Figure 16). Pigment formation rates of 1.78 and 1.55 min-1, 
respectively, confirmed this observation.  
In contrast to the in vivo expression of the PCPAsn-S28A mutant, where no pigment production 
was observed, in vitro this mutant produced blue color at a rate of 0.23 and 0.21 min-1 
(corresponding to 0.46 and 0.41 min-1 glutamine conversion) upon Q and N & Q addition, 
respectively. The same discrepancy was observed for the TE-A1131D mutant of TycC5-6:BpsA, 
even though the pigment production was minimal. The AGln-D372A mutant indeed failed to 
activate Gln and did not produce any pigment. So did the PCPGln-S974A mutant and the two 
TE-S1103A/C mutants. In contrast to the effect of the Ox domain mutation in BpsA, where the 
Figure 16 | In vitro activity of A domains in TycC5-6:BpsA and its mutants. 
The bar graph shows the kcat values calculated from the PPi release assay for 
the indicated TycC(Q-167_AAsn-PCP-C-AGln_R395):(G434)BpsA variants upon 
adding asparagine (N), glutamine (Q) or a combination thereof (N & Q). 
Reactions where the substrate was omitted were run in parallel for each 
variant and served as negative controls, which were subtracted from their 
respective sample values. Enzymes were added at 1 µM, except for 
AAsn-D370A and TE-S1103A, which were added at 2.5 µM, and substrates at 
1 mM in a total volume of 100 µl. n = 3 +SD.  
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glutamine activation decreased by 38% in comparison to the wt, in TycC5-6:BpsA the mutation 
Ox-K600E led to an almost 800% decrease in glutamine activation relative to the “wt”, hinting 
again at a potential role of the oxidation domain in dipeptide formation or splitting of the same, 
as discussed above (section 4.1.4). The activation levels of Asn remained comparably low for all 
TycC5-6:BpsA hybrid enzymes, that should theoretically activate Asn at the native level (Figure 
16), when no mutations interfere with the TycC5 module. Even when the native upstream C 
domain was added to the construct, Asn activation by the TycC5 did not increase (section 4.2.6, 
Figure 17, D). 
 In vivo and in vitro analyses of TycC:BpsA fusions with different start sites emphasize 4.2.6
how intermolecular communication plays a role in pigment production 
For the most promising TycC:BpsA fusion site (TycC(AGln_R395):(G434)BpsA), I reconstituted an 
indigoidine synthetase from TycC6:BpsA and analyzed the effect of the N-terminal start site on 
pigment production in vivo (Figure 17A) and in vitro (Figure 17B). Three different start sites of 
TycC6 A domain were tested for their effect on pigment formation in vivo relative to the 
negative control (BpsA PCP mutant, S974A). The relative absorption at 600 nm of the overnight 
cultures is shown in Figure 17A. Start sites “L-19” and “IndC(M1-M27):(V1_AGln)” were also 
tested for the TycC6:IndC fusion and led to a relative absorption of 0.16 and 0.12 au, respectively 
(compare Figure 13), demonstrating again the different behavior of BpsA and IndC, also in  
association with TycC modules. In vitro analysis of the same TycC6:BpsA constructs revealed that 
in contrast to the in vivo pigment production, the conversion rate of glutamine is highest for 
start site “L-19” (Figure 17B).  
Figure 17 | Comparison of in 
vivo and in vitro activity of 
TycC6:BpsA and TycC5-6:BpsA 
fusions with different start 
sites. Relative absorption at 
600 nm of (A) TycC6:BpsA and 
(C) TycC5-6:BpsA constructs 
featuring the indicated 
N-terminal start sites (=X) after 
overnight expression in BAP1 
cells from pTrc99 relative to the 
negative control (BpsA PCP 
mutant, S974A). The same 
variants of (B) TycC6:BpsA and 
(D) TycC5-6:BpsA were purified 
from the BAP1 cells and the 
activation of their respective 
substrates, N, or Q, or both, 
were measured in the in vitro PPi 
release assay to calculate the kcat 
values. Enzymes were added at 
1 µM, substrates at 100 µM, 
each. For all bar graphs, the 
mean of three replicates 
+standard deviation is shown. 
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Further, I analyzed the effect of the N-terminal start site on pigment production of 
TycC5-6:BpsA. Including the entire upstream C domain (“M1_C”) or the C-A domain linker 
(“Q-167”) did not have a particularly positive effect on pigment production in vivo (Figure 17C). 
The two start sites “T-29” and “L-21”, corresponding to “L-28” and “L-19” of TycC6, had converse 
effects: For TycC6 both led to a similar pigment production level in vivo.  For TycC5, “T-29” had a 
favorable effect on pigment production whereas “L-21” decreased pigment production to a 
value below 0.1 au. In comparison, the in vitro results of the PPi release assay follow an opposite 
trend with regards to the activation rates (kcat) of glutamine (Q). This rate is highest for start site 
“M1-C” and decreases for the other start sites, where “L-21” was not tested (Figure 17D). 
Originally, I hoped to increase the activation of asparagine (N) by leaving the native 
TycC5 C domain in front of the A domain (AAsn), however, the activation rate of N for this start 
site remains very low, just as for “Q-167” and “T-29”. Thus, the activation rate of N & Q 
combined can likely be attributed to the activation of Q alone (Figure 17D). It would be 
interesting to investigate TycC6:BpsA with the native C domain up front to see if the pigment 
production would be increased. 
 TycC5-6:BpsA produces pure indigoidine in vitro 4.2.7
I analyzed the products formed in vitro by BpsA as a control and TycC5-6:BpsA 
(TycC(Q-167_AGln-PCP-C-AAsn_R395):(G434)BpsA), to evaluate which pigment molecule is formed 
by the hybrid enzyme.  On an LC-MS I recorded the LC chromatogram of the products at 600 nm 
(Figure 18A, C) and the ion traces of indigoidine (m/z [M-H]- 247.0) and indigoidine-tagged 
asparagine (m/z [M-H]- 475.0) measured in negative mode MS (Figure 18B and D). 
For both enzymes, one peak with an absorption at 600 nm elutes from the column at 2.9 
minutes. This peak coincides with the ion trace of indigoidine, while the ion trace for 
indigoidine-tagged asparagine does not rise above background level. The identity of the ion trace 
peaks for indigoidine after the main peak could be the tail of indigoidine still eluting from the 
column, which is also visible in the chromatogram at 600 nm. These data provide evidence that 
the TycC5-6:BpsA fusion construct produces pure indigoidine as the only colored product and 
does not tag indigoidine with asparagine. 
An LC-MS measurement of the in vitro reaction of the TycC5-6:BpsA oxidation domain mutant 
(K600E) failed to provide evidence that this mutant produces the dipeptide Asn-Gln 
(m/z [M-H]- 259.0), which was a hypothesis I originally had.  
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To sum up, despite my efforts to generate a fusion enzyme able to produce only 
indigoidine-tagged asparagine, the data rather suggest that the TycC6:BpsA part of the fusion 
works independently to produce pure indidoigine. 
  
Figure 18 | BpsA and TycC5-6:BpsA both produce pure indigoidine in vitro. 
(A) The chromatogram of the BpsA product measured at an absorption 
wavelength of 600 nm. (B) Extracted ion traces of indigoidine (m/z 
[M-H]- 247.0, black line) and indigoidine-tagged asparagine (m/z [M-H]- 475.0, 
gray line) measured via ES-API MS in negative mode. (C) The chromatogram of 
the TycC5-6:BpsA product measured at an absorption wavelength of 600 nm. 
(D) Extracted ion traces of indigoidine (m/z [M-H]- 247.0, black line) and 
indigoidine-tagged asparagine (m/z [M-H]- 475.0, gray line) measured via ES-
API MS in negative mode. Enzymes were added at 3 µM in sodium phosphate 
buffer, pH 8, with 1mM Gln for BpsA and 1 mM Asn and Gln for TycC5-6:BpsA, 
20 mM MgCl2 and 5mM ATP. The pelleted pigment was dissolved in 100 % 
DMSO before subjection to the LC-MS.  
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4.3 Further aspects and engineering approaches towards an improved 
NRP-indigoidine fusion synthetase 
In this section I will summarize other aspects of engineering NRPSs, indigoidine synthetases and 
in particular the fusions thereof, always with the aim in mind to create or improve an 
NRP-indigoidine fusion synthetase to easily monitor the success of NRPS engineering. 
 Engineering the post A10 A domain motif of IndC to match an interrupted termination 4.3.1
module does not increase pigment production significantly 
(Experiments in this section 4.3.1 were partly executed together with Luise Nottmeyer as part of 
an internship during her Bachelor studies) 
In a recent study, the post A10 (pA10) sequences of different A domains were compared54. A 
distinct motif (“LPxP”) was identified and proposed to expand the A10 motif, since it seems to 
play a role in interacting with the A domain to stabilize the catalytic lysine of the preceding A10 
motif. Furthermore, it was reported that this motif is mainly found in the A domains of 
multimodular NPRS and not in standalone A domains. Thus, I aimed to test whether engineering 
this post A10 motif could make IndC behave more like part of a multimodular NRPS, all the while 
decreasing its standalone activity. I aligned different A domain sequences from Photorhabdus 
luminescence and Brevibacillus Brevis, along with one interrupted A domain of an elongation 
module (TgaC, a hybrid PKS/NRPS from the thuggacins synthetase of Sorangium cellulosum, 
elongation A domain interrupted by an Ox domain) and one interrupted A domain of a 
termination module (PchF of the pyochelin synthetase from Pseudomonas aeruginosa, 
interrupted by a methylation domain) and compared their expanded post A10 motifs to IndC. All 
sequences from elongation A domains of NRPS found in Photorhabdus luminescence as well as 
the three sequences included from TycC featured the predicted “LPxP” motif (Figure S 7). While 
TgaC also featured the proposed “LPxP” motif, IndC and PchF both shared the conserved leucine, 
but not the proline residues of that motif, which for PchF is not in line with the findings of Miller 
et al.54(Table 9). 
Table 9 | The extended post A10 
motifs of IndC, TgaC and PchF. The 
pA10 motif is underlined. 
protein extended pA10 motif 
IndC YQSLSES 
TgaC RGALPDP 
PchF RKALTGF 
 
I then engineered the IndC expanded post A10 motif to match either the interrupted elongation 
A domain TgaC (pA10-1: “RKALPEP”) or the interrupted termination A domain PchF (pA10-2: 
“RKALTGF”). Luise and I replaced the native pA10 motif of IndC and TycC5-6:IndC with either one 
of those two, expressed them in BAP1 cells and assessed pigment production (Figure 19A). The 
absorption at 600 nm of both “wild types” was set to one and the pA10 engineered versions 
normalized accordingly to have a better comparison of the effects. In absolute numbers, the 
TycC5-6:IndC fusion produces less pigment than IndC. Changing the pA10 motif of IndC to that of 
TgaC (pA10-1) led to a decrease in pigment formation of the native standalone IndC and also of 
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the fusion construct. Changing the pA10 motif of IndC to match that of PchF (pA10-2) led to a 
decrease in pigment formation by IndC but to a slight increase in pigment formation of 
TycC5-6:IndC (Figure 19A). Hoping that this would be due to the desired effect of having turned 
IndC into an elongation module, we implemented the changes to the post pA10 motif also in the 
TycC5-6:IndC AAsn domain and PCPAsn domain mutants and compared their pigment production 
levels (Figure 19B). For the “wt” as well as the mutants of TycC5-6:IndC, the pA10-2 motif led to 
a slight increase in pigment production, significantly for the PCPAsn domain mutants (p<0.05 in a 
two-sample student’s T-test). Consequently, the desired effect of a high increase in pigment 
production for the “wt” TycC5-6:IndC and a decrease for the mutants of the Asn-incorporating 
module was not achieved.  
 Random mutagenesis of TycC5-6:IndC fusions yields a small number of mutants, all of 4.3.2
which show reduced pigment production 
(Experiments and data analysis of this section were partly executed by Luise Nottmeyer as part 
of an internship during her Bachelor studies) (Figure 20C) 
In a different approach to improve the pigment production levels of TycC5-6:IndC hybrid 
enzymes, I turned towards directed evolution. I performed random mutagenesis of complete or 
partial TycC5-6:IndC fusion constructs and cloned them into a non-mutated expression vector. 
The idea was to transform the mutated variants directly into the expression cells, E. coli BAP1, to 
enable high throughput screening of the different clones. Even though the yield of purified DNA 
after random mutagenesis PCR was comparable to that for the wild type counterpart, the 
transformation into BAP1 cells did not yield many colonies under different conditions such as 
different amounts of Gibson assembly mix or the type of transformation (heat shock versus 
electroporation). Thus, the conventional route via first cloning into competent E. coli TOP10 cells 
Figure 19 | Engineering the 
post A10 motif had an effect on 
pigment production of IndC and 
TycC5-6:IndC in E. coli. (A) In wild 
type IndC and TycC5-6:IndC, the 
effect of post A10 engineering was 
assessed by expressing the 
indicated variants in BAP1 cells 
from the pTrc99 vector, measuring 
the absorption at 600 nm relative 
to the negative control (IndC PCP 
mutant, S980A). Values of the wild 
types were set to one and pA10 
variants normalized to the wt for 
better comparison. (B) For pA10 
version “2”, the effects on 
pigment production of the wt 
TycC5-6:IndC and the AAsn domain 
mutant (D370A) and the PCPAsn  
mutant (S28A) are depicted. 
n = 3 +SD. 
Random mutagenesis of TycC5-6:IndC fusions yields a small number of mutants, all of which 
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was chosen. However, the yield of positive colonies (checked via colony PCR for the presence of 
an insert) was not much higher, despite the optimization of the conditions. 
The DNA was purified from the positive colonies and transformed into BAP1 cells, which were 
then used to express the randomly mutated clones overnight to assess pigment production from 
the absorption measurement at 600 nm relative to the negative control (Figure 20A, B). I 
partially sequenced four random samples and counted about five to fourteen point mutations 
per 1 kbp, which corresponds well with the mutation rate between 0.6% and 2% stated by the 
manufacturer of the mutagenesis kit.  
Changing the expression vector from pCDFDuet to pTrc99 to be able to achieve an expression in 
the cloning strain (TOP10) was not successful since the endogenous PPtase of E. coli did not 
sufficiently activate the hybrid enzyme and even for the “wt” TycC5-6:IndC no pigment 
production was observed (not shown). However, expression of the same TycC5-6:IndC fusion 
construct from pTrc99 instead of pCDFDuet in BAP1 cells led to an increase of pigment 
production for the “wt” (Figure 20C, compare Figure 14).  
Unfortunately, all randomly mutated variants did not produce more pigment than the respective 
“wt”. On the contrary, for almost all of them, the pigment production was largely decreased 
(Figure 20A-C). This is not surprising, since most DNA point mutations do not change the protein 
sequence at all (e.g. at the last position of a triplet). If the DNA point mutation does change the 
protein sequence, the likelihood that it has a loss-of-function effect is higher than a 
gain-of-function effect. Thus, the strategy of introducing random mutations and screening a vast 
number of mutant enzymes needs to be revised and improved, e.g. by using a robotic system 
that can handly a huge number of clones, to be able to find a higher pigment producer in several 
rounds of directed evolution.  
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Figure 20 | Random mutagenesis of TycC5-6:IndC fusion 
constructs did not yield a mutant with higher pigment 
production. (A-C) The absorption at 600 nm of overnight 
expression cultures of the indicated constructs, their site-directed 
(PCPAsn) and randomly mutated variants (numbered 
consecutively) from the indicated vectors in BAP1 cells are shown 
relative to the negative control (IndC PCP mutant, S980A). (A,B) 
n = 3 +SD, (C) nwt = 3 +SD, nmutants = 1 
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 Mutations to the Ox domain cannot be rescued through external supplementation of 4.3.3
the wild type Ox domain 
In a co-culture study from five decades ago, it was found that the only mildly colored 
leuco-indigoidine, produced by one bacterial strain, could be converted to indigoidine by 
external oxidation313. Since my previous experiments pointed towards a role of the oxidation 
domain in preventing the formation of indigoidine-tagged peptides and amino acids, I aimed to 
supplement the oxidation domain externally, though within the expression cells, to first allow 
the formation of the di-peptide intermediate followed by the oxidation step to produce the 
pigment. To this end, I expressed the oxidation domain mutants (K600E) of BpsA and 
TycC5-6:BpsA (TycC(Q-167_AAsn-PCP-C-AGln_R395):(G434)BpsA) alone and concomitantly with the 
BpsA oxidation domain (residues 569-695) from a separate vector in BAP1 cells to assess the 
blue pigment production (Figure 21).  
External supplementation of the BpsA oxidation domain to BpsA and TycC5-6:BpsA oxidation 
domain mutants (K600E) did not lead to pigment production (Figure 21). A possible reason for 
this could be that the oxidation domain is still present in the mutant and therefore the external 
oxidation domain cannot take the place, also not conformationally, of oxidizing glutamine.  
  
 Reconstruction of an indigoidine synthetase from AGln of TycC6 by inserting the 4.3.4
oxidation domain and appending the IndC TE domain did not lead to a functional enzyme 
I tested whether I could turn the glutamine activating module TycC6 into an indigoidine 
synthetase by inserting the oxidation domain of IndC into it (testing two different sites, I. and II.) 
and appending the TE domain of IndC to its C-terminus, which is apparently also necessary to 
form indigoidine. Different start sites were tested for the different oxidation domain insertion 
sites (1, 2, 3). Exact start and fusion sites are listed in Table 10.  
Figure 21 | Co-expression of the 
excised oxidation domain with the Ox 
domain mutants of BpsA and and 
TycC5-6:BpsA does not lead to 
pigment formation. Bar graphs show 
the absorption at 600 nm of the 
indicated constructs after overnight 
expression, without or with (+ Ox) the 
BpsA oxidation domain, in BAP1 cells 
from pTrc99 (NRPS constructs) and 
pCDFDuet (Ox domain) relative to the 
negative control (BpsA Ox mutant, 
K600E) and normalized to the 
absorption of BpsA wt. n = 3 +SD 
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Table 10 | Start and fusion sites of TycC6(AGln):IndC(Ox):TycC6(AGln-PCP):IndC(TE) constructs 
created to test indigoidine production in BAP1 cells. 
 start TycC AGln IndC Ox TycC AGln-PCP IndC TE 
I.  1 Q-167 
V1 – D373 L415 - K862 
V477_AGln – 
PCP_A61 
W1015 -  end I.  2 (M1-M27)IndC 
I.  3 - 
II. 1 Q-167 
V1 – D373 L415 - I804 
K426_AG l n  –  
PCP_A61 
W1015 -  end II. 2 (M1-M27)IndC 
II. 3 A-7 
 
A scheme of the constructs is shown in Figure 22A. These constructs were expressed in BAP1 
cells and their pigment production was assessed via measuring the relative absorption at 600 nm 
(Figure 22B). None of the constructs could yield a functional indigoidine synthetase. 
These data together with the data on the TycC5-6:IndC fusion indicate that keeping the 
Ox-AGln-PCP-TE interface of IndC intact is important for its function. I created a similar construct 
to I. 2 (Table 10) before, without re-inserting the C-terminal AGln and PCP of TycC6, which was 
able to produce blue pigment (Figure 13). 
 Rescuing removal of the TE domain by its external supplementation can be achieved 4.3.5
for BpsA but not for the TycC5-6:BpsA fusion 
Another idea I had was to remove the TE domain of the TycC5-6:BpsA fusion construct to enable 
a slow (see section 4.4.1, Figure 28) formation of the Asn-GlnOx dipeptide which could then be 
released by the externally supplied BpsA TE domain to form indigoidine-tagged asparagine or at 
least prevent standalone activity of the BpsA part, which is impaired by TE domain mutations or 
deletion.  
Figure 22 | Inserting the IndC oxidation domain into TycC6 and adding 
the IndC TE domain does not reconstitute and indigoidine synthetase. 
(A) Schematic depiction of the reconstituted indigoidine synthetase. 
Parts of TycC are shown in gray, parts of IndC are shown in blue. (B) Bar 
graphs show the absorption at 600 nm of the indicated constructs (refer 
to Table 10) after overnight expression in BAP1 cells from pCDFDuet 
(MCS2) relative to the negative control (IndC PCP mutant, S980A). 
n = 3 +SD 
Other NRP-indigoidine synthetase fusions do not produce any pigment 
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To this end I created a truncated BpsA construct consinsting of the wt BpsA up to residue Q1014 
(BpsA(Q1014) ΔTE) and separately cloned the BpsA TE domain starting at residue E1015 
(TE_E1015-A1285) for co-expression in BAP1 cells. The question I intended to answer with these 
experiments is whether the PCP and the TE domains of BpsA are able to interact in vivo even 
when not on the same molecule. In addition, I created the TE deletion construct 
TycC(Q-167_AAsn-PCP-C-AGln_R395):(G434)BpsA(Q1014) for the fusion enzyme and also 
co-expressed it with the BpsA TE domain in BAP1 cells. A schematic depiction of the created 
constructs is shown in Figure 23A. The pigment formation for the TE domain deletion constructs 
alone or with (+) the external BpsA TE domain was assessed by measuring the relative 
absorption at 600 nm (Figure 23B). 
While the indigoidine formation of BpsA could be rescued by supplementing the TE domain in 
vivo, the TycC5-6:BpsA ΔTE construct did not produce any pigment after co-expression with the 
TE domain. One can speculate that the larger TycC5-6:BpsA ΔTE fusion construct might take on a 
different conformation, when the TE domain is missing, leading to a sterical hindrance of 
external TE domain binding. This hypothesis could be examined via analysis of the ΔTE 
constructs in electron microscopy, alone and in combination with the TE domain. To conclude, 
this approach does not serve our purpose, but could be used to test different TE domains for 
their ability to form indigoidine, as also recently proposed by Alistair Brown314 from the Ackerley 
group. 
 Other NRP-indigoidine synthetase fusions do not produce any pigment  4.3.6
Of course, the tyrocidine synthetase is not the only NRPS incorporating a glutamine thus being 
suitable for a fusion to an indigoidine synthetase. I identified three other NRPSs, the lychenisin 
synthetase LchA from Bacillus licheniformis DSM13, the Plipastatin synthetase PpsX from Bacillus 
Figure 23 | Rescue of TE domain deletion of BpsA by co-expression of the BpsA TE domain was 
successful, but not applicable to TycC5-6:BpsA ΔTE. (A) Schematic depiction of the TE domain 
deletion constructs. Parts of TycC are shown in gray, parts of IndC are shown in blue. (B) Bar 
graphs show the absorption at 600 nm of the indicated constructs after overnight expression in 
BAP1 cells from pTrc99 (ΔTE constructs) with (+) or without the BpsA TE domain (from 
pCDFDuet) relative to the negative control (BpsA PCP mutant, S974A). n = 3 +SD 
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subtilis strain 168 and the Iturin synthetase ItuX from Bacillus amyloliquefaciens DSM7, which 
incorporate a glutamine through one of their modules. The LchAA glutamine-incorporating 
module is an initiation module featuring an upstream starter C domain that incorporates a fatty 
acid. The PpsD and ItuB glutamine incorporating modules are elongation modules. 
For the LchAA:IndC fusion (LchAA(X_AGln_T368):(T424)IndC) I tested three different start sites 
(=X), one including the upstream starter C domain (“M1_C”) and two starting with the AGln 
domain (“L-163” and “M-27”). All these LchAA:IndC constructs did not produce any pigment 
(Figure 24A). In the plipastatin synthetase, PpsD, the glutamine-incorporating module, is 
naturally preceeded by a proline-incorporating module. I created two different fusions, one 
reconstituting the indigoidine synthetase (ppsD(L-60_AGln_R393):(G437)IndC) and one which 
should tag proline with indigoidine (PpsD(-174V_APro-PCP-C-AGln_R393):(G438)IndC). Both 
constructs were expressed in BAP1 cells, alone and along with the Bacillus subtilis MbtH-like 
protein YbdZ (Figure 24B). In neither case did the PpsD:IndC fusion produce enough pigment to 
be visible. In the iturin synthetase, the glutamine-specific module features an asparagine-specific 
module upstream, with the specialty, that an additional epimerization domain (E) turns L-Asn 
into D-Asn. However, also for this ItuB(N-175_AAsn-PCP-EAsn-C-AGln_H406):(G434)BpsA fusion, no 
pigment production could be observed, despite the co-expression of YbdZ.  
For the LchAA:IndC fusion including the starter C domain, an external enzyme not present in 
E. coli might be needed to synthesize or prepare the fatty acid for its fusion to glutamine by the 
starter C domain. However, the fusion site chosen for LchAA:IndC (“T368:T424”) also did not 
lead to pigment production for TycC:IndC, indicating that a different fusion site needs to be 
tested to draw a conclusion whether this LchAA AGln is also capable of cooperating with IndC. For 
the PpsD-indigoidine and the ItuB-indigoidine synthetase hybrids, the corresponding fusion site 
Figure 24 | Fusion constructs of other glutamine incorporating NRPS modules to an indigoidine 
synthetase did not produce any pigment. (A-C) Bar graphs show the absorption at 600 nm of 
the indicated constructs after overnight expression in BAP1 cells from (A) pCDFDuet and (B, C) 
pTrc99 without (“wt”) or with (plus YbdZ, from pCDFDuet) relative to the negative control (IndC 
or BpsA PCP mutants). n = 3 +SD 
Attempted experimental validation of the putative dodecylindigoidine synthesis gene cluster of 
Shewanella violacea DSS12 
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to the one that led to pigment production in TycC:IndC/BpsA fusions, were chosen. Yet, neither 
one of them produced any pigment. This could be due to the absence of an MLP protein which 
PpsD and ItuB require for their function; IndC and BpsA do not. The co-expression with the MLP 
YbdZ, however, also did not cause pigment formation, which could be caused by the 
interference of the MbtH-like protein with the indigoidine synthetase part. However, from the 
crystal structure of a MLP-bound A domain, it became clear, that the MLP binds at the 
N-terminal Acore domain and not at the C-terminal Asub domain
75,154, which is where the fusion to 
the indigoidine synthetase is. Theoretically, the oxidation domain of the IndC or BpsA could still 
sterically interfere with the proper MLP binding and thus prevent proper functioning. 
 Attempted experimental validation of the putative dodecylindigoidine synthesis gene 4.3.7
cluster of Shewanella violacea DSS12 
(These experiments were performed in part by Konrad Herbst during an internship221). 
Given the structural similarity between indigoidine and N,N-dodecylindigoidine, we assumed 
that the latter is also produced by a NRPS-like enzyme in Shewanella violacea DSS12. A putative 
gene (SVI_3984) encoding the violet pigment synthetase (WP 013053246.1) was identified via 
homology BLAST using a Bidirectional Best Hits (BBH) approach in comparison to the pigment 
producing Rheinheimera baltica DSMZ 14885221. In order to validate the putative 
N,N-dodecylindigoidine synthetase dIndS, we chose an untargeted gene disruption approach as 
described before305. An overview of this approach is depicted in Figure 25A. In short, the 
pMiniHimar-Rb1 plasmid harbors a transposase under the control of the Plac promoter (both 
shown in gray). This plasmid was conjugated via an E. coli host into Shewanella violacea. The 
transposase randomly integrated the inverted repeat (IR, shown in yellow)-flanked R6K origin of 
replication and the kanamycin resistance (kanr) gene (shown in red) into the Shewanella 
genome. The resulting S. violacea cells were grown on kanamycin supplemented MB agar plates 
to select for successful integration. Colonies were checked for pigmentation (Figure 25B). Four 
pigment producing (“1-4 +”, circled in purple) and four non-pigment producing (“1-4 -“ circled in 
yellow) S. violacea colonies were picked, grown and their whole genome was extracted. At this 
point, two different means of mapping the integration site were used (Figure 25A): a) The 
genomic DNA was digested, re-ligated and transformed into E. coli EC100 pir+, where only 
re-ligated plasmids harboring the R6K origin of replication and the kanr gene could survive and 
replicate on LB agar plates supplemented with kanamycin. The plasmids would then have been 
purified from the individual colonies and sequenced using a primer binding to kanr facing 
outwards. b) The genomic DNA was used to perform a PCR covering the complete putative dIndS 
gene to see whether the kanr and the R6K ori were inserted, leading to a longer PCR product. 
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BamHI whole genome digest seems to have been successful (Figure S 8). After re-ligation with T4 
DNA ligase, the resulting circularized genomic DNA fragments were transformed into 
E. coli EC100 pir+ via electroporation. However, after several attempts, no colonies were 
obtained (not shown). The positive control plasmid containing the R6K origin of replication and 
the kanamycin resistance gene did yield plenty of colonies E. coli EC100 pir+, confirming the 
competence of the bacteria and the correct implementation of the transformation protocol. 
Figure 25 | Experimental approach to validate the putative violet pigment synthetase in 
Shewanella violacea. (A) Scheme of untargeted gene disruption to identify the gene location 
responsible for violet pigment production. (B) S. violacea colonies after conjugation with 
pMiniHimar-RB1 at 12 °C, diluted 1:10 on Marine Broth 2216 supplemented agar. Four pigment 
producing (circled in purple) and four non-pigment producing colonies (circled in yellow) were 
grown in liquid medium and the genomic DNA was extracted for a) digest and relegation or b) a 
PCR across the putative dIndS.  
Neither wild type nor engineered dIndS lead to pigment production in E. coli 
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Thus, we decided for a more targeted analysis of the putative gene whose disruption should 
abrogate pigment production in S. violacea. We designed three DNA primer pairs with which the 
complete gene could be amplified via PCR in circa 2 kbp steps. In case of an insertion of the 
IR-flanked R6K/kanR cassette, the PCR product should be larger (about 4.5 kbp). Successful 
amplification of 2 kbp fragments for both, the pigment producing and non-producing colonies 
(not shown), indicates that, in none of those colonies, the putative dIndS gene was targeted by 
the transposon.  
Given the number of non-pigmented colonies on the MB agar plate and the fact that both 
pigmented and non-pigmented clones did not show an interruption of the putative dIndS gene, 
we conclude that there are likely many factors influencing pigment production. Thus, our 
untargeted gene disruption approach did not lead to the experimental validation of the putative 
dodecylindigoidine synthesis gene. However, from the bioinformatical predictions, we are 
confident that WP 013053246.1 is indeed responsible for N,N-dodecylindigoidine production.    
 Neither wild type nor engineered dIndS lead to pigment production in E. coli 4.3.8
Since we were confident about the predicted putative dIndS in S. violacea, we continued 
investigating it. In addition, we applied an engineering approach replacing the lauric acid 
A domain of dIndS by three different TycC A domains (specific for Val, Orn and Leu) with the aim 
to produce indigoidine-tagged amino acids (Figure 26A). To this end, we amplified the putative 
pigment synthetase from the Shewanella genome and cloned it seamlessly into the second MCS 
of pCDFDuet. We then determined possible insertion sites for the TycC A domains to replace the 
lauric acid A domain of dIndS via multiple protein sequence alignment of Clustal Omega. We 
chose relatively conserved residues, five amino acids upstream and three amino acids 
downstream of the A domain border according to Pfam (Figure 26B). We amplified the dIndS 
and the backbone, leaving out only the sequence of the lauric acid A domain. Via Gibson 
assembly we inserted each of the TycC A domains specific for either Val, Orn or Leu amplified 
with primers featuring the overlapping dIndS DNA sequence of the insertion site. In addition, we 
amplified the putative Shewanella PPtase (WP_013050488.1) and inserted it into the pTrc99 
backbone via Gibson assembly. 
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We expressed the wt dIndS and TycC AVal/Orn/Leu-dIndS fusion constructs in E. coli BAP1 cells 
(Figure 26C) and co-expressed them with the putative PPtase in M9 minimal medium. 
Unfortunately, neither the wt nor the engineered versions resulted in pigment production 
(Figure 26C).  
Based on the hypothesis that the putative dIndS we have identified from S. violacea is indeed 
the NRPS responsible for dodecylindigoidine production, I assumed that the TE domain of dIndS 
is capable or even responsible for the release of an indigodine-tagged lauric acid. I performed a 
protein alignment of the PCP-TE domains of IndC, BpsA, TycC10+TE and dIndS using Clustal 
Omega315 to find suitable fusion sites and obvious differences between the analyzed TE domains. 
One obvious difference that I found was that dIndS featured a complete catalytic triad, including 
aspartate (D), which was replaced by alanine (A) in the indigoidine synthetases. Mutations of this 
residue in IndC, BpsA and the TycC5-6:BpsA fusion are described elsewhere (sections 4.1.2 and 
4.2.5). Another obvious difference was located in the PCP-TE linker, where dIndS features an 
elongated alpha helix in comparison to the other PCP-TE linkers. 
Figure 26 | Neither wild type 
nor engineered dIndS 
produce a violet pigment in 
E. coli. (A) Engineering 
approach to create an NRPS 
that can tag an amino acid 
with indigoidine. In our 
engineered versions of dIndS, 
the wt A domain specific for 
lauric acid was replaced by 
TycC A domains (Val, Orn or 
Leu) to produce N,N-valine-, 
ornithine-, or leucine-
indigoidine. (B) Protein 
Alignment of the insertion 
sites of the TycC A domains 
into the wt dIndS. The wt  
N-terminus of dIndS was kept 
up to T12, where the 
respective TycC A domain was 
inserted up to R559. Thus, the 
complete lauric acid A domain 
was replaced. (C) Expression 
of wt and engineered dIndS in 
E. coli did not lead to pigment 
production.  Neither when 
expressed in BAP1 alone nor 
in together with the putative 
S. violacea PPtase could we 
detect any pigment, i.e. 
absorption around 600 nm. 
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I created three different fusion constructs, replacing the IndC PCP-TE or TE domain(s) with the 
respective dIndS version: (i) IndC(AGln-Ox_L896):(S1536_AA9-A10-PCP-TE)dIndS, which sets the 
fusion site right after the IndC Ox domain and before the A9 motif; 
(ii) IndC(AGln-Ox-A-PCP_A1013):(A1651_TE)dIndS replacing exclusively the TE domain while still 
keeping the PCP-TE linker from dIndS, as suggested by Beer at al. before116 and 
(iii) TycA(M1-S28):TycC(I-5_AAsn-PCP-C-AGln_D373):(L415)IndC(L896):(S1536)dIndS, where the 
same PCP-TE domains were replaced as in (i), just added onto the TycC5-6:IndC fusion shown in 
Figure 12A. I expressed these fusion constructs in BAP1 cells and measured their absorption at 
600 nm relative to the empty vector control. No pigment production was detected for any of the 
constructs (Figure 27). 
  
Figure 27 | Exchange of the PCP-TE (i) or TE 
domain of IndC (ii) and TycC5-6:IndC (iii) fusion 
construct with the equivalent of dIndS does not 
lead to pigment production in vivo. The indicated 
constructs (please refer to the main text for 
details) were expressed in BAP1 cells from 
pCDFDuet (MCS1) over night. Their absorption at 
600 nm was measured relative to the negative 
control (IndC PCP mutant S980A). n = 3 +SD. 
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4.4 Context-dependent activity of A domains in the tyrocidine synthetase 
(Parts of this section were submitted to Scientific Reports as a research article: A. Degen, 
F. Meyerthaler, H.D. Mootz and B. Di Ventura “Context-dependent activity of A domains in the 
tyrocidine synthetase”)  
During the validation of the asparagine-indigoidine fusion synthetase, I discovered that, in the 
synthetic dimodular fusion construct TycC5-6:BpsA, inactivation of the first module via A domain 
mutation did not disable the second module from activating its substrate and turning it into the 
blue pigment indigoidine in vivo. In vitro, this A domain mutation of the first module even 
seemed to boost the activity of the A domain of the second module in comparison to the wt 
fusion construct. In contrast, inactivation of the first module by PCP domain mutation 
completely prohibited pigment production in vivo, while in vitro activity of the second A domain 
was still measurable though at a reduced rate along with blue color formation (section 4.2.5, 
Figure 16). To follow up on these discoveries, I decided to investigate the effects of module 
inactivation on neighboring modules in a (more) native environment. 
Thus, I first analyzed the TycC5-6:BpsA dimodular system further, including and omitting the 
BpsA TE domain and comparing it to the wt excised TycC5-6 dimodule, naturally without TE 
domain and after adding the BpsA TE domain. To investigate a more natural, multimodular NRPS 
system, I focused on the last three modules of the tyrocidine synthetase, naturally followed by a 
TE domain, to analyze the context-dependent activity of A domains. I constructed a library 
consisting of individual A-PCP di-domains, namely TycC8, 9 or 10, two dimodular constructs 
(TycC8-9 and TycC9-10, each plus and minus TE domain) and one trimodular construct 
(TycC8-9-10+TE). All constructs were either kept wt or mutated within the A or PCP domain, at 
the same amino acids mutated in the fusion constructs before. Upon expression in BAP1 cells, 
the PPantylated enzymes56,316 were purified and analyzed in vitro using a PPi release assay
70,91 
(Figure 3E). 
 Activity of A domains embedded in the dimodular constructs TycC5-6 with or without 4.4.1
fusion to BpsA 
In order to comprehend if the TycC5-6:BpsA fusion construct behaves differently than a native 
dimodular construct consisting of TycC5-6 upon upstream domain I created different variants of 
of TycC5-6, with or without BpsA fused at its C-terminus (Table 11). From the best TycC5-6:BpsA 
fusion construct, I removed the TE domain (TycC5-6:BpsAΔTE) but kept the BpsA oxidation and 
C-terminal AGln domains, to see if the substrate activation rate changes without the TE domain. 
Further I generated the native TycC5-6 dimodule (TycC5-6ΔTE), which naturally does not have 
any TE domain and no other part of BpsA. Finally, I added just the BpsA TE domain to the 
C-terminus of TycC5-6 (TycC5-6:TE (BpsA)), namely right after the TycC6 PCP domain. I analyzed 
these constructs using the online PPi release assay. Instead of inactivating the domains with 
point mutations, here I control the individual domain activity by selectively adding the substrates 
Asn (N) and Gln (Q) individually or simultaneously.   
Activity of A domains embedded in the dimodular constructs TycC5-6 with or without fusion to 
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Table 11 | Overview of potential Asn-Gln producing NRPS fusion constructs analyzed using the 
online PPi release assay. 
name construct 
TycC5-6:BpsA TycC(Q-167_AAsn-PCP-C-AGln_R395):(G434_Ox-A-PCP-TE)BpsA 
TycC5-6:BpsAΔTE TycC(Q-167_AAsn-PCP-C-AGln_R395):(G434_Ox-A-PCP_E1004)BpsA 
TycC5-6ΔTE (native) TycC(Q-167_AAsn-PCP-C-AGln-PCP_A58) 
TycC5-6:TE (BpsA) TycC(Q-167_AAsn-PCP-C-AGln-PCP_A58):(K1005_TE)BpsA 
 
The kcat values for all constructs in the presence of N, Q or both were calculated (Figure 28). For 
TycC5-6:BpsA these conversion rates were presented in Figure 16 already and show that Q is 
activated at a much higher rate than N. Here I analyzed the same construct without the TE 
domain. Deleting the TE domain results in lower activity for all substrate combinations, most 
severely for Q alone and the combination of N & Q. This effect is very similar to the effect of the 
various TE domain mutations presented before (Figure 16) and argues that indeed the TE 
domain is greatly involved in product release and is thus a driver of standalone activity of BpsA 
in the fusion construct.  
This hypothesis is supported by the conversion rates of TycC5-6:TE (BpsA), where the TE domain 
of BpsA is fused to the native TycC5-6 dimodule. For this construct, the conversion of Q is still 
higher than that of N, however not to the same degree as for the TycC5-6:BpsA construct. This 
Figure 28 | Impact of the BpsA TE domain on the TycC5-6:BpsA 
fusion in comparison to the native TycC5-6 construct. The 
graph shows kcat values for the indicated constructs in the 
presence of the indicated amino acids, after background 
subtraction (value w/o substrate). Amino acids were added at 
1 mM, enzymes at 0.5 µM. Data represent the mean 
(+ standard deviation, SD) of three technical replicates. 
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indicates that the BpsA TE domain preferably releases the oxidized (and possibly cyclized) 
glutamine to form the pigment. Unmodified glutamine is not the preferred substrate resulting in 
a rather low activation rate of Q even in the presence of the BpsA TE domain. This assumption is 
further supported by the native TycC5-6ΔTE dimodular construct, where the conversion rates of 
all substrates are similar, even without any TE domain, indicating that all substrates can be 
released by unintended hydrolysis. Note that, irrespective of the presence of a TE domain, each 
module can activate its substrate independently from the neighboring module. 
Because of these results, I decided to switch to a native system where the last module is 
naturally followed by a TE domain to compare it to the artificial TycC5-6:BpsA fusion construct 
and the effects that perturbations have on each of the components of the system. Most 
conveniently, I switched to the last three modules of TycC, ending in a TE domain, which has 
previously been reported to also release unnatural substrates as a linear product34. 
 Analysis of A-PCP di-domains of TycC8, 9, or 10 4.4.2
First, I chose two different start sites consistent for each of the last three modules of TycC. The 
first one (1) is located about 20 bp upstream of the A domain start according to Pfam and was 
previously identified to work well for TycC5 and 6 in the indigoidine synthetase fusion in vivo and 
in vitro (Figure 12 and Figure 17). The second one (2) is located about 30 bp upstream of the 
A domain start and was previously established by Mootz and colleagues34. For both start sites, 
the A-PCP di-domains TycC8, 9 and 10 were analyzed in vitro using the online PPi release assay to 
calculate the conversion rate of their native substrates (Figure 29). 
These experiments show that for the di-domain constructs, the start site though only differing in 
about 10 bp in length seems to have a large impact on substrate activation. Based on these 
results, I chose to apply start site (1) for all constructs in the upcoming experiments.  The values 
are within a range of about 1 min-1, making them more comparable, especially with regards to 
evaluating the effects of domain inactivation.  
Figure 29 | Impact of the start site on activity of A domains within A-PCP di-domain 
constructs. (A) Sequence alignment of the indicated constructs, where (1) and (2) indicate two 
different start sites. Amino acids are color-coded according to the Clustal coloring scheme.  
Numbers above the sequence indicate the amino acid position relative to the predicted start site 
of the A domain which is set to zero. (B) Bar graphs showing kcat values for the indicated 
constructs in the presence of the indicated amino acids after subtraction of the background (=no 
substrate) value. Amino acids were added at 1 mM, enzymes at 0.5 µM. Data represent the 
mean (± standard deviation, SD) of three independent experiments. 
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These effects of domain inactivation, I validated using the minimal component of an NRPS 
system, namely the A-PCP di-domains depicted in the alignment in Figure 30A. To inactivate the 
A domain, we introduced the same point mutation as described before (sections 4.1.2 and 
4.2.5), namely the D to A conversion of the aspartic acid of core motif A7 (Y[R/K]TGDL)51. These 
mutants I abbreviate with TycC8A*, TycC9A* and TycC10A*. To inactivate the PCP domain, I also 
revert to the previously described S to A mutation of the PPant attachment site within the PCP 
domain [I/L]GG[D/H]SL100 (Figure 30B and Figure S 10A, D, G).  
For all three constructs, the wt A domains showed activity only towards the expected substrates 
(Figure 30C-E), even when additional amino acids were present (Figure S 10C, F and I). As 
Figure 30 | Activity of A domains within “wild type” or mutated TycC 8, 9 and 10 A-PCP 
di-domain constructs. (A) Protein sequence alignment of the indicated constructs. Amino acids 
are color-coded following the Clustal scheme based on their category and degree of 
conservation. The amino acids of all constructs are numbered consecutively beginning with 1 at 
the start of construct TycC9. Predicted boundaries for A and PCP domains are shown above the 
sequences. Gray arrows indicate a residue critical for ATP binding and the serine needed for 
PPant arm attachment. “Tag” indicates a GSG linker plus the 6x His tag. (B) Position and identity 
of mutations used to inactivate the A and PCP domains. (C-E) Upper panel: schematic depiction 
of construct with amino acid attached to the PPant arm. Colors as in Figure 1, A. Lower panel: 
bar graph showing kcat values for the constructs in the upper panel in the presence of the 
indicated amino acids, calculated using the online PPi release assay after subtraction of the 
background (=no substrate) value. Amino acids were added at 1 mM, enzymes at 0.5 µM. Data 
represent the mean (± standard deviation, SD) of three independent experiments. 
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expected, A domain inactivation lead to an almost complete stall of activity. With the 
PCP domain mutation, two of the three A domains could still continuously activate their 
substrates, namely TycC8PCP*and TycC10PCP* (Figure 30C, E). This observation was reported in 
other studies before, where either the PCP domain was mutated in the same position or the 
A domain activity was observed in complete isolation31. However, in opposition to these 
observations, the PCP domain mutant of TycC9PCP* strongly affected the adenylation activity 
(Figure 30D). In search of an explanation we came across an early publication by Mootz and 
colleagues34 describing that the ornithine thioester can undergo intramolecular cyclization 
thereby releasing itself from the PPant arm, which is prohibited in the absence of that very 
PPant arm in the PCP mutant. This auto release mechanism could also explain why the TycC9 wt 
conversion of ornithine can be faster than the activity of its two neighbors towards their 
substrates (Figure 29A). To test this assumption, I replaced Orn with Lys, which was also shown 
to be accepted by TycC9 in vitro34, but cannot undergo this self-cyclization. I fed Orn as the sole 
substrate to TycC9 (start sites 1 and 2) and TycC9PCP* (start site 1) and measured the kcat value 
(Figure S 3J). For “wt” and PCP mutant with the start site (1), I could not finally resolve this 
hypothesis. Both were activating Lys only to a very low degree, which makes it difficult to draw a 
conclusion even though both kcat values are very similar, which is what you would expect if the 
substrate cannot release itself from the PCP domain. For start site (2), Lys was activated at a 
higher speed, though not as much as Orn (Figure 30D), but I did not have the PCP mutant 
available for comparison (Figure S 3J).  
 Activity of A domains embedded in the dimodular constructs TycC8-9 and TycC9-10 4.4.3
The construction and analysis of the di-domain constructs served to find the best start site and 
validate the effects of the point mutations as well as the reliability of the online PPi release 
assay. The main objective however is to investigate the effects of module inactivation, through 
either lack of substrate or the introduction of point mutations, on surrounding modules. With 
that objective, I generated two dimodular constructs, TycC8-9 and TycC9-10 with start site (1), 
for analysis (Figure 31A, B). To shortly resume the investigation of the effect that natural and 
artificially placed TE domains can have on upstream A domains (section 4.4.1), I also added the 
TycC TE domain to Tyc8-9 (Figure 31A) and removed it from TycC9-10 (Figure 31B). The four 
constructs were expressed in and purified from BAP1 cells (Figure S 9A, B), then analyzed in vitro 
adding the amino acid substrates in various constellations using the online PPi release assay 
(Figure 31C, D).  
The two elongation modules, TycC8-9, with an without TE domain, both activated their 
respective substrates, valine and ornithine, regardless of the absence of the neighboring 
module’s substrate (Figure 31C) or presence of another amino acid (Figure S 9C). This finding 
supports the notion, that A domains in elongation modules can continuously activate their 
substrates without waiting for the upstream A domain to do so first. Comparing the A domain 
activity of the “wt” TycC8-9ΔTE with the version where the TycC TE domain was added 
(TycC8-9+TE = TycC(V-19_AVal-PCP-C-AOrn-PCP_A+4):(-F16)TE(TycC)), I realized that the artificially 
added TE domain did not cause a change in A domain substrate activation pattern. This is an 
observation I have also made for another dimodular construct TycC5-6:TE(BpsA) (Figure 28). 
Thus, I conclude that an artificial TE domain that naturally releases a different intermediate 
substrate does not aid substrate release and thus does not accelerate substrate activation 
rounds of non-native upstream modules. 
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For TycC9-10 in contrast, where the module 10 is naturally followed by the TE domain, its 
presence does make a difference (Figure 31D). In the presence of both substrates, ornithine and 
leucine, TycC9-10+TE seems to be capable of releasing the dipeptide at double the speed which 
results in a kcat value about twice as high as for the TycC9-10ΔTE variant. The corresponding 
mass of the linear dipeptide Orn-Leu was detected by Florian Meyerthaler (Mootz Lab, 
University of Münster) using LC-MS (Figure S 12A). When feeding the substrates individually, I 
discovered something unexpected: Ornithine as the sole substrate was activated by module 9, 
while leucine was not activated by its corresponding module 10, neither with nor without the TE 
domain (Figure 31D). The presence of an additional amino acid in the reaction did not change 
this outcome (Figure S 9D). It seems that in TycC9-10, the A domain for leucine (10) is unable to 
repeatedly activate its own substrate unless the upstream module (9) does so as well. This is the 
opposite of how the second modules in the dimodular constructs TycC5-6 and TycC8-9 reacted 
to a lack of substrate for the upstream module.  
To exclude that TycC9-10 suffers from an inherent dysfunction in module 10, Florian 
Meyerthaler performed a thiolation assay (described in section 1.2.5) using radiolabeled leucine 
and measuring the radioactivity of the precipitated enzyme (in CPM). With that, we could show 
that TycC9-10+TE can indeed activate and covalently tether leucine to its PPant arm in the 
presence of ornithine (Figure 31E) to the same degree as the positive control (TycC10ΔTE).  At 
the same time, thiolation was reduced significantly (p < 0.01) when ornithine was not available 
to the same construct (Figure 31E), but still well about background level (module 10PCP* mutants 
in TycC9-10+TE and TycC10ΔTE). This suggests that TycC9-10+TE does activate leucine in the 
absence of ornithine, though not repeatedly.  
In both native dimodular constructs, TycC8-9ΔTE and TycC9-10+TE, I inactivated each A and PCP 
domain individually through the established point mutations and investigated the effect on 
substrate activation of the affected and its neighboring module by comparing their kcat values. All 
mutants were purified with good yields (Figure S 9E, F).  
In TycC8-9ΔTE, module 8 does not show activity towards its native substrate valine upon 
A domain mutation (Figure 31F), which is the same effect observed for the di-domain construct 
TycC8A* (Figure 30C). Inactivation of the PCP domain in module 8 lead to a 31% decrease of the 
activity (p<0.005) towards valine(Figure 31F), which is a higher drop in activity than in TycC8PCP* 
(15% decrease, p=0.016, Figure 30C). Module 9 exhibited a differential effect of A domain 
mutation depending on whether it was embedded in this dimodular versus the di-domain 
context: The A domain mutation of module 9 in TycC8-9ΔTE only mildly affected ornithine 
activation, even in the absence of valine (Figure 31F), while in TycC9A* activity was completely 
abolished (Figure 30D). For the PCP domain mutation, the reactions were in line again. In both, 
TycC8-9PCP* (Figure 31F) and TycC9PCP* (Figure 30D) the A domain activity for Orn of that module 
was decreased. To test the hypothesis of ornithine auto release increasing the reaction speed of 
the upstream A domain, I replaced it by lysine. As expected, the 9PCP* mutant of TycC8-9ΔTE is 
not affected by the mutation when fed with lysine, but rather maintains the same activity level 
towards Lys as the “wt” (Figure S 11A). This activity level, in turn, is much higher than the 
activity towards the native substrate Orn, in the presence and absence of Val (compare Figure S 
11A and Figure 31F). Taken together, these data suggest that the presence of upstream 
elements changes the specificity of the A domain in module 9. 
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The native TycC9-10+TE dimodular construct was also mutated within each A and PCP domain 
separately and the effects on kcat values towards various substrates were recorded (Figure 31G). 
In this case, module 9 took the role of an initiation module and both mutations of this module, 
9A* and 9PCP*, resulted in loss of continuous A domain activity (Figure 31G). This observation is in 
agreement with what I observed for the single TycC9 module (Figure 30D). The effects of 
mutations of module 10 cannot be assessed individually for this construct, since its activity 
depends on the presence of Orn (Figure 31B). The result of the thiolation assay, however, shows 
that the module 10PCP* mutant is incapable of leucine thiolation (Figure 31E). By comparing the 
activation rates of “wt”, module 9 and module 10 mutants of TycC9-10+TE when both substrates 
are added to the reaction, it appears that both module 10 mutants do affect A domain activity, 
though not that of the upstream module (Figure 31G). 
Figure 31 | Activity of A domains within “wt” or mutated dimodular constructs of TycC8-9 and 
TycC9-10, with or without TE domain. (A, B) Schematic depiction of constructs with amino acids 
attached to the PPant arms. Brackets highlight the TE domain that is either present (+) or absent 
(-). Colors as in Figure 1, A. (C, D, F, G) Graphs showing kcat values for the indicated constructs in 
the presence of the indicated amino acids. Amino acids were added at 1 mM, enzymes at 
0.5 µM, except for TycC9-10ΔTE, which was added at 0.25 µM due to a lower yield in the 
purification. (E) Thiolation assay with [3H]-labelled L-Leu in the presence or absence of Orn. 
Counts per minute (CPM) were normalized to the value for TycC9-10+TE wt. ** p<0.01. Data 
represent the mean ± standard deviation, SD of three independent experiments. 
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 Analysis of A domains embedded in the tri-modular construct TycC8-9-10+TE 4.4.4
Finally, I created a tri-modular construct comprising the last three modules of the tyrocidine 
synthetase, TycC8-9-10+TE (Figure 32A) and the respective A and PCP mutants of all modules. 
Despite their large size of 326 kDa, I could purify them from BAP1 cells at a good yield (Figure 
32B). I again analyzed the “wt” and all mutant constructs adding Val, Orn and Leu, either 
individually or in combination and calculating the respective kcat values. For the “wt”, I detected 
that all modules were capable of repeatedly activating their respective substrate when it was the 
only one present in the reaction (Figure 32C). For module 10, this is contradicting to its 
performance in the di-module TycC9-10 (Figure 31D). The “wt” tri-modular construct also 
accepted lysine as a substrate instead of ornithine (Figure S 11C), also at a higher activation rate 
than the original ornithine and without any effect of the module 9PCP* mutant. From the overall 
higher activation rate when all amino acids were added, I assumed that the tripeptide was 
formed in vitro, which was confirmed by LC-MS (Figure S 12B). 
Analysis of the mutants upon feeding the different amino acids in different combinations 
illustrates the increasing complexity with increasing NRPS length. Also, drawing clear conclusions 
becomes more difficult. What I could observe is that embedded in the tri-modular construct, all 
A domains were still able to repeatedly activate their respective substrate despite carrying the 
mutation (Figure 32C-E) that completely abolished A domain activity in the initiation part of the 
dimodular constructs (Figure 31F, G) and in the minimal constructs (Figure 30C-E). I speculated 
whether the presence of an increasing number of modules facilitated a more native fold and 
thus rescued the A domain mutation by still binding ATP. However, no tripeptide was formed by 
the TycC8-9A*/PCP*-10+TE mutants as the LC-MS measurement confirmed (not shown). In 
addition, the mutation of module 9PCP* had no effect on Orn (Figure 32E) and Lys activation 
(Figure S 11C) as opposed to the di-domain TycC9 construct (TycC9PCP*, Figure 30D) and the 
dimodular TycC8-9 and TycC9-10 constructs (TycC8-9PCP* and TycC9PCP*-10, Figure 31F, G).  
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Figure 32 | Activity of A domains within the “wt” or mutated tri-modular construct 
TycC8-9-10+TE. (A) Schematic depiction of the construct with amino acids attached to the PPant 
arms. Colors as in Figure 1, A. (B) Coomassie-stained SDS-gel showing the indicated purified 
proteins. (C-F) Bar graphs showing kcat values for the indicated constructs in the presence of the 
indicated amino acids, calculated from the online PPi release assay after subtraction of the 
background (=no substrate) value. Amino acids were added at 1 mM, enzymes at 0.5 µM. Data 
represent the mean (± standard deviation, SD) of three independent experiments. 
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5. Discussion and Outlook  
5.1 Summary of achievements of this work and conclusions for future 
(engineering) approaches 
Through quantification of in vivo pigment production and in vitro PPi release, I analyzed a variety 
of different mutants of the two homologous indigoidine synthetases, IndC and BpsA, and 
conclude that the proposed biosynthesis mechanism is doubtful. Most notably, I propose that 
the TE domain plays a crucial role, not acknowledged in the current model, since pigment 
production in vivo and substrate activation in vitro are greatly affected by point mutations within 
this domain, in particular when mutating the conserved serine. Additional experiments, such as 
thiolation assays, whole enzyme MS detecting attached intermediate substrates and the crystal 
or cryo-EM structure of an indigoidine synthetase, could provide the missing information to 
finally elucidate the detailed biosynthesis mechanism. 
I continued to test the feasibility of using an indigoidine synthetase as a tag to monitor upstream 
NRPS module engineering with the premise that a blue pigment is exclusively formed if a module 
upstream of the indigoidine synthetase is present and functional. For the development of this 
system, I chose modules from the well-studied tyrocidine synthetase, namely modules 5 and 6, 
successively incorporating asparagine and glutamine. I screened various fusion sites between 
TycC6 and IndC, all located within the AGln domain of both NRPSs. From this screen, I identified a 
functional chimeric enzyme, which was capable of pigment production. I refer to it as  
TycC5-6:IndC “wt”. Upon impairing its upstream TycC5 module by a PCP domain mutation, this 
fusion enzyme almost completely lost its pigment formation ability. I changed the expression 
backbone of this promising construct and the indigoidine synthetase from IndC to BpsA and 
could thereby increase the pigment production in vivo by about 10 fold for the “wt”, while 
keeping it close to zero for the upstream PCPAsn mutant. However, in this TycC5-6:BpsA 
construct, mutation of the upstream AAsn domain did not impair pigment production. LC-MS 
analysis of the pigment formed by TycC5-6:BpsA in vitro revealed that the product is pure 
indigoidine without any asparagine attached. Taken together, these data suggest that 
engineered asparagine-indigoidine synthetases form the pigment only due to the activity of the 
TycC6:BpsA part and not due to the function of the fusion enzyme. Therefore, it is unclear why 
the N-terminal start site or the PCP domain mutation in the upstream TycC5 module can still 
have an influence on pigment production. Through these experiments it became evident yet 
again, how little is known about the cooperation and interaction of domains and modules within 
the context of larger NRPSs.  
For this reason, I investigated the behavior of natively connected NRPS modules of TycC, namely 
modules 8, 9 and 10 incorporating valine, ornithine and leucine, respectively. I purified all three 
modules, either individually (TycC8, 9, 10), as dimodules (TycC8-9 or TycC9-10) or trimodules 
(TycC8-9-10), introduced the same mutations to the A and PCP domains as I did for TycC5 and 6 
and analyzed the activation rates via PPi release feeding different substrate combinations. In this 
more native context, I found that the individual modules (A-PCP domains) all activated their 
native substrates and the activation rates differed depending on the N-terminal start site. In the 
dimodular constructs, the upstream module of the “wt” enzyme always activated its substrate 
while the downstream module did (in TycC8-9) or did not (in TycC9-10) repeatedly activate its 
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substrate in the absence of the upstream module substrate. For TycC9-10, the presence of the 
TE domain seemed to enhance the substrate conversion rate in case both substrates were 
present. In the trimodular construct, on the other hand, the A domains of all modules activated 
their substrate irrespective of the presence of other substrates. The mutations in the different 
modules had different effects on surrounding modules, depending on the context they were in. 
Sometimes, but not always, these effects matched the effects of not feeding the substrate of the 
mutated module. From these data I infer that a general conclusion about the cooperation of 
NRPS modules in their native context cannot be drawn as the module behavior varies extensively 
depending on its molecular environment. 
In summary, my results suggest that NRPS domains and modules of engineered as well as native 
NRPSs act differently depending on the context they are embedded in. Therefore, 
generalizations should be done with great caution. This finding also means that for every single 
engineering approach, the context might need to be evaluated anew, which would make a 
method for easy and high throughput screening of engineered NRPS function, as explored in this 
work, all the more valuable.    
5.2 Indigoidine synthetases and the proposed roles of the Ox and TE 
domains in the biosynthesis process 
Even though indigoidine and its synthetase have been used as a reporter system in various 
studies, the detailed biosynthesis mechanism remains elusive. In the currently proposed model, 
the order of events and the role of the TE domain are unclear. 
The investigation of indigoidine synthetases in vivo showed that the effects of point mutations 
can be assessed by measuring the absorption at 600 nm of the expression culture, thereby 
estimating product formation. Thus, indigoidine is a feasible reporter molecule for in vivo 
screening of NRPS modifications. This approach revealed differences in effects of point 
mutations between two homologous indigoidine synthetases, IndC and BpsA. In addition, an in 
vitro PPi release assay provided further information about the indigoidine production 
mechanism underlining the role of the TE domain and providing insights into why some of the 
mutants failed to produce indigoidine. Lastly, the attempts of generating an indigoidine-tagged 
amino acid by feeding BpsA with dipeptides containing a C-terminal glutamine led to the 
formation of pure indigoidine and the individual AA, suggesting that splitting of the dipeptide 
and concurrent or subsequent indigoidine production occurred. 
Indigoidine-tagged amino acids could not be detected after feeding BpsA with dipeptides, 
possibly due to the action of the oxidation domain 
From in vitro substrate activation of the different BpsA mutants, I tried to infer the order of 
events during indigoidine biosynthesis. As expected, an A domain mutant did not activate 
glutamine anymore. An oxidation domain mutant in contrast did still activate glutamine, though 
at a lower speed. This observation indicates that the substrate is activated by the A domain prior 
to oxidation. It is assumed that thiolation happens immediately upon activation and thus also 
prior to oxidation. It would be interesting to conduct further experiments, such as thiolation 
assays or PPi release assays of the Ox/PCP double mutant to elucidate this.  
Feeding dipeptides to wt BpsA revealed that the BpsA A domain is capable of activating a 
dipeptide even though it is natively intended to accept a single amino acid. This finding is 
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consistent with data from the Ackerley group317. After incubation with the dipeptides 
glycine-glutamine (GQ) and alanine-glutamine (AQ) for 72 hours (3 days), neither they314 nor I 
detected glycine or alanine attached to indigoidine. My hypothesis is that the oxidation domain 
might play a role in detaching the upstream amino acid from glutamine during the oxidation 
process, thereby producing pure indigoidine. This hypothesis is based on the observation that 
for wt IndC, pure indigoidine was only detectable after 3 days of incubation with the dipeptide. 
In addition, the BpsA oxidation domain mutant was still capable of activating glutamine at a time 
scale of minutes, not days but did not activate the dipeptide anymore. This observation 
contradicts the proposed order of events, because oxidation would need to happen before the 
activation. Further experiments as described above could clarify this ambiguity. 
The TE domain of IndC/BpsA differs from the TE domain of other NRPSs and plays a crucial role in 
indigoidine biosynthesis 
Most NRPSs feature a C-terminal thioesterase domain to release the final peptide product via a 
variety of release mechanisms, e.g. a linear peptide via hydrolysis or a cyclic peptide via 
intramolecular nucleophilic attack. In most NRPSs, the TE domain features a catalytic triad 
consisting of the amino acids serine (nucleophile), histidine (base) and aspartate (acid) common 
among many hydrolases and transferases. Indigoidine synthetases also feature a C-terminal TE 
domain, however, its contribution to indigoidine production is rather neglected in the current 
model of indigoidine biosynthesis. 
In contrast to other NRPSs, indigoidine synthetases only feature a potentially catalytic dyad 
consisting of serine and histidine. According to amino acid sequence alignments, the aspartate of 
other TE domains has been replaced by a small, neutral alanine in indigoidine synthetases. To 
establish the catalytic role of the conserved serine, I mutated this residue to alanine. This 
mutation prevented indigoidine formation in vivo and greatly reduced substrate activation in 
vitro. Since this conserved serine is not part of any predicted secondary structure within the TE 
domain, I conclude that it likely has a catalytic role in indigoidine biosynthesis. For a fatty acyl-
thioester hydrolase TE domain, it has been shown that the mutation of the conserved serine to a 
cysteine does not decrease the substrate activation rate kcat (wt = 0.11 s
-1 vs. S101C = 0.1 s-1)318 
presumably because cysteine can also serve as a nucleophile. In contrast, S to C mutation of 
indigoidine synthetase did have a great impact on substrate activation and decreased compound 
production by the same level as the S to A loss of function mutation. In a different study, a 
double S to C and H to R mutant slowed down the reaction kinetics of the polyketide 
Tautomycetin thioesterase very  much to effectively label the TE domain with the product 
intermediate, whereas the single mutants (S  C or H  R) failed to trap the intermediate 
product at the TE domain319. Single S to C mutation of indigoidine synthetases also failed to trap 
the intermediate product at the cysteine as assessed by LC-MS by Thomas Ruppert. During the 
lengthy sample preparation, involving sample digestion into smaller peptides that can be loaded 
onto the LC-MS, all substrates detached and were not found on the PPant arm or the TE domain. 
Thus, to elucidate the individual steps and order of events leading to indigoidine synthesis, the 
different BpsA mutants can serve as a basis to perform a combination of thiolation assays, 
including radio-labelled dipeptide substrates, and whole enzyme LC-MS to find the status of 
intermediate products still attached to the enzyme. In further experiments, both components of 
the catalytic dyad (S and H) could be mutated to test if the intermediate substrate (oxidized 
glutamine) is loaded onto the TE domain during biosynthesis.  
Analysis of A domains embedded in the tri-modular construct TycC8-9-10+TE 
102 
 
Reconstitution of the catalytic triad of the TE domain in IndC and BpsA through an alanine (A) to 
aspartate (D) mutation had ambiguous effects: for IndC, the pigment production was completely 
abrogated in vivo, while the BpsA mutant was still able to form indigoidine at a lower level. 
Replacing this alanine with another small, unpolar amino acid (glycine) in BpsA did not much 
affect pigment production. Thus, the third position of the triad might also serve a specific 
purpose in indigoidine synthetases, but in contrast to other NRPSs rather through its absence 
than its presence.  
Indigoidine formation rates inferred from the absorption at 600 nm differ from glutamine 
activation rates estimated by PPi release  
In vitro indigoidine formation by BpsA measured at 600 nm (~ 6 indigoidine per minute, 
corresponding to about 12 activated glutamine molecules) is about three times slower than 
glutamine activation as measured in the PPi release assay (about 36 molecules per minute) in the 
very same assay (Figure 9). These two values could deviate that much for different reasons: one 
is that the in vitro assay takes place in aqueous buffer, so some indigoidine might be in solution, 
but some of it might precipitate and thus not be available for proper absorption measurement. 
The extinction coefficient of indigoidine in buffer might be also different from DMF leading to a 
miscalculation of indigoidine levels. In addition, the adenylation step might not be the rate-
limiting step in indigoidine formation and thus more substrate might be activated than actually 
thiolated and further modified. This is expensive for the cell since it consumes ATP, but in this 
way the assembly line is always ready to continue. In favor of the second scenario is the 
observation that for lower substrate concentrations, kcat of indigoidine formation decreases too 
(~3 for 1 mM Q, 2.6 for 0.5 mM Q and 1.9 for 0.1 mM Q, as calculated from Figure 9A). 
BpsA mutants could serve as the basis for a crystal or cryo-EM structure 
A deeper insight into the indigoidine biosynthesis mechanism would be provided by a crystal 
structure of this enzyme. Upon its discovery in 2007, Takahashi et al. aimed to provide the 
crystal structure of BpsA202, but have not yet succeeded. Owen et al.115 sought to extract a 
homology model of the BpsA PCP-TE di-domain from the PCP-TE di-domain of EntF (PDB: 
2ROQ165). However, these two enzymes share less than 24% amino acid identity in the 
corresponding domains, which is well below the threshold needed to assume structural 
homology320,321. One reason for the difficulty to resolve the crystal structure of BpsA, is the high 
flexibility of this enzyme, which prevents the formation of crystals unless they are trapped in a 
certain, rigid state by a mutation or a functional inhibitor. Thus, the BpsA mutants I created, 
which showed only very low activation rates in the PPi release assay, could serve as a basis for 
solving the crystal structures of BpsA trapped in different states. Alternatively, cryo electron 
microscopy could be used to study the structure of BpsA. An advantage of this method is that it 
would potenitally allow the analysis of the enzyme in different states76 in presence of the 
substrate. 
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5.3 Exploration of an asparagine-indigoidine fusion synthetase 
constructed from TycC5-6 and IndC/BpsA 
An indigoidine synthetase was successfully reconstituted from the N-terminal part of the TycC6 
AGln domain followed by the Ox, C-terminal AGln, PCP and TE domain of IndC (Figure 13). This 
shows that the TycC6 A domain is capable of cooporating with the other domains of IndC to 
produce indigoidine. Further, the TycC6 A domain lies within a native elongation module that 
can be turned into an initiation module using different start sites. Some of these non-native start 
sites of the TycC6 A domain do not comprise parts of the upstream TycC6 C domain, which has 
been proposed to be a pre-requisite to turn an elongation into an initiation A domain80,81,266. 
Thus, to my knowledge, this is the first example of a successful elongation to initiation A domain 
transition functional in vivo, that does not feature a native C-A domain interface. 
Through screening different combinations of fusion sites between the TycC6 and indigoidine 
synthetase AGln domain, alternative TycC5 start sites, expression vectors and different indigodine 
synthetases, I identified a TycC5-6:BpsA construct, which was capable of producing a well visible 
amount of pigment while keeping it reasonably low upon PCPAsn mutation (Figure 14). Assuming 
that the naturally contiguous modules TycC5 and 6 sucessfully produce the dipeptide and TycC6 
meanwhile cooperates with BpsA to form the pigment, I suspected that the tagging can work to 
monitor the success of future NRPS engineering efforts. However, many observations point in 
the opposite direction: inactivation of the upstream TycC5 module via AAsn domain mutation did 
not lead to a decrease in pigment formation in comparison to “wt” TycC5-6:BpsA, indicating that 
the downstream indigoidine producing module is not necessarily dependent on upstream 
module functionality. Furthermore, the in vitro analysis revealed that the downstream module, 
specific for glutamine, can activate its substrate at high rates in the absence of asparagine, the 
substrate of the upstream module, while asparagine alone is activated at very low rates. The 
addition of both, asparagine and glutamine, to the reaction lead to a total kcat similar to when 
only glutamine was added, indicating that glutamine is converted to indigoidine irrespective of 
the upstream module input. Pigment production rates, monitored in parallel to the PPi release, 
confirmed this hypothesis. Both, the Ox as well as the TE domain, seem to play a crucial role in 
keeping the indigoidine assembly line running. This is also the case for the TycC5-6:BpsA fusion 
(Figure 16) since upon point mutations in either one of these two domains, the kcat value for 
glutamine is largely reduced and no pigment is formed anymore. At the same time, these 
mutations did not lead to a differential activation of asparagine by the upstream module. 
Unfortunately, all attempts to detect the indigoidine-tagged asparagine as the predicted product 
of “wt” TycC5-6:BpsA via ESI-MS (together with Heiko Rudy from the IPMB, Heidelberg) or the 
intermediate product still attached to the PPant arm of the second module of TycC5-6:BpsA 
Ox-K600E or TE-S1103A mutants (together with Thomas Ruppert from the ZMBH, Heidelberg) 
were unsuccesfull. As we only detected the unloaded PPant arm on the PCP domain (not 
shown), possibly the digest of TycC5-6:BpsA prior to loading the fragments onto the LC-MS took 
too long causing hydrolyzation of all intermediate substrates. Since in other publications, this 
approach led to the identification of bound substrates, further development of the experimental 
setup could help clarifying this issue118–122. Finally, the blue pigment formed by the TycC5-6:BpsA 
fusion construct in vitro was identified to be the same as the product of BpsA, i.e. pure 
indigoidine (Figure 18, in collaboration with Aubry Miller, Cancer Drug Development, DKFZ, 
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Heidelberg). The attachment of an additional amino acid onto indigoidine should lead to a shift 
in the absorption maximum (as for the attachment of lauric acid, Figure 5), which was not 
observed. One possible explanation why asparagine is not attached to indigoidine, is that, after 
asparagine and glutamine are successfully fused together at one point of the reaction, the 
oxidation of glutamine might lead to the elimination of asparagine, resulting in the formation of 
pure indigoidine. In this scenario, the oxidation domain mutant might produce the colorless 
dipeptide Asn-Gln, since it does not split off the Asn in the oxidation process. Alternatively, the 
oxidation of Gln could lead to the rejection by the C domain, which might be only able to process 
unmodified Gln. However, also the dipeptide hypothetically formed by the TycC5-6:BpsA 
oxidation domain mutant was not identified in LC-MS from the filtered in vitro reaction 
supernatant. Potentially, an alkaline34 or cysteamine-HCl322 treatment to release the 
intermediate product from the PCP domain and a specialized column optimized for separation of 
polar substances could still lead to the discovery of Asn-Gln formed by the hybrid enzyme 
oxidation domain mutant.  
Another proof of principle experiment would be to engineer a fusion synthetase where more 
than one NRPS module is placed upstream of the TycC6:BpsA tagging module. It could then be 
assessed whether the polypeptide is formed along with pure indigoidine. With the recently 
discovered, more general fusion sites within C domains266, this approach becomes feasible. 
Finally, I was surprised to see such different effects of the inactivation of module TycC5 on the 
downstream TycC6:BpsA part, depending on the type of inactivation (AAsn domain mutant versus 
PCPAsn domain mutant) and the type of analysis (in vivo expression and absorption at 600 nm 
versus in vitro PPi release assay). The discrepancy between in vivo and in vitro analysis could 
have a variety of reasons. Enzyme folding might be suboptimal in vitro, influenced by the 
purification process and the storage buffer. Another stabilizing effect might be caused by the 
presence of other proteins in vivo, the so-called crowding effect. I also tried to mimic this effect 
in vitro through the addition of 30% Ficoll 70, which has been shown to decrease the formation 
of linear side products of the enterobactin synthetase reconstituted in vitro323. However, this 
additive did not have an influence on the kcat values of TycC5-6:BpsA (not shown). Another 
condition that might cause the deviation between absorption at 600 nm of the bacterial 
expression culture and the in vitro reaction is the concentration of reactants. It is very hard to 
estimate or measure the concentration of e.g. amino acids in bacterial cells. On the other hand, 
in vitro the local concentration of amino acids is set up precisely and is at 1 mM, likely higher 
than in vivo, possibly influencing the reaction of the enzyme. The reaction product also 
accumulates in vitro, which in the case of NRPSs can have a product inhibition effect, e.g. for 
higher concentrations of PPi
64. In the used coupled PPi release assay, however, the PPi is also 
converted and should not cause any problem. The conditions of in vitro assays need to be 
defined carefully with regards to the buffer system, pH and reactant concentrations, to ensure 
enzyme viability. At the same time, these defined conditions enable the comparison of different 
enzymes and mutants. Thus, I decided to investigate the same mutations and effects of selective 
substrate feeding in a more native multi-modular construct to find out whether they do wait for 
the upstream substrate activation in vitro, also in the termination module. These questions were 
addressed in section 4.4 and will be discussed in section 5.5.  
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5.4 Other NRP-indigoidine synthetase fusions – an opportunity for the 
production of indigoidine-tagged NRPs  
I undertook several different approaches to still produce an indigoidine-tagged AA. They 
included changing the post A10 motif within the TycC:BpsA fusions, randomly mutagenizing the 
hybrid enzyme, externally supplementing the oxidation domain to Ox-K600E mutants or 
inserting the Ox domain into the TycC6 module, externally supplementing the TE domain to 
delta TE constructs as well as creating fusions between IndC/BpsA and other known NRPSs 
modules incorporating glutamine. Unfortunately, none of these approaches lead to substantial 
progress in the production of an indigoidine-tagged AA. 
A putative natural dodecylindigoidine synthetase (dIndS), however, demonstrates that it is 
indeed possible for an enzyme to fuse an upstream module substrate (here a fatty acid) to the 
downstream module product indigoidine, though apparently via a different mechanism than I 
envisioned for the artificial AA-indigoidine fusion synthetase. Thus, in this part of the discussion, 
I will focus on the initial experiments done to elucidate the functional mechanism of the putative 
dIndS and how it could be validated for further use in engineering. 
Possible reasons for the problems of investigating dIndS and proposed further experiments to 
elucidate its function 
The pigment N,N-dodecylindigoidine produced in Shewanella violacea proofs that a fatty acid 
(and thus maybe also amino acids or peptides) can be tagged with indigoidine. Furthermore, it 
shows that if another molecule is attached via a peptide bond to the original N-terminus of 
glutamine, which corresponds to the free primary amino group of indigoidine, this molecule still 
has an absorption maximum around 600 nm, here 635 nm, and is thus visible by the naked eye. 
This absorption maximum could differ, if other molecules, e.g. amino acids instead of fatty acids, 
are fused to indigoidine. For these reasons, it is of interest to understand how 
N,N-dodecylindigoidine is formed and which NRPS and other enzymes or co-factors are 
responsible for its production. Nonetheless, Konrad Herbst’s and my own attempts to 
experimentally validate and engineer the putative dIndS to tag amino acids with indigoidine 
were unsuccessful. In the following, I will speculate why and present some ideas what to 
consider for future investigations.  
In the initial in silico identification of the putative dodecylindigoidine synthetase (dIndS) gene, six 
other proteins exclusively shared between the two pigment producing organisms S. violacea and 
Rheinmera baltica were identified221. Four of them are part of a gene cluster related to 
polysaccharide biosynthesis and export324, while the other two (accession number 
WP _013051036.1 and WP_041420101.1) are characterized by domains of unknown function 
(DUF1772 and DUF1302, respectively) according to the conserved domain database222. 
Additionally, it is known that in S. violacea the pigment is only produced on solid medium (e.g. 
supplemented MB agar plates) and not in liquid culture217. This could be due to an external 
trigger needed to activate an internal pathway necessary to initiate pigment production. These 
associated proteins and pathways might be concertedly responsible for pigment production and 
make an easier target for gene disruption than just one sole gene. 
Likely for that reason, the random transposase-mediated integration of the R6K/kanamycinr 
cassette into the S. violacea genome yielded a high number of non-pigment producing colonies 
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(Figure 25B), at least four of which did not have an insertion in the putative dIndS gene as 
confirmed by PCR. Thus, it would be interesting to perform a sequencing reaction from the 
kanamycin resistance gene outwards to map the integration site back to the genome as 
originally planned305 (Figure 25A, b). Unfortunately, there were no bacterial colonies after digest 
and re-ligation of the S. violacea genomic DNA of the non-pigment producing clones (scheme in 
Figure 25) and thus no sequencing could be done from the extracted plasmids containing the 
kanr interrupted DNA fraction. A technical problem might have compromised the experimental 
outcome as after BamHI digest, the genomic fragments were too big (10-30 kbp on average, 
Figure S 8) for efficient transformation into E. coli. This experimental approach should be 
reassessed adding a second restriction enzyme to the digest reaction.  
A different approach would be to perform a targeted gene disruption of the putative 
dodecylindigoidine synthetase gene to verify that dIndS is one of the crucial enzymes in 
dodecylindigoidine production. An advantage of that approach is that all other components of 
the pathway or other factors would be left untouched and that is why the lack of pigment 
production could really be attributed to the inactivation of the single gene of interest.   
Judging from the bioinformatical predictions, I was nevertheless quite convinced that we had 
identified the correct NRPS gene responsible for N,N-dodecylindigoidine production. Therefore, I 
shifted to a bottom-up approach to prove its function. I amplified the gene from Shewanella 
violacea, inserted it into an E. coli compatible backbone (pCDFDuet) and expressed it in BAP1 
cells. The enzyme was successfully expressed without any further codon optimization (Figure S 
8C). However, it did not show any pigment production on solid (LB agar plate, not shown) or 
liquid medium (M9 minimal medium, Figure 26C), neither when co-expressed with the PPtase 
from Bacillus subtilis or with the endogenous PPtase (WP_013050488.1) from S. violacea.  
The replacement of the first A domain of the native dIndS specific for dodecanoic (= lauric) acid 
by A domains of the tyrocidine synthetase (TycC) specific for valine, ornithine or leucine, likewise 
did not lead to any pigmentation of the liquid expression culture (Figure 26C) despite proper 
enzyme expression. Therefore, I conclude that additional enzymes of the dodecylindigoidine 
production pathway need to be present in order to form the final product. An external trigger 
needed in native S. violacea should not be crucial when being expressed under the IPTG 
inducible promotor of the pCDFDuet vector. However, an external oxidation or condensation 
domain could be missing to successfully produce dodecylindigoidine in E. coli. Putative proteins 
found in a BLAST search of IndC and BpsA oxidation domain sequence within the S. violacea 
DSS12 genome include BAJ02469.1, BAJ01856.1, BAJ03901.1 and BAJ00582.1. They could be 
tested for co-expression with the native dIndS in E. coli and other host organisms more closely 
related to the marine bacterium Shewanella. Once dodecylindigoidine is successfully produced, 
engineering of the first A domain and addition of further upstream NRPS modules could be 
tackled.  
Overall, experimental identification of the enzyme(s) required for dodecylindigoidine production 
and its/their successful re-engineering presents a great challenge but worthwhile to be 
continued. 
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5.5 A domains activate their substrate dependent on the context 
Since during analysis of the TycC5-6:indigoidine synthetase fusions it became evident that 
A domain activity differs depending on which domains are around and in which status they are 
(e.g. absence of substrate or mutation), I wanted to investigate whether this is also the case for 
A domains of modules naturally belonging together. For this experiment I chose the last three 
modules of TycC from the tyrocidine synthetase and analyzed their A domains in the presence 
and absence of the native neighboring domains as wt and mutants and when feeding different 
substrate combinations (section 4.4). Here I rely almost entirely on the PPi release assay, which is 
why I will discuss its advantages and drawbacks prior to discussing the data obtained with it. 
Advantages and drawbacks of the coupled online PPi release assay in comparison to the ATP/PPi 
exchange assay 
The coupled PPi release assay was recently adapted to be used for analysis of NRPS A domains
70. 
This assay is suitable to measure either one distinct round of activation in a photospectrometer 
where substrates can be added while the absorption measurement continues or, as I used it, for 
higher throughput measurement of repeated activation cycles in a plate-reader. Since we 
measure the release of PPi (subsequently converted by an enzymatic cascade resulting in the 
oxidation of 2 NADH to 2 NAD
+), the adenylation reaction and the transition of the A domain to 
the thiolation state need to happen prior to this release. For this reason, a point of criticism of 
this type of assays is that, if the aminoacyl-AMP cannot be thiolated or further processed, e.g. 
because of the absence of the downstream module or the mutation of the downstream PCP 
domain, no repeated activation and thus PPi release can be detected.Consequently, for these 
impaired enzymes, what is measured in the PPi release assay is the frequency of loss of the 
aminoacyl-AMP from the A domain active site325 or the hydrolysis from the upstream PCP 
domain, both prerequisites to clear the way for another cycle of substrate activation. 
In contrast, the most commonly used assay to study NRPS A domains, the ATP/PPi exchange 
assay326, measures the reverse reaction of AMP+[32]PPi after adenylation has taken place and 
thus does not require a release of the aminoacyl-AMP. Therefore, the ATP/PPi exchange assay 
cannot provide information about the concerted action of A domains in intact NRPS systems, 
which the online PPi assay is able to provide to some degree (e.g. the effect of the TE domain 
speeding up substrate activation of the upstream modules). Of course, also with the PPi release 
assay it is not possible to determine which A domain of a multimodular NRPS executed the 
activation; however, one can draw conclusions from selective substrate feeding. Further 
disadvantages of the ATP/PPi exchange assay are that it requires radioactive PPi and that the 
reaction setup cannot be used to compare the substrate activation rate with product formation. 
On the other hand, using the PPi release assay, one could measure the product formation rate 
using an LC-MS from the very same reaction and compare it to the calculated A domain 
activation rates, which could demonstrate whether these two values match.  
In studies comparing (other) PPi release assays with the ATP/PPi exchange assay, the estimated 
kcat values do differ significantly, often resulting in higher values for the ATP/PPi exchange 
assay325,327. In one example, the ATP/PPi exchange assay did not exhibit any substrate activation 
in vitro for the fatty acid adenylating enzyme FadD28, while in a PPi release assay, a kcat value for 
the respective module could be determined328.  
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In conclusion, no assay is perfect and the best approach is to combine several methods when 
investigating a biological process. For the activity of A domains this would include a combination 
of the PPi release with product formation and thiolation assays, as done for critical samples in 
section 4.4, the results of which will be discussed next. 
Context dependent activity of A domains of the tyrocidine synthetase TycC 
A more detailed biochemical characterization of NRPSs, in particular within a larger cluster of 
NRPS modules naturally belonging together, is needed for a better understanding of the 
processes during NRP formation. To this end, I measured the A domain activity for different 
constructs combined from the last three modules of TycC with different substrate combinations 
in otherwise identical conditions. Moreover, I introduced the A (D to A) and PCP (S to A) domain 
mutations as described before, preventing ATP binding and conversion to a holo-enzyme, 
respectively, and assessed their influence on A domain activity.  
Mutations of the ATP binding site of A domains led to the loss of adenylation ability in single 
modules (A-PCP di-domains, Figure 30) and the initiation module of both dimodular constructs 
(Figure 31). In contrast, the A domains of the downstream modules of the di- and trimodular 
constructs were still capable of activating their substrates (Figure 32). One could speculate that 
upstream neighboring modules stabilize the A domain conformationally to still bind ATP since 
the aspartic acid we mutated is not catalytically active. However, the trimodular construct 
TycC8-9A*-10+TE, where the A domain of module 9 was mutated, did not yield a tripeptide 
product as confirmed via LC-MS product formation assay (not shown). Another explanation why 
I detected adenylation activity for mutated A domains in elongation modules is that a different 
A domain activates their non-native substrate. However, this explanation is also rather unlikely 
because for the di-domains I showed that each A domain primarily activates its cognate amino 
acid. Furthermore, in that case the initial A domains would also be affected. 
Mutation of the PCP domain also has different consequences on A domain activity depending on 
which context they are in. Two out of the three A-PCP di-domains tested could still activate their 
substrates upon PCP domain mutation, as has been described before for other partial NRPSs 
without PPant arm47,316. The di-domain specific for ornithine fails to activate its substrate upon 
PCP domain mutation. Possibly this is because ornithine can auto-cyclize and thereby release 
itself quickly from the PPant arm allowing the enzyme to undergo another round of activation. 
By feeding an alternative substrate, lysine, I tested this hypothesis, but could not finally resolve 
the question. The same PCP domain mutation in constructs consisting of two modules impairs 
the adenylation activity of the cognate A domains (Figure 31). Again, there are differences in the 
quantity of impairment depending on the context, since the A domain of module 8 is less 
affected by the PCP domain mutation than the A domain of module 9 (32 % decrease versus 
67 % decrease, respectively). In addition, I investigated module 9, specific for Orn, when acting 
as initiation (in TycC9-10) or termination module (in TycC8-9). The effect of the PCP domain 
mutation of this same module 9 is much more severe when it acts as an initiation module (Figure 
31F versus G). Notably, the same mutation in the TycC8-9PCP*-10+TE trimodular construct does 
not lead to a decrease in adenylation by its cognate A domain in comparison to the “wt” (Figure 
32).  
Finally, whether a module is repeatedly activating its substrate seems to depend on the state of 
the upstream module(s) only in rare cases. Most of the time, downstream modules do not seem 
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to wait for an incoming substrate from their upstream module to activate their own substrate, 
which is what we observe for the trimodular enzyme. For native NRPSs in vivo, this continuous 
substrate activation would be expensive for the producer organism as it would also continuously 
consume ATP. Thus, it is likely, that in vivo, each A domain activates and thiolates its substrate 
irrespective of the status of the surrounding modules and is then “locked” in a conformation 
awaiting the incoming donor amino acid/peptide. With this mechanism, the assembly line is 
constantly ready for the instant production of the NRP, once all substrates are available. The 
dimodular construct TycC9-10 represents an exception, as it does not repeatedly activate the 
substrate of the downstream module 10, leucine, in the absence of the upstream module 
substrate ornithine, or in case of any of the two mutations (A or PCP domain) of the upstream 
module (Figure 31D, G). Possibly, module 10 in this case undergoes only two cycles of 
adenylation (one to load the PCP domain and another one where the activated substrate 
remains in the active site pocket A domain) unless the upstream C domain is presented with an 
acceptor substrate. At least one round of successful thiolation was confirmed by the thiolation 
assay (Figure 31E). A similar observation was recently reported in a different study70. 
In conclusion, I believe that generalizations for domain and modules of NRPSs should be done 
with great caution, as their behavior appears to be very much dependent on the context they 
are embedded into.  
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6. Supplementary information 
6.1 Primers 
 Sequencing primers 6.1.1
For inserts into pTrc99 and pCDFDuet 
# name sequence 
42  ACYCDuetUP1 GGATCTCGACGCTCTCCCT 
43  DuetDOWN1 GATTATGCGGCCGTGTACAA 
44 DuetUP2 TTGTACACGGCCGCATAATC 
45 T7 Terminator Primer GCTAGTTATTGCTCAGCGG 
46  pTrc99a Seq  fwd gtgtggaattgtgagcgg 
226 FW ptrc99a Seq fwd GCGCCGACATCATAACGGTTC 
227 FW ptrc99a_rv CGCTACTGCCGCCAGGC 
278 226_pTrc99Seq_rv cagaaccgttatgatgtcggcgc 
Within IndC 
101 IndC_Ad_rv cccaatacccaccgaactc 
116 IndC(K1014)_fwd tggattgaacagacagac 
117 IndC(C803)_rv gcagaaataaaatgccgcc 
203 IndC_ox-A_linker_fwd attccacgctgtgtccctg 
253 IndC_R524_rv ggaagtaagaatgtagggcg 
Within BpsA 
299 BpsA-G362_Seq-fwd GGGAGAGATTGGGGAACTG 
300 BpsA-L709_Seq-fwd GGACGTGGCTGACGAGG 
329 BpsA-L709_Seq-rv CCTCGTCAGCCACGTCC 
334 BpsA_I777_rv CTGGTACACGCTCTGGTTG 
Within the Tyrocidine synthetase 
202 TycA-I366_fwd CGAAGGCGAATTGTGCATC 
204 TycA_T841_fwd ACCGAGCAGTTGTTGAAGCACG 
88 TycC_M6-A_fwd CAG ATG GTT CCG TCC TTG C 
88rv TycC_M6-A_rv GCAAGGACGGAACCATCTG 
90 TycC(AGln)_fwd GTGGAGGAGCAAGCAG 
91 TycC(AGln)_rv CTGCTTGCTCCTCCAC 
104 TycC_CAsn-Gln_rv GCTGATTCCGTTGCCTTC 
143 (TycA_S28)TycC(I-5)fwd ATTTTCGAGCTGATCGCGG 
159 TycC(HxxPF+x-AGln)_fwd GGATCAGTGAGCAGCCAAC 
160 TycC(HxxPF+x-AGln)_rv GTTGGCTGCTCACTGATCC 
332 TycC-CAsn-Gln-L140_rv CTCGGCAAATTCACGCAGC 
333 TycC-CAsn-Gln-HxxxPF_fwd CCAGCTCACATTCGCAACC 
349 TycC(COrn-Leu_F278)_fwd CGTGAACACCTTGGCGATGC 
350 TycC(COrn-Leu _F278)_rv GCATCGCCAAGGTGTTCACG 
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369 TycC-AVal(L239)_fwd GTCGCCGAAGCACATCAACC 
370 TycC-AOrn(P296)_fwd CGCTTCCGAACATGACGATG 
371 TycC-ALeu(Q234)_fwd GTTGCGTTGCGTCACTTTGG 
352 TycC(-41L_AOrn)_fwd CTGCACAGCTTCCTCGCAACC 
353 TycC(-41L_AOrn)_rv GGTTGCGAGGAAGCTGTGCAG 
397 TycC-AOrn(E135)_fwd GAGCACCGCAGCTATGCC 
398 TycC-ALeu(E61)_fwd GAGCGCATTCAGTACCTGCTC 
Within LchAA 
138 LchAA_AGln_657_fwd GCTGCCGATGATCTTTCAG 
139 LchAA(AGln_F2)_fwd TTCGAACAAAAAGCAGC 
Within the dIndS 
20 a Sviola 4553224 fwd CGATGTAAACCACCAAGTGC 
58 a Sviola 4552808 fwd ATCTGGCTCCGCATACTGG 
21 a Sviola 4555179 rv CTGGGTGTGCGATTGTTAGC 
22 b Sviola 4555179 fwd GCTAACAATCGCACACCCAG 
23 b Sviola 4557222 rv GCACTAGCGAGTATGAGTTTCC 
24 c Sviola 4557222 fwd GGAAACTCATACTCGCTAGTGC 
25 c Sviola 4559501 rv CGCTGTTAGTCGTCATCAATGG 
62 Tn903_Kan_fwd CTCTTCCGACCATCAAGC 
63 Tn903_Kan_rv GCTTGATGGTCGGAAGAG 
 Primers for Gibson assembly 6.1.2
To prepare empty vectors pTrc99, pCDFDuet(MCS1) and pCDFDuet(MCS2) 
39 pTrc99_Orf_fwd tgagagaagattttcagcctg 
40 pTrc99_Orf_rv catggtctgtttcctgtgtg 
32 pCDFDuet_MCS1_rv catggtatatctccttattaaagttaaac 
33 pCDFDuet_MCS1_fwd taatgcttaagtcgaacagaaag 
26 pCDFDuet_MCS2_fwd taattaacctaggctgctg 
27 pCDFDuet_MCS2_rv catatgtatatctccttcttatacttaac 
IndC in pCDFDuet or pTrc99 
93 IndC_MCS2_fwd gttaagtataagaaggagatatacatatgttagaaaataatattacac 
94 IndC_MCS2_rv cagcagcctaggttaattagattattttctcaatctc 
106 
IndC(TE_GSG-His6):(MCS
2)_rv50C 
cagcagcctaggttaattagtggtgatggtgatgatgACCTGATCCgattatt
ttctcaatctca 
107 
IndC(TE_GSG-His6):(MCS
2)_rv63C 
cagcagcctaggttaattagtggtgatggtgatgatgACCTGATCCgattatt
ttctcaatctcagcaacac 
95 IndC(MCS2-M27)_fwd gttaagtataagaaggagatatacatatgcttgagagtcaact 
109 IndC(MCS2-A21) gtataagaaggagatatacatatggcaataacattgatgg 
206 IndC(T1023)_MCS2_fwd gaaggagatatacatatgacaatatcaagattaattttattg 
207 
IndC(His6-GSG)_MCS1_fw
d 
ctttaataaggagatataccatgcatcatcaccatcaccacGGATCAGGTtta
gaaaataatattacacaatgtgac 
208 IndC(K1022)_MCS1_rv ctttctgttcgacttaagcattatttagagtctgtctgttcaatcc 
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225 IndC(pTrc99)_fwd cacacaggaaacagaccatgttagaaaataatattacacaatgtgactc 
BpsA in pTrc99, BpsA TE domain in pCDFDuet(MCS1) and BpsA Ox domain in pCDFDuet(MCS1) 
279 
BpsA(pMM64)_pTrc99_f
wd 
cacacaggaaacagaccatgACTAGTACACTGCAGGAAACAAGC 
280 
BpsA(pMM64)_(GSG-
His6)pTrc99_rv 
ggctgaaaatcttctctcagtggtgatggtgatgatgACCTGATCCAGCTT
CCCCCAGCAGGTATC 
339 BpsA(E1015)-pCDF1_fwd ctttaataaggagatataccatgGAGTCTAGTCGCTTCGTCCG 
340 
BpsA(pMM64)_(GSG-
His6)pCDF1_rv 
ctttctgttcgacttaagcattagtggtgatggtgatgatgACCTGATCCAGC
TTCCCCCAGCAGGTATC 
341 BpsA(Q1014)-pTrc_rv caggctgaaaatcttctctcaCTGAGCCACTTCTCTCTCCAG 
346 BpsA(Y569)-pCDf1_fwd ctttaataaggagatataccatgTACTCTCGGAAGGCAGCCG 
347 BpsA(L695)-pCDF1_rv ctttctgttcgacttaagcattaCCAGGCCATAGGCTGGC 
TycA with TycB-ComD in pCDFDuet(MCS1) 
114 TycA(MCS1)_fwd gtttaactttaataaggagatataccatgTTAGCAAATCAGGC 
113 
TycA(Ed1+L135)-
TycB_ComD):(MCS1) 
CAATTGAGCCAAAGTTATCAAAAGCATCTGCTTGGCATCATCG
AGCATTGCATGGCAAAAGAAGAAGGCGAGTACACCCCGAGC
GACCTGGGGGATGAAGAGCTGTCCATGGAGGAGCTGGAAAA
CATCCTGGAATGGATTtaatgcttaagtcgaacagaaagtaatcgta 
115 TycA(L1046)_rv2 GCAGATGCTTTTGATAAC 
TycC modules Asn (5) and Gln (6) different start sites in pCDFDuet(MCS2) 
112 
TycC(M1_CD-Phe-
Asn):(MCS2)_fwd 
gttaagtataagaaggagatatacatatgAAAAAGCAGGAAAACATC
GC 
85 
TycC(Q-167_AAsn)_(MCS2)_
fwd 
gttaagtataagaaggagatatacatatgCAGACGAACAAACAACAG
ACGTTCAGC 
192 
TycC(I-
30_AAsn):(MCS2)_fwd 
gtataagaaggagatatacatatgATCACCGAAGAGGAAAAGCAG 
193 
TycC(ML-E-27_AAsn)- 
(MCS2)_fwd 
gtataagaaggagatatacatatgCTGGAGGAAAAGCAGCAACTGC
TC 
147 
(MCS2)TycC(MLA-Y-
18_AAsn)fwd 
gtataagaaggagatatacatatgCTGGCCTACAACGACACGGCTG
CTG 
141 
TycC(Y-
18_AAsn):(MCS2)_fwd 
gttaagtataagaaggagatatacatatgTACAACGACACGGCTGCTG 
144 
(MCS2)TycA(M1-
S28):(I-5_AAsn)TycC 
aagtataagaaggagatatacatatgTTAGCAAATCAGGCCAATCTC
ATCGACAACAAGCGGGAACTGGAGCAGCATGCGCTAGTTCC
ATATGCACAGGGCAAGTCGATTTTCGAGCTGATCGCGG 
142 
TycC(I-5_ AAsn)- 
(MCS2)_fwd 
aagtataagaaggagatatacatatgATTTTCGAGCTGATCGCGG 
131 
TycC(Q-
167_AGln):(MCS2)_fwd 
gtataagaaggagatatacatatgCAGCCTGCCAGCAGCAAAAC 
105 
TycC(S-42_AGln):(MCS2)_fw
d 
G TAT AAG AAG GAG ATA TAC ATA TGA GTG AGC AGC 
CAA CGG CAAG 
96 
IndC(M1-27):(V1_AGln 
_TycC)_rv 
CTGCTTGCTCCTCCACcatatccatcaatgttatt 
148 (MCS2)TycC(L-19_AGln)fwd 
gtataagaaggagatatacatatgCTGAACGTGAACGATACGTTTGT
CG 
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108 TycC(A-7_AGln):(MCS2)_fwd gtataagaaggagatatacatatgGCGACCGCTTTGCATCAATTAG 
81 TycC(AGln_V1)_(MCS2)_fwd 
gttaagtataagaaggagatatacatatgGTGGAGGAGCAAGCAGCA
CGC 
TycC:IndC different fusion sites 
145 
TycC(V-37_ 
AGln):(N3_IndC)rv 
gtaatattattCACGTTCAGAAGGAGTGTGCG 
146 IndC(N3)_(V-17_AGln)_fwd TCTGAACGTGaataatattacacaatgtgactc 
149 
TycC(A20_ 
AGln):(L48_IndC)_rv 
gcgtaactgagGGCATATTCTTCGTACACGACGG 
150 
IndC(L48)_(A20_AGln)TycC_f
wd 
AGAATATGCCctcagttacgctgatttc 
151 
TycC(L173_ 
AGln):(G210)IndC_rv 
gaatgacatccCAGCGGGAACGTCTCTCTC 
152 
IndC(G210)_(L173_AGln)Tyc
C_fwd 
GTTCCCGCTGggatgtcattcccggattttac 
153 
TycC(F270_ 
AGln):(L306)IndC_rv 
gtaaaactattcaaAAAACGCGAGACGAGGGC 
154 IndC(L306):(F270_AGln)_fwd CTCGCGTTTTttgaatagttttactcactg 
155 
TycC(K309_ 
AGln):(P349)IndC_rv 
tatctacaggTTTGCCGATCGGAATTGC 
156 
IndC(P349):(K309_AGln)TycC
_fwd 
GATCGGCAAAcctgtagataataccgaatac 
97 
TycC(AGln_D372):(L415)IndC
_rv 
ctggttaccagGTCTCCGGTACGGTACATGGTGC 
98 
IndC(L415):(D372_ 
AGln)TycC_fwd 
GTA CCG GAG ACC TGG TAA CCA GAG GGG CTG 
82 
TycC(AGln_G425)_(R468)Ind
C_rv 
gagattttggaaacccgttctGCCATCCTGGCGGGCCATG 
83 
IndC(R468):(G425_AGln)Tyc
C)_fwd 
CATGGCCCGCCAGGATGGCagaacgggtttccaaaatctc 
194 
TycC(K426_ 
AGln):(G470)IndC_rv 
gattttggaaaccTTTGCCATCCTGGCGGG 
195 
IndC(G470):(K426_AGln)Tyc
C_fwd 
GGATGGCAAAggtttccaaaatctcatcgc 
243 
TycC(AGln 
_K426):(T469)IndC_rv 
ggaaacccgtTTTGCCATCCTGGCGG 
244 
IndC(T469):(K426_AGln)TycC
_fwd 
GGATGGCAAAacgggtttccaaaatctcatc 
157 
TycC(R395_ 
AGln):(G438)IndC_rv 
tacggtaaccTCTGATTTTGACTTGATGGTCG 
158 
IndC(G438):(R395_AGln)Tyc
C_fwd 
CAAAATCAGAggttaccgtattgagc 
196 
TycC(A437_ 
AGln):(D481)IndC_rv 
ctttctcatcCGCTACGACATAGGCGTAC 
197 
IndC(D481):(A437_AGln)Tyc
C_fwd 
TGTCGTAGCGgatgagaaagaagctgcattg 
245 
IndC(E876):(G427_AGln)TycC
_rv 
CTGTTTTGCCCttcacacatatattgcgcttgg 
246 TycC(G427_ atatgtgtgaaGGGCAAAACAGCCTGTACG 
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AGln):(E876)IndC_fwd 
247 
TycC(PCPGln-
A58):(K1014)IndC_rv 
caatccacttCGCGATCGTTGGCGAT 
248 
IndC(K1014):(PCPGln -
A58)TycC_fwd 
AACGATCGCGaagtggattgaacagacagactc 
118 
IndC(K922)-TycC(AGln_V477-
PCP_A565):(W1015)IndC 
gatagacctatggcggcattttatttctgcataggtgggggtattagccaagcgc
aatatatgtgtgaaggcatgaaagaagatgttgttcatatgaaagggccagttg
aaatcattaaagatgatcttcaacaacaactccctcaatatatgattccaaata
aggtattagttttcgataaattacctttgacggccaatggaaaaGTGGATCG
CAAGGCATTGCCTCAACCGGAGGATGCCGCCGCCTCTGCTG
CCGTGTATGTGGCGCCGCGCAACGAATGGGAAGCCAAGCTC
GCAGCGATATGGGAAAGTGTGCTTGGAGTCGAGCCGATCG
GGGTTCACGATCATTTCTTTGAACTGGGCGGACATTCTTTGA
AAGCGATGCACGTCATTTCTTTGCTCCAGCGCAGCTTCCAGG
TGGACGTACCGTTGAAAGTCCTGTTTGAATCGCCAACGATC
GCGGGCCTGGCCtggattgaacagacagactctaaaac 
119 
IndC(I864)-TycC(AGln_K426-
PCP_A565):(W1015)IndC 
cttgatagacctatggcggcattttatttctgcataAAAGGGCAAAACAG
CCTGTACGCCTATGTCGTAGCGGAGCAGGACATCCAGACAG
CGGAGCTGAGAACGTACCTGTCTGCCACCTTGCCAGCCTAC
ATGGTTCCGTCCGCTTTTGTTTTCTTGGAGCAGCTGCCGCTTT
CAGCGAACGGCAAAGTGGATCGCAAGGCATTGCCTCAACCG
GAGGATGCCGCCGCCTCTGCTGCCGTGTATGTGGCGCCGCG
CAACGAATGGGAAGCCAAGCTCGCAGCGATATGGGAAAGT
GTGCTTGGAGTCGAGCCGATCGGGGTTCACGATCATTTCTTT
GAACTGGGCGGACATTCTTTGAAAGCGATGCACGTCATTTCT
TTGCTCCAGCGCAGCTTCCAGGTGGACGTACCGTTGAAAGT
CCTGTTTGAATCGCCAACGATCGCGGGCCTGGCCtggattgaac
agacagactctaaaacaatatcaag 
TycC:IndC/BpsA in pTrc99a 
209 
TycC(Q-167_AGln)_pTrc99_f
wd 
cacacaggaaacagaccatgCAGACGAACAAACAACAG 
395 TycC(-29T_AAsn)_pTrc_fwd cacacaggaaacagaccatgACCGAAGAGGAAAAGCAGC 
372 TycC(-21-AAsn)-pTrc_fwd cacacaggaaacagaccatgCTCGTCGCCTACAACGACAC 
381 
TycC(PCPGln_A5):(GSG-
H6)_rv 
gatgatgACCTGATCCGCGGGCAGCCGCAAC 
383 TycC(PCPAsn_+E4)_rv gatgatgACCTGATCCTTCCGACCGCGAAAGGAAG 
396 TycC(-29T_AGln)_pTcr_fwd cacacaggaaacagaccatgACGGAAGCGGAAAAACGC 
242 
TycC(L-19_ 
AGln)_pTrc99_fwd 
cacacaggaaacagaccatgCTGAACGTGAACGATACGTTTG 
218 
TycC(P157-
CDphe-Asn)_pTrc99_fwd 
cacacaggaaacagaccatgCCGCGGGAAGCGAC 
219 
TycC(-I6- 
CDphe-Asn)_pTrc99_fwd 
cacacaggaaacagaccatgATTCAACCCGTGGCAGC 
281 
BpsA(G434)- (Ad6-
R395)TycC_fwd 
GTCAAAATCAGAGGATATAGAGTCGAGCTGGATG 
282 
TycC(AGln-
R395):(G434)BpsA_rv 
CGACTCTATATCCTCTGATTTTGACTTGATGGTCG 
342 
TycC(PCPGln-A58):(GSG-
H6)pTrc_rv 
caggctgaaaatcttctctcagtggtgatggtgatgatgACCTGATCCCGC
GATCGTTGGCGATTC 
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343 
TycC(PCPGln-A58):(K1005-
BpsA)_rv 
CGGGCCAGCTTCGCGATCGTTGGCGATTC 
344 
BpsA(K1005):(PCPGln-
A58)TycC_fwd 
CAACGATCGCGAAGCTGGCCCGACGGC 
345 
BpsA(E1004):(GSG-
H6)pTrc_rv 
caggctgaaaatcttctctcagtggtgatggtgatgatgACCTGATCCTTCA
ATTGTTGGTGACTCCAGG 
210 Ghis6_pTrc99_rv ggctgaaaatcttctctcagtggtgatggtgatgatgACC 
Dodecylindigoidine synthetase, S. violacea Pptase and TycC-dIndS fusions 
166 SVDodecInd-(MCS2)_fwd gtataagaaggagatatacatatgGAACCTAAGTCGTTCAAC 
167 SVDodecInd-(MCS2)_rv cagcagcctaggttaattaGCTCTCGTTAATTACCACCTG 
168 SV-Pptase-(pTRc99)_fwd cacacaggaaacagaccatgGTTCGTGGTTACCTTAG 
169 SV-Pptase-(pTRc99)_rv aggctgaaaatcttctctcaAAAAGTACTTGATACCAGTTTAGC 
373 pSV1(ALauric acid_R541)_fwd CGTTTAACCCGTCAAATGTTGG 
374 pSV1(E11)_rv CGTTGTTTGTTCCGCTAAGTTGAAC 
375 
TycC(AVal_-
26T):(11T_dIndS)_fwd 
CTTAGCGGAACAAACAACGATTCAGGAGCTGTTCGAGC 
376 
TycC(AVal_60R):(R541_Alauric 
acid-dIndS)_rv 
CATTTGACGGGTTAAACGGCGGTCGACCTTTCCGTTC 
377 
TycC(AOrn_T-
26):(11T_dIndS)_fwd 
CTTAGCGGAACAAACAACGTTCCAGAAGCTGTTCGAG 
378 
TycC(AOrn_60R):(R541_Alauric
 acid-dIndS)_rv 
CATTTGACGGGTTAAACGTCTGTCTACTTTGCCATTGGCAG 
379 
TycC(ALeu_-
26T):(11T_dIndS)_fwd 
CTTAGCGGAACAAACAACGCTGCACCAGCTATTCG 
380 
TycC(ALeu_61R):(R541_Alauric 
acid-dIndS)_rv 
CATTTGACGGGTTAAACGGCGATCCACTTTTCCATTGG 
Tyrocidine synthetase with IndC and dIndS 
172 
IndC(A1013):(A1651)DindS
_1rv 
CGACCACGGCagccaattctgctatattag 
173 
IndC(A1013):(A1651)DindS
_2rv 
CGACCACGGCagccaattctgctatattaggagattg 
174 
DindS(A1651):(A1013)IndC
_fwd 
gcagaattggctGCCGTGGTCGAAAATAATG 
175 DindS-His6-(MCS2)_rv 
cagcagcctaggttaattagtggtgatggtgatgatgACCTGATCCGCTCTC
GTTAATTACCACCTGTG 
176 
DindS(S1536):(L896)IndC_f
wd 
ttaaagatgatcttTCCCAAGCCTTGCCTAG 
177 
IndC(L896):(S1536)DindS_1
rv 
GGCTTGGGAaagatcatctttaatgatttc 
ppsD:IndC fusions 
249 
ppsD(-174V_AGln)-
Ptrc99_fwd 
tcacacaggaaacagaccatgGTGCAGGGGGCAAAAACG 
250 
ppsD(AGln_R393):(G437)Ind
C_rv 
tacggtaaccGCGGATTTTCACCTGATCATC 
251 
IndC(G437):(AGln_R393)pps
D_fwd 
GAAAATCCGCggttaccgtattgagcttgatg 
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252 
ppsD(-60L_AGln)-
Ptrc99_fwd 
cacacaggaaacagaccatgCTTTTCACCACGCTTGTGG 
262 Ybdz_pCDF(MCS2)_fwd gtataagaaggagatatacatatgGCAAATCCTTTTGAAAATGCG 
263 Ybdz_pCDF(MCS2)_rv cagcagcctaggttaattaCACATTTTCAACAGTCTTTAGGC 
LchAA:IndC fusions 
120 LchAA(MCS2_M1)_fwd gtataagaaggagatatacatATGGGAAACACATGTTACCC 
140 
IndC(MCS2_LchAA_F2-
AGln)_rv 
GCTGCTTTTTGTTCGAAcatatccatcaatgttatt 
123 
LchAA(AGln_T368)_(IndC_T4
24)_rv 
caacaaaataagtCGTACCGTCAGGAAGCC 
124 
IndC(T424):( T368_ 
AGln)LchAA_fwd 
CTGACGGTACGacttattttgttggtcgggttg 
125 
LchAA(MCS2_ AGln_M-
27)_fwd 
gtataagaaggagatatacatATGACCCTGCACGGTTTATTC 
126 LchAA(MCS2_H323)_fwd 
GTA TAA GAA GGA GAT ATA CAT ATG CAT CAA AAG TAT 
CCG TAC AAT C 
127 yngIA(MCS1)_fwd ctttaataaggagatataccatgGTTACATTAAAAAAACAAACG 
128 yngIA(MCS1)_rv ctgttcgacttaagcattaCTGCACCGGGCTC 
ItuB-BpsA fusions in pTrc99 
303 ItuB(M1)_pTrc99_fwd 
cacacaggaaacagaccatgTCGGTATTTAGAAATCAAGAAACGTA
CTGGG 
304 ItuB(AAsn_T-18)_rv GCGCAGACGTGTCGTTAAGCG 
305 ItuB(AAsn _T-18)_fwd CGCTTAACGACACGTCTGCGC 
306 
ItuB(AGln_H406):(G434)Bps
A_rv 
GACTCTATATCCGTGAATTTTCACCTGATGGTCAATCCG 
307 
BpsA(G434)-
ItuB(AGln_H406)_fwd 
GGTGAAAATTCACGGATATAGAGTCGAGCTGGATG 
310 ItuB(EpiAsn_A-7)_fwd GCCGATCAGGGTGAAGTCAAAGG 
311 ItuB(EpiAsn_A-7)_rv CCTTTGACTTCACCCTGATCGGC 
312 ItuB(AGln _E212)_fwd GAGGTCGTGTCAGACGGTAC 
313 ItuB(AGln _E212)_rv GTACCGTCTGACACGACCTC 
314 
ItuB(ATyr_M-
79)_pTrc99_fwd 
cacacaggaaacagaccatgGAGAACAACGGGGTTCACTTG 
315 
ItuB(ATyr_N-
156)_pTrc99_fwd 
cacacaggaaacagaccatgAATACGCTTACAAGCGAAAGCACGTT
C 
330 
ItuB(AAsn_I-175)_pTrc99_fw
d 
cacacaggaaacagaccatgATTAACACCATTCCCGTCCGAATCC 
331 
ItuB(AAsn 
_P-77)_pTrc99_fwd 
cacacaggaaacagaccatgCCGGGTGACGCGATGAAC 
TycC8, 9, 10 ±TE and combinations thereof in pTrc99 
355 TycC(-185E_AVal)-pTrc_fwd cacacaggaaacagaccatgGAGACGAAACACTTCCAGGCATTTTTG 
392 TycC(-49S_AVal)_pTrc_fwd cacacaggaaacagaccatgAGCGAGGAAGAGCGCCGAATTG 
356 TycC(-40V_ AVal)-pTrc_fwd cacacaggaaacagaccatgGTTGATTTCAACAACACGTTTGCCG 
384 TycC(PCPVal_A4)_rv gatgatgacctgatcctgcgctctcggcaatatgcg 
354 TycC(-185G_AOrn)-pTrc_fwd cacacaggaaacagaccatgGGCAGCCTGAGCTTCCGC 
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393 TycC(-49S_AOrn)_pTrc_fwd cacacaggaaacagaccatgTCCAAAGCAGAGACGGAGCACATG 
351 
TycC(-41L_ AOrn)-
pTrc99_fwd 
cacacaggaaacagaccatgCTGCACAGCTTCCTCGC 
385 TycC(PCPOrn_A4)_rv gatgatgACCTGATCCGGCTGTCTCTTCGATGAACGCC 
388 TycC_MOrn+TE1_rv GCCGTATCTGCTCTCAAAGGCTGTCTCTTCGATGAACGC 
389 TycC MOrn+TE1_fwd     TTTGAGAGCAGATACGGCAC 
390 TycC MOrn+TE2_rv     CTCAAAGCGCTTATGCGTGATGAACGCCGCCAGTTC 
391 TycC MOrn+TE2_fwd     ACGCATAAGCGCTTTGAG 
394 TycC(-49L_ALeu)_pTrc_fwd 
cacacaggaaacagaccatgTTGCCAGAAGAAAAACAGCAGATTTT
GG 
386 TycC(-40L_ ALeu)-pTrc_fwd cacacaggaaacagaccatgGCCGGGTTCAACGATACGG 
387 TycC(PCPLeu _R4)_rv gatgatgACCTGATCCGCGCTTATGCGTGATGAAATCG 
382 pTrc99-GSG-H6_fwd GGATCAGGTcatcatcacc 
348 
TycC(TE):(GSG-
H6)Ptrc99_rv 
caggctgaaaatcttctctcagtggtgatggtgatgatgACCTGATCCTTTCA
GGATGAACAGTTCTTGCAGG 
 Primers for site-directed mutagenesis 6.1.3
All primers used to introduce point mutations are complementary to each other. In the 
following, only the forward primer of the pair is listed. 
IndC site-directed mutations 
228 IndC-Ad-TS179VA_fwd 
GTCTGGCTTATATTATTTATGTGGCGGGTAGCACGGGTAAGCC
AAAG 
230 IndC-Ad-D414A_fwd GTTATATCGAACGGGAGCACTGGTAACCAGAGGGG 
221 IndC-Oxd-N571S_fwd GACAGCCACTCAATCGAGCGAAATTAGCTCTTTGC 
223 IndC-Oxd-N571A_fwd GACAGCCACTCAATCGGCGGAAATTAGCTCTTTGCC 
186 IndC-OxD-K605A_fwd CATCAACGTTTATTGCCCGCGTATGCCTATGCTTCACC 
188 IndC-OxD-K605E_fwd CCATCAACGTTTATTGCCCGAATATGCCTATGCTTCACCG 
200 IndC-Ox-Y615A_fwd GCTTCACCGGGTGCTCTCGCGGCGACACAAATGTATTTTG 
232 IndC-Ad-K922A_fwd GACGGCCAATGGAGCGGTGGATTATCAATC 
274 IndC-pA10_1_fwd cgtaaagcgttaccggaaccgaaagccgtggagaatgtttcaacacagcg 
275 IndC-pA10_1_rv cggttccggtaacgctttacgatccacttttccattggccgtcaaagg 
276 IndC-pA10_2_fwd cgtaaagcgttaaccggctttaaagccgtggagaatgtttcaacacagcg 
277 IndC-pA10_2_rv aaagccggttaacgctttacgatccacttttccattggccgtcaaagg 
240 IndC-PCP-K13G_fwd 
GAAAAATTTGGATGGAAGTACTGGGCTGGGATTCAGTATCTG
CCCTCG 
238 IndC-PCP-S18G_fwd CTGAAATGGGATTCAGTAGGCGCCCTCGATGATTTTTTC 
234 IndC-PCP-N979D_fwd CGAAAGTGGGGGTGATTCTTTGATGGCC 
236 IndC-PCP-N979H_fwd CGAAAGTGGGGGTCATTCTTTGATGGCC 
136 IndC-PCP_S980A_fwd GAAAGTGGGGGTAATGCGTTGATGGCCGTTGC 
190 IndC-TE-S1108A_fwd 
GCCATATATATTGTGGGGATATGCGTTTGGTGCCCGAGTAGC
ATTTG  
254 IndC-TE-S1108C_fwd 
CCATATATATTGTGGGGATATTGCTTTGGTGCCCGAGTAGCAT
TTG 
178 IndC-TE_A1135D_fwd GCATTGAATTTATTGGATCCGGGATCTCCTCATC 
180 IndC-TE_APG98DAE_fwd 
GTTAACGCATTGAATTTATTGGATGCGGAATCTCCTCATCTTG
ATATGAAGC 
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BpsA site-directed mutations 
285 BpsA-D410L_fwd CGGCTGTACAAGACCGGGCTGCTGGGCCAGTGGAACAATG 
301 BpsA-K600E_fwd GAACGCCTGCTGCCTGAATACGGCTATGCCTC  
287 BpsA-Y603F_fwd CTAAGTACGGCTTTGCCTCCCCAGG 
289 BpsA-Y603A_fwd CTGCTGCCTAAGTACGGCGCGGCCTCCCCAGGAGCACTG 
291 BpsA-S974A_fwd CTTTGAGTCCGGCGGAAACGCGCTGATCGCCGTCGGCCTG  
293 BpsA-S1103A_fwd CCCTGTGGGGATATGCGTTCGGAGCTCGCGTG 
337 BpsA-S1103C_fwd CCTGTGGGGATATTGCTTCGGAGCTCG 
295 BpsA-A1131G_fwd CAACCTGTTCCTGATCGGCCCTGGGTCACCAAAAG 
297 BpsA-A1131D_fwd CAACCTGTTCCTGATCGATCCTGGGTCACCAAAAG 
DindS site-directed mutations 
182 DindS-TE_D106A_fwd GTGTTTATCTCCATAGCGGCTGAGGCACCCTATG 
184 
DindS-
TE_DAE106APG_fwd 
GAGGTGTTTATCTCCATAGCGCCGGGCGCACCCTATGTGCCAA
AAG 
Tyrocidine synthetase site-directed mutations 
198 TycA(PCPD-Phe-S27A)_fwd GCTCGGCGGAGATGCGATCCAAGCGATC 
256 TycC-AAsn-TS142VA_fwd 
GATTTGGCGTACATGATCTACGTGGCGGGTTCTACCGGCAATC
CAAAAG 
258 TycC- AAsn -D370A_fwd GTATCGAACAGGCGCGCTGGCAAAATGGCTG 
260 TycC- AAsn -K474A_fwd CCGCTGACCGCGAACGGAGCCGTAGAGCGAAAAAAATTGC 
129 TycC(PCPAsn _S28A)_fwd CTTGGGCGGACACGCGTTGAAGGCGATG 
99 
TycC(CAsn-Gln)_HaxxxDG_f
wd 
GTTTTTGCTCGACATGCACGCGATCATCTCGGACGGCGTTTC 
110 
TycC(CAsn-Gln)_HaxxxAA_f
wd 
CATGCACGCGATCATCTCGGCGGCGGTTTCTTCGCAAATTTTG
C 
335 TycC-AGln_D372A_fwd CATGTACCGTACCGGAGCGATGGTCCGCTATTTGCC 
357 TycC-AVal-D349A_fwd GATGTATCGCACCGGAGCGTTGGCGAGATGGCTGC 
359 TycC- PCPVal -S28A_fwd GAAATCGGCGGTCATGCGTTGAAGGCGATGAACG 
361 TycC-AOrn-D352A_fwd GTACCGCACAGGTGCGCTGGCGAAGTGGC 
363 TycC- PCPOrn -S28A_fwd GCTCGGCGGTCACGCTTTGCGTGCCATGC 
365 TycC-ALeu-D354A_fwd CATGTACAAAACAGGCGCGTTGGTAAAATGGCGGAC 
367 TycC- PCPLeu -S29A_fwd GAACTCGGAGGACATGCCTTAAAAGCTACGC 
6.2 Plasmids 
  (Dodecyl-) and Indigoidine Synthetases 6.2.1
dIndS and TycC A domain insertion variants 
name backbone insert origin 
pSV1 
pCDFDuet – 
MCS1 
dIndS(Alauric acid -PCP-C-AGln-PCP-TE  
(WP 013053246.1) 
This work 
pSV2 pTrc99a 
Shewanella violacea Pptase 
(WP_013050488.1) 
This work 
pST4 pCDFDuet-MCS1 
(E1-T11_dIndS):(T-
26_AVal)TycC(+60R):(R541_Alauric acid)dIndS 
This work 
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pST5 pCDFDuet-MCS1 
(E1-T11_dIndS):(T-
26_AOrn)TycC(+60R):(R541_Alauric acid)dIndS 
This work 
pST6 pCDFDuet-MCS1 
(E1-T11_dIndS):(T-
26_ALeu)TycC(+61R):(R541_Alauric acid)dIndS 
This work 
IndC and BpsA variants 
pID8H pCDFDuet-MCS2 IndC(AGlnOxA-PCP-TE)- H6 This work 
pID9aH pCDFDuet-MCS2 IndC(A21_AGlnOxA-PCP-TE)- H6 This work 
pID9H pCDFDuet-MCS2 IndC(M27_AGlnOxA-PCP-TE)- H6 This work 
pTrc8H pTrc99a IndC(AGlnOxA-PCP-TE)- H6 This work 
pMM64 pETDuet – MCS1 BpsA(AGlnOxA-PCP-TE) 
Fussenegger 
Lab199 
pTrc64H pTrc99a BpsA(AGlnOxA-PCP-TE)-H6 This Work 
pTrc64dTE pTrc99a H6-GSG-BpsA(AGlnOxA-PCP_Q1014) This Work 
pCDF64Ox pCDFDuet-MCS1 BpsA-Ox(Y569-L695) This Work 
pCDF64TE pCDFDuet-MCS1 BpsA-TE(E1015-end)-H6 This work 
 Tyrocidine-Indigoidine Synthetase fusion constructs 6.2.2
TycC(AGln):IndC(Ox):TycC(AGlnPCP):IndC(TE) fusion constructs 
pID12eH pCDFDuet-MCS2 
TycC(Q-167_AGln-
D372):(L415)IndC(K862):(AGln_V477)TycC(PCPGl
n_A61):(W1015)IndC-H6 
This work 
pID12aH pDCFDuet-MCS2 
IndC(M1-M27)-TycC(V1_AGln-
D372):(L415)IndC(K862):(AGln_V477)TycC(PCP_
A61):(W1015)IndC-H6 
This work 
pID12dH pDCFDuet-MCS2 
TycC(A-
7_AGln_D372):(L415)IndC(K862):(AGln_V477)Tyc
C(PCP_A61):(W1015)IndC 
This work 
pID12H pCDFDuet-MCS2 
TycC(V1_AGln_D372):(L415)IndC(K862):(AGln_V4
77)TycC(PCP_A61):(W1015)IndC-H6 
This work 
pID13eH pCDFDuet-MCS2 
TycC(Q-167_AGln-
D372):(L415)IndC(I804):(AGln_K426)TycC(PCP_
A61):(W1015)IndC-H6 
This work 
pID13aH pCDFDuet-MCS2 
IndC(M1-M27)-
TycC(V1_AGln_D372):(L415)IndC(I804):(AGln_K4
26)TycC(PCP_+A61):(W1015)IndC-H6 
This work 
pID13dH pCDFDuet-MCS2 
TycC(A-
7_AGln_D372):(L415)IndC(I804):(AGln_K426)Tyc
C(PCP_A61):(W1015)IndC-H6 
This work 
pTrc22c2H 
+Td 
pTrc99 
TycC(L-
19_AGln_K426):(T469)IndC(E876):(G427_AGln)T
ycC(PCP-A58):(K1014)IndC-H6 
This work 
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IndC:dIndS fusion constructs 
pIS1H pCDFDuet-MCS2 IndC(L896):(S1536)DindS-H6 This work 
pIS2H pCDFDuet-MCS2 IndC(A1013):(A1651)DindS-H6 This work 
pIS3H pCDFDuet-MCS2 
TycA(M1-S28)-TycC(I-5_AAsn-PCP-C-
AGln_D372):(L415)IndC(L896):(S1536)DindS-H6 
This work 
TycC(AGln):IndC fusion constructs 
Different start sites for fusion site “10”=TycC(AGln_D372):(L415)IndC 
pID10eH pCDFDuet-MCS2 TycC(Q-167_AGln_D372):(L415)IndC-H6 This work 
pID10cH pCDFDuet-MCS2 TycC(S-42_AGln_D372):(L415)IndC-H6 This work 
pID10aH pCDFDuet-MCS2 
IndC(M1-
M27):(V1)TycC(AGln_D372):(L415)IndC-H6 
This work 
pID10c2H pCDFDuet-MCS2 TycC(L-19_AGln_D372):(L415)IndC-H6 This work 
pID10dH pCDFDuet-MCS2 TycC(A-7_AGln_D372):(L415)IndC-H6 This work 
pID10H pCDFDuet-MCS2 TycC(V1_AGln_D372):(L415)IndC-H6 This work 
TycC(AAsn-PCP-C-AGln):IndC fusion constructs 
Different start sites for fusion site “14”=TycC(AAsn-PCPC-C-AGln_V-17):(N3)IndC 
pID14bH pCDFDuet-MCS2 
TycC(Q-167_AAsn-PCP-C-AGln_V-17):(N3_AGln-
Ox-A-PCP-TE)IndC-H6 
This work 
pID14hH pCDFDuet-MCS2 
TycA(M1-S28)-TycC(I-5_AAsn-PCP-C-AGln_ V-
17):(N3_AGln-Ox-A-PCP-TE)IndC-H6 
This work 
pID14iH pCDFDuet-MCS2 
TycC(LA-Y-18_AAsn-PCP-C-AGln_ V-17):(N3_AGln-
Ox-A-PCP-TE)IndC-H6 
This work 
pID14fH pCDFDuet-MCS2 
TycC(Y-18_AAsn-PCP-C-AGln_ V-17):(N3_AGln-Ox-
A-PCP-TE)IndC-H6 
This work 
pID14gH pCDFDuet-MCS2 
TycC(I-5_AAsn-PCP-C-AGln_ V-17):(N3_AGln-Ox-
A-PCP-TE)IndC-H6 
This work 
Different start sites for fusion site “10”=TycC(AAsn-PCPC-C-AGln_D372):(L415)IndC 
pID2-10H pCDFDuet-MCS2 
TycC(M1_C-AAsn-PCP-C-AGln_D372):(L415_AGln-
Ox-A-PCP-TE)IndC-H6 
This work 
pID10bH pCDFDuet-MCS2 
TycC(Q-167_AAsn-PCP-C-
AGln_D372):(L415_AGln-Ox-A-PCP-TE)IndC-H6 
This work 
pID10hH pCDFDuet-MCS2 
TycA(M1-S28)-TycC(I-5_AAsn-PCP-C-
AGln_D372):(L415_AGln-Ox-A-PCP-TE)IndC-H6 
This work 
pID10iH pCDFDuet-MCS2 
TycC(LA-Y-18_AAsn-PCP-C-
AGln_D372):(L415_AGln-Ox-A-PCP-TE)IndC-H6 
This work 
pID10fH pCDFDuet-MCS2 
TycC(Y-18_AAsn-PCP-C-AGln_D372):(L415_AGln-
Ox-A-PCP-TE)IndC-H6 
This work 
pID10gH pCDFDuet-MCS2 
TycC(I-5_AAsn-PCP-C-AGln_D372):(L415_AGln-
Ox-A-PCP-TE)IndC-H6 
This work 
Different start sites for fusion site “19”=TycC(AAsn-PCPC-C-AGln_R395):(G437)IndC 
pID2-19H pCDFDuet-MCS2 
TycC(M1_C-AAsn-PCP-C-AGln_ 
R395):(G437_AGln-Ox-A-PCP-TE)IndC-H6 
This work 
pID19bH pCDFDuet-MCS2 
TycC(Q-167_AAsn-PCP-C-
AGln_R395):(G437_AGln-Ox-A-PCP-TE)IndC-H6 
This work 
pID19hH pCDFDuet-MCS2 TycA(M1-S28)-TycC(I-5_AAsn-PCP-C- This work 
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AGln_R395):(G437_AGln-Ox-A-PCP-TE)IndC-H6 
pID19jH pCDFDuet-MCS2 
TycC(I-30_AAsn-PCP-C-AGln_R395):(G437_AGln-
Ox-A-PCP-TE)IndC-H6 
This work 
Different fusion sites for start site “b”=(Q-167)AAsn 
pPW04 pSB1C3 
TycC(Q-167-AAsn-PCP-C-AGln_T-161):(M1_AGln-
Ox-A-PCP-TE)IndC-H6 
P. Walch, 
iGem Team 
Heidelberg, 
2013 
pID14bH pCDFDuet-MCS2 
TycC(Q-167_AAsn-PCP-C-AGln_V-17):(N3_AGln-
Ox-A-PCP-TE)IndC-H6 
This work 
pID15bH pCDFDuet-MCS2 
TycC(Q-167_AAsn-PCP-C-AGln_A20):(L48_AGln-
Ox-A-PCP-TE)IndC-H6 
This work 
pID16bH pCDFDuet-MCS2 
TycC(Q-167_AAsn-PCP-C-
AGln_L173):(G210_AGln-Ox-A-PCP-TE)IndC-H6 
This work 
pID17bH pCDFDuet-MCS2 
TycC(Q-167_AAsn-PCP-C-AGln_F270):(L306_AGln-
Ox-A-PCP-TE)IndC-H6 
This work 
pID18bH pCDFDuet-MCS2 
TycC(Q-167_AAsn-PCP-C-
AGln_K309):(P349_AGln-Ox-A-PCP-TE)IndC-H6 
This work 
pID10bH pCDFDuet-MCS2 
TycC(Q-167_AAsn-PCP-C-
AGln_D372):(L415_AGln-Ox-A-PCP-TE)IndC-H6 
This work 
pID19bH pCDFDuet-MCS2 
TycC(Q-167_AAsn-PCP-C-
AGln_R395):(G437_AGln-Ox-A-PCP-TE)IndC-H6 
This work 
pID20bH pCDFDuet-MCS2 
TycC(Q-167_AAsn-PCP-C-
AGln_G425):(R468_AGln-Ox-A-PCP-TE)IndC-H6 
This work 
pID21bH pCDFDuet-MCS2 
TycC(Q-167_AAsn-PCP-C-
AGln_K426):(G470_AGln-Ox-A-PCP-TE)IndC-H6 
This work 
TycC:IndC fusions in pTrc99a 
pTrc10c2H pTrc99a 
IndC(M1-
M27):(V1)TycC(AGln_D372):(L415)IndC-H6 
This work 
pTrc10aH pTrc99a TycC(L-19_AGln_D372):(L415)IndC-H6 This work 
pTrc19c2H pTrc99a 
IndC(M1-
M27):(V1)TycC(AGln_R395):(G437)IndC-H6 
This work 
pTrc19aH pTrc99a TycC(L-19_AGln_ R395):(G437)IndC-H6 This work 
pTrc2-
19bH 
pTrc99a 
TycC(M1_C-AAsn-PCP-C-AGln_ 
R395):(G437_AGln-Ox-A-PCP-TE)IndC-H6 
This work 
pTrc19bH pTrc99a 
TycC(Q-167_AAsn-PCP-C-
AGln_R395):(G437_AGln-Ox-A-PCP-TE)IndC-H6 
This work 
pTrc19bH-
pA10-1 
pTrc99a 
TycC(Q-167_AAsn-PCP-C-
AGln_R395):(G437_AGln-Ox-A_pA10-1: 
RKALPEP_PCP-TE)IndC-H6 
This work 
pTrc19bH-
pA10-2 
pTrc99a 
TycC(Q-167_AAsn-PCP-C-
AGln_R395):(G437_AGln-Ox-A_pA10-2: 
RKALTGF_PCP-TE)IndC-H6 
This work 
pID22bH pTrc99a 
TycC(Q-167_AAsn-PCP-C-
AGln_A437):(D481_AGln-Ox-A-PCP-TE)IndC-H6 
This work 
TycC-BpsA fusions in pTrc99a 
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TycC(AGln)-BpsA fusion constructs 
pSA19aH pTrc99a IndC(M1-M27):(V1)TycC(AGln_R395):(G434)BpsA-H6 This work 
pSA19o2H pTrc99a TycC(T-29_AGln_R395):(G434)BpsA-H6 This work 
pSA19c2H pTrc99a TycC(L-19_AGln_R395):(G434)BpsA-H6 This work 
Different start sites of TycC(AAsn-PCPC-C-AGln_R395):(G434)BpsA fusion constructs 
pSA2-19H pTrc99a 
TycC(M1_C-AAsn-PCP-C-AGln_ R395):(G434_AGln-Ox-A-
PCP-TE)BpsA-H6 
This work 
pSA19bH pTrc99a 
TycC(Q-167_AAsn-PCP-C-AGln_ R395):(G434_AGln-Ox-A-
PCP-TE)BpsA-H6 
This work 
pSA19oH pTrc99a 
TycC(T-29_AAsn-PCP-C-AGln_ R395):(G434_AGln-Ox-A-
PCP-TE)BpsA-H6 
This work 
pSA19c3H pTrc99a 
TycC(L-21_AAsn-PCP-C-AGln_ R395):(G434_AGln-Ox-A-
PCP-TE)BpsA-H6 
This work 
pSA19bH-
dTE 
pTrc99a 
TycC(Q-167_AAsn-PCP-C-AGln_ R395):(G434_AGln-Ox-A-
PCP_Q1014)BpsA-H6 
This work 
TycA(BComD)-TycC(BComD_C-AAsn-PCP-C-AGln):IndC fusion 
pID3-10H pCDFDuet 
MCS1: TycA(M1_APhe-PCP-
E_+L135):(+G128_E)TycB 
MCS2: TycC(M1_C-AAsn-PCP-C-
AGln_D372):(L415_AGln-Ox-A-PCP-TE)IndC-H6 
This work 
pID3-19H pCDFDuet 
MCS1: TycA(M1_APhe-PCP-
E_+L135):(+G128_E)TycB 
MCS2: TycC(M1_C-AAsn-PCP-C-
AGln_R395):(G437_AGln-Ox-A-PCP-TE)IndC-H6 
This work 
 Other NRPS-Indigoidine Synthetase Fusions 6.2.3
LchAA:IndC fusions 
pLI3H pCDFDuet-MCS2 LchAA(M1_C-AGln_T368):(T424)IndC-H6 This work 
pLI3bH pCDFDuet-MCS2 LchAA(H-163_AGln_T368):(T424)IndC-H6 This work 
pLI3aH pCDFDuet-MCS2 LchAA(M-27_AGln_T368):(T424)IndC-H6 This work 
ppsD:IndC fusions 
pPS1 pCDFDuet-MCS2 Ybdz (MbtH protein) This work 
pPS19c2H pTrc99a ppsD(-60L_AGln_R393):(G437)IndC-H6 This work 
pPS19bH pTrc99a 
ppsD(V-174_Apro-PCP-C-
AGln_R393):(G437)IndC-H6 
This work 
ItuB:BpsA fusions 
pItu19bH pTrc99a 
ItuB(N-175_ AAsn-PCP -EpiAsn -C-
AGln_H406):(G434)BpsA-H6 
This work 
pItu25bH pTrc99a 
ItuB(N-156_ ATyr- PCP-EpiTyr-C-AAsn-PCP -EpiAsn -
C-AGln_H406):(G434)BpsA- H6 
This work 
pItu25zH pTrc99a 
ItuB(M1_ATyr- PCP-EpiTyr-C-AAsn-PCP -EpiAsn -C-
AGln_H406):(G434)BpsA- H6 
This work 
Others 
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pID5 pTrc99a TycF (TEII) This work 
pID4 pDCFDuet-MCS1 
TycA(M1_ APhe-PCP-
Epi_+L135):(+G128_E)TycB 
This work 
 TycC single-, di-, and trimodular constructs 6.2.4
TycC single module constructs = di-domain A-PCP 
pTycC1c2H pTrc99a TycC(L-21_AAsn-PCP_+E4)-H6 This work 
pTycC2c2H pTrc99a TycC(L-19_AGln-PCP_+R6)-H6 This work 
pTycC4c2H pTrc99a TycC(V-40_AVal-PCP_+A4)-H6 This work 
pTycC4oH pTrc99a TycC(S-49_AVal-PCP_+A4)-H6 This work 
pTycC5c2H pTrc99a TycC(L-41_AOrn-PCP_+A4)-H6 This work 
pTycC5oH pTrc99a TycC(S-49_AOrn-PCP_+A4)-H6 This work 
pTycC6c2H pTrc99a TycC(L-40_ALeu-PCP_+R4)-H6 This work 
pTycC6oH pTrc99a TycC(L-49_ALeu-PCP_+R4)-H6 This work 
pTycC6c2+TE-
H 
pTrc99a TycC(L-40_ALeu-PCP-TE)-H6 This work 
TycC dimodular constructs 
pTycC12c2H pTrc99a TycC(L-21_AAsn-PCP-C-AGln-PCP_+R6)-H6 This work 
pTycC45c2H pTrc99a TycC(V-40_AVal-PCP-C-AOrn-PCP_+A4)-H6 This work 
pTycC45c2H 
+TE1 
pTrc99a TycC(V-40_AVal-PCP-C-AOrn-PCP_+A4):(F-16)TE-H6 This work 
pTycC45c2H 
+TE2 
pTrc99a TycC(V-40_AVal-PCP-C-AOrn-PCP):(T-20)TE-H6 This work 
pTycC56bH pTrc99a TycC(G-185_AOrn-PCP-C- ALeu-PCP-TE)-H6 This work 
pTycC56c2H-
ΔTE 
pTrc99a TycC(L-41_AOrn-PCP-C- ALeu-PCP_+R4)-H6 This work 
pTycC56c2+TE pTrc99a TycC(L-41_AOrn-PCP-C- ALeu-PCP-TE)-H6 This work 
TycC trimodular constructs 
pTycC456bH pTrc99a TycC(E-185_AVal-PCP-C-AOrn-PCP-C-ALeu-PCP-TE)-H6 This work 
pTycC456c2H pTrc99a TycC(V-40_AVal-PCP-C-AOrn-PCP-C-ALeu-PCP-TE)-H6 This work 
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6.3 Supplementary figures 
 Indigoidine production by IndC, BpsA and their mutants 6.3.1
LR-MS (ESI-):  
Exact mass calculated for C10H8N4O4 [M - H]
- 247.05. Found: 247.0.  
NMR 
1H NMR (500 MHz, (CD3)2SO): 11.29 ppm (s; NH), 8.17 ppm (s; CH), and 6.46 ppm (s; NH2).  
 
 
 
 
Figure S 2 | 1H NMR spectrum at 500 MHz of indigoidine extracted from IndC expression in 
BAP1.  Indigoidine was dissolved in DMSO-d6. Relevant peaks are at 11.29 ppm (s; NH), 8.17 
ppm (s; CH), and 6.46 ppm (s; NH2).  
Figure S 1 | ESI-MS of indigoidine purified from E. coli. (A) m/z detected 
in negative mode ESI-MS of indigoidine in DMSO:MeOH (1:1) plus 1% 
formic acid matches the (B) expected m/z for indigoidine (C10H8N4O4). 
Indigoidine production by IndC, BpsA and their mutants 
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Figure S 4 | SDS-PAGE of BpsA wt 
and mutants. A 7% Tris-Acetate 
gel was loaded with equal 
amounts of the overnight 
expression of the indicated 
constructs and stained with 
Coomassie. The arrowhead 
indicates the position of the BpsA 
variants at an approximate 
expected size of ~150 kDa. 
 
  
Figure S 3 | 1H NMR spectrum at 500 MHz of indigoidine produced by purified IndC in vitro. 
Indigoidine pellet was dissolved in DMSO-d6. Relevant peaks are at 11.29, 8.17 and 6.46 ppm.  
Figure S 5 | Influence of 
truncating the IndC 
N-terminus on pigment 
production. Absorption 
of three overnight BAP1 
cultures expressing the 
indicated proteins was 
measured, the back-
ground (PCP mutant) was 
subtracted, and values 
were normalized to IndC 
wt absorption at 600 nm.  
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Figure S 7 | The post A10 motif differs between elongation, 
interrupted elongation and interrupted termination modules 
analyzed here. Protein sequence alignment of the post A10 motif 
of different NRPS modules from Photorhabdus luminescence, 
Brevibacillus Brevis, IndC, one interrupted elongation (TgaC) and 
one interrupted termination module A domain (PchF).  
 Development of a tyrocidine-indigoidine synthetase 6.3.2
 
 Further engineering approaches on NRP-indigoidine fusion synthetases 6.3.3
Figure S 6 | Effects of point mutations in the Asn 
incorporating module on pigment production of 
TycC(Q-167_AAsn-PCP-C-AGln_R395):(G438)IndC. The 
“wt” and the indicated mutants were expressed in 
BAP1 cells from the pTrc99 vector and the 
absorption at 600 nm was calculated relative to the 
negative control (BpsA PCP mutant, S974A) and 
normalized to the “wt” levels. n = 3 +SD. 
Further engineering approaches on NRP-indigoidine fusion synthetases 
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Figure S 8 | Quality control of BamH1 digest of whole S. violacea genomes and control of 
dIndS variant expression in BAP1. (A) Agarose gel of the intact versus BamHI digested whole 
genomes of pigment producing (1-4 +) and non-pigment producing (1-4 -) S. violacea. For the 
intact whole genomes, a distinct band at a very high molecular weight is visible, which 
disappears for the BamHI digested version. This indicates a successful digest. (B) Predicted 
band pattern for the whole genome digest with BamHI. The prediction was done in ApE and 
the size distribution of resulting genomic fragments ranges between 30 kb and 3 kb, which is 
what we also observed in A. (C) 4-12 % Bis-TRIS SDS-PAGE of dIndS wt and engineered variants 
expressed in BAP1 along with the putative S. violacea PPtase. The dIndS wt and engineered 
versions where the dodecanoic acid specific A domain was replaced by TycC A domains specific 
for Val, Orn or Leu, respectively, are indicated by the black arrow. For the negative control, 
empty pTrc99 and pCDFDuet vectors were transformed. 
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 Context-dependent activity of A domains in the tyrocidine synthetase 6.3.4
 
Figure S 9 | Activity of A domains within “wt” dimodular constructs of TycC8-9 and TycC9-10 
plus or minus TE domain. (A, B and E, F) Coomassie-stained SDS-gels showing the indicated 
purified proteins. (C, D) Bar graphs showing kcat values for the indicated constructs in the 
presence of the indicated amino acids, calculated from the online PPi release assay after 
background (=no substrate) value subtraction. Amino acids were added at 1 mM, enzymes at 
0.5 µM, except for TycC9-10ΔTE, which was added at 0.25 µM. Data represent the mean (± 
standard deviation, SD) of three independent experiments.   
Context-dependent activity of A domains in the tyrocidine synthetase 
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Figure S 10 | Activity of A 
domains within wt and mutated 
A-PCP di-domain constructs of 
TycC8, 9 and 10. (A, D, G) 
Schematic depiction of the wt 
constructs and the respective 
mutants. (B, E, H) Coomassie-
stained SDS-gels showing the 
indicated purified proteins. (C, F, 
I, J) Bar graphs showing kcat values 
for the indicated constructs in the 
presence of the indicated amino 
acids. Amino acids were added at 
1 mM, enzymes at 0.5 µM. Data 
represent the mean ± SD of three 
independent experiments.  
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Figure S 12 | Product formation measured by mass spectrometry.  (A)  MS spectrum of the 
peptide product Orn-Leu of TycC9-10+TE. (B) MS spectrum of the peptide product Val-Orn-Leu 
of TycC8-9-10+TE. Only in the presence of enzyme, ATP, and all substrates, the peptides could be 
detected. Black represents experimental data and red a simulation using mMass for the 
expected signal.  The measured signal shows strong resemblance of the simulation indicating 
product formation. 
Figure S 11 | Activity of A domains of different di-, and trimodular TycC constructs when 
replacing the native substrate Orn by the similar Lys. (A-C) Bar graphs showing kcat values for 
the indicated constructs in the presence of the indicated amino acids, calculated using the online 
PPi release assay after subtraction of the background (=no substrate) value. Amino acids were 
added at 1 mM, enzymes at 0.5 µM, except TycC9-10ΔTE, which was added at 0.25 µM. Data 
represent the mean (± standard deviation, SD) of three independent experiments.   
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7. List of Abbreviations 
7.1 Amino acids 
A - Ala alanine H - His histidine S- Ser serine 
R - Arg arginine I - Ile isoleucine T - Thr threonine 
N - Asn asparagine L - Leu leucine W- Trp tryptophane 
D - Asp aspartic acid K - Lys lysine Y - Tyr tyrosine 
C - Cys cysteine M - Met methionine V - Val valine 
G - Gly glycine P -Pro proline   
E - Glu glutamic acid F - Phe phenylalanine Non- proteinogenic 
Q - Gln glutamine U - Sec selenocysteine O -Orn ornithine 
 
7.2 Chemicals 
ATP adenosine triphosphate 
BisTris 2-[Bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol 
CaCl2 calcium chloride 
CDA calcium-dependent antibiotic 
DHAP dihydroxyacetone phosphate 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
DNA desoxyribonucleic acid 
EDTA ethylenediaminetetraacetic acid 
F1,6P fructose‐1,6‐diphosphate 
F6P d‐fructose‐6‐ phosphate 
FMN flavin mononucleotide 
GAP glyceraldehyde‐3‐phosphate 
GDH glycererophosphate dehydrogenase 
H(2) hydrogen 
HCl hydrochloric acid 
IPTG isopropyl β-D-1-thiogalactopyranoside 
LB Lysogeny broth 
MES 2-(N-morpholino)ethanesulfonic acid 
MesG 2‐amino‐6‐mercapto‐7‐methylpurine ribonucleoside 
MOPS 3-(N-morpholino)propanesulfonic acid 
NaCl sodium chloride 
NAD(H) nicotinamide adenine dinucleotide 
Ni-NTA nickel - nitrilotriacetic acid 
PNP purine nucleoside phosphorylase 
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PP polypropylene 
PPant 4′-phosphopantethein 
PPi pyrophosphate 
PPiase pyrophosphatase 
PPi-PFK phosphofructokinase (pyrophosphate dependent) 
PVDF polyvinylidene fluoride 
TA TRIS-acetate 
TEA TRIS-acetate-EDTA 
TEAB triethylammonium bicarbonate buffer 
TPI triosephosphate isomerase 
TRIS tris(hydroxymethyl)aminomethane 
7.3 Units and more 
(k)Da (kilo) Dalton 
(m)M (mili-)Molar 
°C degrees celcius 
µ micro 
ATCC American Type Culture Collection   
BBH bidirectional best hits 
BLAST Basic Local Alignment Search Tool 
bp base pairs 
BpsA blue pigment synthetase A 
CCD charge-coupled device 
dIndS N,N-dodecylindigoidine synthetase 
DUF domain of unknown function 
EM electron microscopy 
ESI-MS electronspray ionization - mass spectrometry 
FACS fluorescence activated cell sorting 
g g-force 
IM-2 [(2R,3R,1’R)-2-1’-hydroxybutyl-3-hydroxymethyl-γ-butanolide] 
IndC Indigoidine Synthetase C 
IPMB  Institute of Pharmacy and Molecular Biotechnology 
IR inverted repeats 
kcat 
catalytic constant  
(kinetic constant of the theoretical maximum rate of catalysis, specific for an 
enzyme towards a substrate under the conditions tested)  
l liter 
m mili 
m/z atomic mass number / charge number of the ion 
min minutes 
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MS mass spectrometry 
MWCO molecular weight cut off 
NMR nuclear magnetic resonance 
NRP nonribosomal peptide 
NRPS nonribosomal peptide synthetase 
o/n over night 
OD optical density 
ORF open reading frame 
p pico 
PCR polymerase chain reaction 
PKS polyketide synthetase 
PPTase 4′-phosphopantetheinyl transferase 
rpm rounds per minute 
s seconds 
SD standard deviation 
SDS-PAGE sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
wt wild type 
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